<SEC-DOCUMENT>0001193125-21-106460.txt : 20210405
<SEC-HEADER>0001193125-21-106460.hdr.sgml : 20210405
<ACCEPTANCE-DATETIME>20210405170224
ACCESSION NUMBER:		0001193125-21-106460
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20210517
FILED AS OF DATE:		20210405
DATE AS OF CHANGE:		20210405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		21806358

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d41684ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Pursuant to Rule <FONT STYLE="white-space:nowrap">14a-11(c)</FONT> or Rule <FONT STYLE="white-space:nowrap">14a-12</FONT></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules <FONT STYLE="white-space:nowrap">14a-6(i)(4)</FONT> and <FONT STYLE="white-space:nowrap">0-11</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule
<FONT STYLE="white-space:nowrap">0-11:</FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g41684g89m19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4200 Marathon Blvd. Suite 200, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX 78756 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(737) <FONT
STYLE="white-space:nowrap">255-7194</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;5, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To Our Stockholders: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Plus
Therapeutics team wishes good health to you and your families as we hopefully move beyond the quarantines and lockdowns to more normal times. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Despite the global pandemic, the Plus team made substantial progress in 2020 guided by our mission to discover, and develop complex and
innovative treatments for patients battling rare cancers. In the first quarter of fiscal 2020, we acted to strengthen our drug pipeline by <FONT STYLE="white-space:nowrap">in-licensing</FONT> a novel portfolio of cancer therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The lead <FONT STYLE="white-space:nowrap">in-licensed</FONT> product candidate is called Rhenium NanoLiposome, or RNL<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, a complex radiotherapeutic drug that has shown in clinical trials to deliver approximately 20 times more cancer-killing radiation than currently available therapies for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat,</FONT></FONT> radiation-sensitive tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following <FONT
STYLE="white-space:nowrap">in-licensing</FONT> of the RNL investigational drug technology, we made substantial progress on several fronts. First, we are much closer to completing enrollment in the U.S. National Institutes of Health/National Cancer
Institute (NIH/NCI) funded Phase 1/2 ReSPECT trial of RNL for the treatment of patients with recurrent glioblastoma (GBM) or brain cancer. We have added two additional clinical sites and enrolled the requisite patients in the sixth cohort of the
study. As of the time of the penning of this letter, 19 patients have been treated with RNL, with promising results thus far in terms of feasibility and safety. Second, we have made progress in completing key manufacturing objectives for Phase 3
drug supply and are on a path to achieving key related milestones in 2021. Finally, we have evaluated a number of new potential indications for RNL beyond GBM and plan to interface with the U.S. Food and Drug Administration with the goal of bringing
additional indications into clinical trials in 2021 and hopefully one day to approval for the benefit of patients that need them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Also in
2021, we continue to evaluate additional <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities and <FONT STYLE="white-space:nowrap">out-licensing</FONT> partnership deals for both our new RNL portfolio and our clinical stage DocePLUS<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> and DoxoPLUS assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We look forward in the forthcoming year to keeping you
apprised of our ongoing progress. As always, please allow me to express my sincere gratitude to our operations and governance team, our strategic partners and, of course, to you, our stockholders. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sincerely,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g41684g07d97.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Marc H. Hedrick</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>President&nbsp;&amp; Chief Executive Officer</I></P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g41684g89m19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF 2021 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON MAY&nbsp;17, 2021 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PLUS THERAPEUTICS, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Headquarters</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4200 MARATHON BLVD. SUITE
200,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">AUSTIN, TX 78756</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>MEETING LOCATION</B>:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>www.virtualshareholdermeeting.com/PSTV2021</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dear Plus Therapeutics, Inc. Stockholder: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You are cordially invited to attend the 2021 Annual Meeting of the stockholders of Plus Therapeutics, Inc. (the &#147;Annual
Meeting&#148;). The Annual Meeting will be held on May&nbsp;17, 2021, commencing at 9:00 a.m., Central Time, and will be a completely virtual meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The items of business for the meeting are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">elect members of our board of directors (the &#147;Board&#148;) for a
<FONT STYLE="white-space:nowrap">one-year</FONT> term; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2021
fiscal year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">approve the amendment and restatement of the Company&#146;s 2020 Stock Incentive Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">provide a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on the compensation of our named
executive officers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">transact such other business as may be properly brought before the meeting or any adjournment or
postponement thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board recommends the approval of each of these proposals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Due to the public health impact of the coronavirus outbreak <FONT STYLE="white-space:nowrap">(&#147;COVID-19&#148;)</FONT> and
to support the health and well-being of our stockholders and employees, the Annual Meeting will be held via live webcast only. In addition, we believe that the virtual meeting format will expand stockholder access and participation and improve
communications. However, we have not decided if we will use a virtual meeting only format for future meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You will
be able to attend and participate in the Annual Meeting online, vote your shares electronically, and submit your questions prior to and during the meeting by visiting: <U>www.virtualshareholdermeeting.com/PSTV2021</U>. To vote at the meeting, you
must have your control number that is shown on your proxy card. There will not be a physical meeting location and you will not be able to attend the annual meeting in person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Only stockholders of record at the close of business on March&nbsp;22, 2021 are entitled to notice of, and to vote while
attending the Annual Meeting on the Internet. For 10 days prior to the Annual Meeting, a complete list of stockholders entitled to vote at the Annual Meeting will be available at the Secretary&#146;s office at 4200 Marathon Blvd. Suite 200, Austin,
TX 78756. We expect to commence mailing these proxy materials on or about April&nbsp;5, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>You are cordially
invited to attend the Annual Meeting live via the Internet. It is important that your shares are represented at the Annual Meeting. Even if you plan to attend the Annual Meeting live via the Internet, we hope that you will promptly vote and submit
your proxy by dating, signing, and returning the enclosed proxy card or vote via the Internet or by telephone. This will not limit your rights to attend or vote during the Annual Meeting. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By Order of the Board,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g41684g07d97.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MARC H. HEDRICK</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>President&nbsp;&amp; Chief Executive Officer</I></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin, Texas, USA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;5, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc41684_1">PROPOSAL #1 ELECTION OF DIRECTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc41684_2">CORPORATE GOVERNANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc41684_3">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc41684_4">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc41684_5">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc41684_6">AUDIT MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc41684_7">PROPOSAL #2 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
 FIRM</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc41684_8">PROPOSAL #3 APPROVAL OF THE AMENDMENT AND RESTATEMENT OF THE 2020 STOCK INCENTIVE
 PLAN</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc41684_9">PROPOSAL #4 <FONT STYLE="white-space:nowrap">NON-BINDING</FONT> ADVISORY VOTE ON
 EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc41684_10">OTHER MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g41684g89m19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4200 Marathon Blvd. Suite 200, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX 78756 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(737) <FONT
STYLE="white-space:nowrap">255-7194</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020 is being made available
to stockholders together with these proxy materials on or about April&nbsp;5, 2021. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Proxy Statement is being
furnished in connection with the solicitation of proxies by and on behalf of our board of directors (&#147;Board&#148;) to be used at our 2021 Annual Meeting of Stockholders to be held on May&nbsp;17, 2021 at 9:00 a.m., Central Time (&#147;Annual
Meeting&#148;), and at any adjournment or postponement of the Annual Meeting, for the purposes set forth in the accompanying notice of Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have fixed the close of business on March&nbsp;22, 2021 as the record date for the determination of the stockholders
entitled to notice of and to vote at the Annual Meeting. Only holders of record of shares of our common stock on that date are entitled to notice of and to vote at the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Due to the public health impact of the coronavirus outbreak <FONT STYLE="white-space:nowrap">(&#147;COVID-19&#148;)</FONT> and
to support the health and well-being of our stockholders and employees, the Annual Meeting will be held via live webcast only. In addition, we believe that the virtual meeting format will expand stockholder access and participation and improve
communications. However, we have not decided if we will use a virtual meeting only format for future meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You will
be able to attend and participate in the Annual Meeting online, vote your shares electronically, and submit your questions prior to and during the meeting by visiting: <U>www.virtualshareholdermeeting.com/PSTV2021</U>. To vote at the meeting, you
must have your control number that is shown on your proxy card. There will not be a physical meeting location and you will not be able to attend the annual meeting in person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Questions and Answers about the Meeting and Voting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: What is a proxy statement and why has this Proxy Statement been provided to me? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: A Proxy Statement is a document that SEC regulations require us to give you when we ask you to provide a proxy to vote your
shares at the Annual Meeting. Among other things, this Proxy Statement describes the proposals on which stockholders will be voting and provides information about us. Our Board is soliciting your proxy to vote at the Annual Meeting and at any
adjournment or postponement of the Annual Meeting. We will use the proxies received in connection with proposals to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">elect members of our Board for a <FONT STYLE="white-space:nowrap">one-year</FONT> term;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2021
fiscal year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">approve the amendment and restatement of the Plus Therapeutics, Inc. 2020 Stock Incentive Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">provide a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on the compensation of our named
executive officers. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: What is a proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: A proxy is your legal designation of another person to vote the stock you own. That designee is referred to as a proxy
holder. Designation of a particular proxy holder can be effected by completion of a written proxy card, or by voting via the Internet or by telephone. If you return a proxy card, or vote by phone or internet, our President and Chief Executive
Officer, Marc H. Hedrick, M.D., and our Chief Financial Officer, Andrew Sims, will act as your designated proxy holder at the Annual Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: Why is the Annual Meeting being held as a virtual meeting via webcast? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: Due to the public health impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and to support the health and well-being
of our stockholders and employees, the Annual Meeting will be a completely virtual meeting of stockholders. There will not be a physical meeting location and you will not be able to attend in person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: How can I attend the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: The Annual Meeting will be a virtual meeting of stockholders, which will be conducted exclusively by webcast. You are
entitled to participate in the Annual Meeting only if you were a stockholder of the Company as of the close of business on March&nbsp;22, 2021, or if you hold a valid proxy for the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No physical meeting will be held. You will be able to attend the Annual Meeting online and submit your questions during the
meeting by visiting <U>www.virtualshareholdermeeting.com/PSTV2021</U>. You also will be able to vote your shares online by attending the Annual Meeting by webcast. To participate in the Annual Meeting, you will need the sixteen-digit control number
provided on your proxy card. For more information, review the information included on your proxy card, or the instructions that accompanied your proxy materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The online meeting will begin promptly at 9:00 a.m., Central Time, on May&nbsp;17, 2021. We encourage you to access the
meeting prior to the start time, leaving ample time for the check in. Please follow the instructions as outlined in this Proxy Statement and on your proxy card. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: What is the difference between a stockholder of record and a beneficial owner who holds stock in street name? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: You are a stockholder of record, or a &#147;registered holder&#148;, if your shares are registered in your own name through
our transfer agent. If you have a stock certificate, you are also a stockholder of record. You are a beneficial owner of our stock in street name if you hold your shares through a broker, bank or other third-party institution (in this situation, the
banks, brokers, etc. are the stockholders of record). The vast majority of our stockholders hold their shares in street name. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: What different methods can I use to vote? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: If you are a registered holder and you are viewing this proxy over the Internet, you may vote electronically over the
Internet. For those stockholders who receive a paper proxy in the mail, you may also vote electronically over the Internet or by telephone or by completing and mailing the proxy card provided. The website identified on your proxy card provides
specific instructions on how to vote electronically over the Internet. Those stockholders who receive a paper proxy by mail, and who elect to vote by mail, should complete and return the mailed proxy card in the prepaid and addressed envelope that
was enclosed with the proxy materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you are the beneficial owner of stock held in street name, follow the
instructions from your broker, bank or other nominee that must be followed in order for you to vote your shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stockholders who have previously elected to access our proxy materials and annual report electronically over the Internet will
continue to receive an <FONT STYLE="white-space:nowrap">e-mail,</FONT> referred to in this Proxy Statement as an <FONT STYLE="white-space:nowrap">&#147;e-mail</FONT> notice&#148;, with information on how to access the proxy information and voting
instructions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Only proxy cards and voting instruction forms that have been signed, dated and timely returned and only
proxies that have been timely voted electronically or by telephone will be counted in the quorum and voted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 2
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stockholders who vote over the Internet or by telephone need not return a
proxy card or voting instruction form by mail, but may incur costs, such as usage charges, from telephone companies or Internet service providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You may also vote your shares at the Annual Meeting. If you are a registered holder you must join live online at
<U>www.virtualshareholdermeeting.com/PSTV2021</U>. The webcast will start at 9:00 a.m., Central Time. You may vote and submit questions while attending the meeting online. You will need the control number included on your proxy card (if you received
a printed copy of the proxy materials) to vote during the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you receive more than one email notice, proxy card
or voting instruction form because your shares are held in multiple accounts or registered in different names or addresses, please vote your shares held in <I>each account </I>to ensure that all of your shares will be voted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: What is the record date and what does it mean? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: The record date for the Annual Meeting is March&nbsp;22, 2021. The record date is established by our Board as required by
Delaware General Corporation Law. Owners of our common stock at the close of business on the record date are entitled to receive notice of the meeting and to vote at the meeting and any adjournment or postponement of the meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: How can I change my vote? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: You may revoke your proxy and change your vote at any time before the final vote at the meeting. You can revoke a proxy by
giving written notice of revocation to our Corporate Secretary, following the Internet voting instructions, delivering a later dated proxy, or voting at the meeting. However, your attendance at the Annual Meeting will not automatically revoke your
proxy unless you vote again at the meeting or specifically request in writing that your proxy be revoked. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: What are
my voting choices when voting for director nominees and what vote is needed to elect directors? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: In voting on the
election of director nominees to serve until the 2022 Annual Meeting, stockholders may vote in favor of each nominee, or may withhold votes as to each nominee. In addition, if any other candidates are properly nominated at the meeting, stockholders
of record who attend the meeting could vote for the other candidates. Directors are elected by a plurality vote, which means that the six nominees receiving the most affirmative votes will be elected. Stockholders are not entitled to cumulative
voting rights with respect to the election of directors. Only votes &#147;FOR&#148; or &#147;WITHHELD&#148; will affect the outcome. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: What are my voting choices when voting to ratify the appointment of our independent registered public accounting firm,
and what vote is needed to ratify the appointment? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: In voting on the ratification of the appointment of our
independent registered public accounting firm, stockholders may vote in favor of or against the appointment or may abstain from voting on the appointment. The affirmative vote of a majority of the common stock present at the meeting or represented
by proxy at the meeting is required to approve this proposal. Abstentions will be counted as present for purposes of determining a quorum and are considered shares present and entitled to vote and thus will have the effect of a vote
&#147;AGAINST&#148; this proposal. We do not expect any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> in connection with this proposal since we expect brokers to have discretionary authority to vote on this proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This vote is advisory, and therefore not binding on the Board. Although the vote is
<FONT STYLE="white-space:nowrap">non-binding,</FONT> the Board will review the voting results, seek to determine the cause or causes of any significant negative voting, and take them into consideration when making decisions regarding our independent
registered public accounting firm for this fiscal year and future fiscal years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: What are my voting choices when
voting to approve the amendment and restatement of the Plus Therapeutics, Inc. 2020 Stock Incentive Plan? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: In voting
on the approval of the amendment and restatement of the Plus Therapeutics, Inc. 2020 Stock Incentive Plan, stockholders may vote in favor of or against the proposal or they may abstain from voting on the proposal. The affirmative vote of a majority
of the common stock present in person or represented by proxy at the meeting is required to approve this proposal. Abstentions will be counted as present for purposes of determining a quorum and are considered shares present and entitled to vote and
thus will have the effective of a vote &#147;AGAINST&#148; this proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 3
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: What are my voting choices when voting to approve, on an advisory
basis, the compensation of the Company&#146;s named executive officers? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A. In voting on the approval, on an advisory
basis, of the compensation of our named executive officers, stockholders may vote in favor or against the proposal, or they may abstain from voting on this proposal. The affirmative vote of a majority of the common stock present at the meeting or
represented by proxy at the meeting is required to approve this proposal. Abstentions will be counted as present for purposes of determining a quorum and are considered shares present and entitled to vote and thus will have the effect of a vote
&#147;AGAINST&#148; this proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This vote is advisory, and therefore not binding on the Board. Although the vote is <FONT
STYLE="white-space:nowrap">non-binding,</FONT> the Board will review the voting results, seek to determine the cause or causes of any significant negative voting, and take them into consideration when making future decisions regarding executive
compensation programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: How will a proxy get voted? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: If you properly complete and return a proxy card or vote by Internet or by telephone, the designated proxy holders will vote
your shares as you have directed. If you sign a proxy card but do not make specific choices or if you vote by Internet or telephone but do not make specific choices, the designated proxy holders will vote your shares as recommended by the Board as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>FOR</B>&#148; the election of each listed director nominee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>FOR</B>&#148; ratification of the appointment of BDO USA, LLP as our independent registered public
accounting firm for the 2021 fiscal year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>&#147;FOR&#148; </B>approval of the amendment and restatement of the Plus Therapeutics, Inc. 2020 Stock
Incentive Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>FOR</B>&#148; approval, on an advisory basis, of the compensation of our named executive officers.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect to the election of directors, if any nominee is unable or declines to serve, or for good
cause will not serve, as a director at the time of the Annual Meeting, an event not currently anticipated, the designated proxy holders will have the express discretionary authority to vote for a replacement nominee designated by our Board, and
proxies will be voted for any nominee designated by our Board to fill the vacancy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: How are abstentions and broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> counted? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: Abstentions and broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted as present for purposes of determining a quorum. An abstention occurs when a stockholder chooses to &#147;ABSTAIN&#148; from voting on a matter. A broker <FONT
STYLE="white-space:nowrap">non-vote</FONT> occurs when a broker, bank, or other stockholder of record, in nominee name or otherwise, exercising fiduciary powers submits a proxy for the Annual Meeting, but does not vote on a particular proposal
because that holder does not have discretionary voting power with respect to that proposal and has not received voting instructions from the beneficial owner. Under the rules that govern brokers who are voting with respect to shares held in street
name, brokers have the discretion to vote those shares on routine matters, but not on <FONT STYLE="white-space:nowrap">non-routine</FONT> matters. We expect the ratification of the appointment of our independent registered public accounting firm to
be a routine matter, and therefore, broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are not expected to exist with respect to this proposal. We expect the other proposals described in this proxy statement to be <FONT
STYLE="white-space:nowrap">non-routine.</FONT> Brokers and nominees do not have discretionary voting power over these <FONT STYLE="white-space:nowrap">non-routine</FONT> proposals and, therefore, broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> may exist with respect to these proposals. Thus, broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will not affect the outcome of any matter being voted on at the Annual Meeting, assuming that
a quorum is obtained. However, we strongly encourage you to submit your proxy and exercise your right to vote as a stockholder to ensure your shares are voted in the manner in which you want them voted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 4
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: Who pays for the solicitation of proxies? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: We will pay the entire cost of the solicitation of proxies for the Annual Meeting. This includes preparation, assembly,
printing, and mailing of the Notice, this Proxy Statement and any other information we send to stockholders. We have engaged The Proxy Advisory Group, LLC to assist in the solicitation of proxies and provide related advice and information support,
for a services fee and the reimbursement of customary reimbursements. In addition, we may supplement our efforts to solicit your proxy in the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may contact you using the telephone or electronic communication; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our directors, officers or other regular employees may contact you personally; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proxy Advisory Group, LLC or any other third parties we may hire as agents for the sole purpose of
contacting you regarding your proxy, may contact you. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will not pay directors, officers or other
regular employees any additional compensation for their efforts to supplement our proxy solicitation. We anticipate banks, brokerage houses and other custodians, nominees and fiduciaries will forward soliciting material to the beneficial owners of
shares of common stock entitled to vote at the Annual Meeting and that we will reimburse those persons for their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in performing such
services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: What constitutes a quorum? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: For business to be conducted at the Annual Meeting, a quorum must be present. A quorum exists when the holders of at least
33<SUP STYLE="vertical-align:top">1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the shares of our common stock issued, outstanding and entitled to vote are represented at the meeting. Shares of common stock represented in person or by
proxy (including broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and shares that abstain or do not vote with respect to one or more of the matters to be voted upon) will be counted for the purpose of determining whether a quorum exists.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: How many votes may I cast? How many shares are eligible to be voted? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: You may cast one vote for every share of our common stock that you owned on the record date. As of the record date,
March&nbsp;22, 2021, there were 9,221,902 shares of common stock outstanding, each of which is entitled to one vote. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: How will voting on any &#147;other business&#148; be conducted? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: Although we do not know of any business to be considered at the Annual Meeting other than the proposals described in this
Proxy Statement, if any additional business is presented at the Annual Meeting, your proxy gives authority to the designated proxy holders to vote on such matters according to their best judgment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Q: Where can I find the voting results of the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A: We will publish the final voting results in a current report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> which we
expect to file with the SEC within four business days of the Annual Meeting. If the final voting results are unavailable in time to file a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the SEC within four business days
after the Annual Meeting, we intend to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> to disclose the preliminary results and, within four business days after the final results are known, we will file an additional current report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> with the SEC to disclose the final voting results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 5
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc41684_1"></A>PROPOSAL #1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board currently consists of six (6)&nbsp;persons. The Board, upon the recommendation of our governance and nominating
committee, has nominated the persons listed below for election as directors. All of the nominees are currently serving as members of our Board. All directors are elected annually and serve <FONT STYLE="white-space:nowrap">one-year</FONT> terms until
the next Annual Meeting, or until they resign, are removed, or their respective successors are duly elected and qualified. If any nominee should decline or be unable to accept such nomination or to serve as a director, or for good cause will not
serve as a director, an event which our Board does not currently anticipate, our Board reserves the right to nominate another person or to vote to reduce the size of our Board. The designated proxy holders will have the express discretionary
authority to vote for a replacement nominee and proxies will be voted for any nominee designated by our Board to fill the vacancy. If another person is nominated, the proxy holders intend to vote the shares to which the proxy relates for the
election of the persons nominated by our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The names of the nominees and certain biographical information about the
nominees, including each nominee&#146;s business experience, director positions held currently or at any time during the last five years, information regarding involvement in certain legal or administrative proceedings, if applicable, and the
experiences, qualifications, attributes, or skills that caused the nominating and corporate governance committee to recommend that the nominee should continue to serve on our Board, are set forth below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Nominees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Howard Clowes. </I>Mr.&nbsp;Clowes has served on our Board since April&nbsp;1, 2020. From January 2005 until he retired as a
lawyer in December 2018, Mr.&nbsp;Clowes was a partner in the law firm DLA Piper (US) LLC. From 1982 until the formation of DLA Piper in 2005, he was an associate and then a partner in the predecessor firms of DLA Piper, holding various management
positions, including serving on its board of directors. Mr.&nbsp;Clowes currently serves on the board of Equalize Health and as Chair of its Governance Committee. Equalize Health is a nonprofit product development company focused on equalizing
access to health care around the world. Mr.&nbsp;Clowes served on the board of the Law Foundation of Silicon Valley from 2008 until December 2018, serving during that period in various positions, including President of its board of directors, and
Chair of a Strategic Planning and CEO Search Committee. Since 2017, Mr.&nbsp;Clowes has served as a Lecturer at U.C. Berkeley&#146;s Berkeley School of Law, teaching a course in International Business Negotiations. Mr.&nbsp;Clowes earned his J.D. at
U.C. Berkeley and his B.A. in Experimental Psychology at U.C. Santa Barbara. We believe Mr.&nbsp;Clowes&#146; qualifications to serve on the Board include his extensive experience as a lawyer advising boards of directors and their audit,
compensation and governance committees on a wide range of matters, his experience with a wide range of transactions, and his experience serving on various boards of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>An van <FONT STYLE="white-space:nowrap">Es-Johansson,</FONT> M.D</I>. Dr.&nbsp;An van
<FONT STYLE="white-space:nowrap">Es-Johansson</FONT> has served on our Board since January&nbsp;1, 2020. Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT> served as the Chief Medical Officer for AlzeCure Pharma, a Swedish
pharmaceutical company with a primary focus on Alzheimer&#146;s disease, from September 2018 through March&nbsp;1, 2021 and now serves as Senior Advisor. From May 2005 to September 2018, Dr.&nbsp;van
<FONT STYLE="white-space:nowrap">Es-Johansson</FONT> served in a range of executive roles of increasing responsibility at Sobi, an international rare disease company headquartered in Stockholm, Sweden, including as Vice President and Head of EMENAR
Medical Affairs for Specialty Care and Partner Products from March 2013 to January 2018. Prior to her time at Sobi, Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT> served in leadership positions within large pharmaceutical and
smaller biotechnology companies, including Roche, Pharmacia, Eli Lilly, Active Biotech, and BioStratum. From 2004 to 2016, she was a member of the Scientific Adboard for Uppsala Bio and currently serves on the board of directors at Medivir AB
(NASDAQ Stockholm), Savara, Inc. (NASDAQ: SVRA), Lumos Pharma, Inc. (NASDAQ: LUMO) and privately held Agendia BV. She also served on the board of directors at BioInvent International AB (NASDAQ OMX Stockholm), from June 2016 to February 2021.
Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT> received a M.D. from Erasmus University, Rotterdam, The Netherlands. We believe Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT> brings extensive medical knowledge
and experience in the pharmaceutical industry to our Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 6
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Richard J. Hawkins</I>. Mr.&nbsp;Hawkins has served on our Board since
December 2007 and as Chairman of our Board since January 2018. In 1982, Mr.&nbsp;Hawkins founded Pharmaco, a clinical research organization, or CRO, that merged with the predecessor of <FONT STYLE="white-space:nowrap">PPD-Pharmaco</FONT> in 1991 and
is one of the largest CROs in the world today. In 1992, Mr.&nbsp;Hawkins <FONT STYLE="white-space:nowrap">co-founded</FONT> Sensus Drug Development Corporation, or SDDC, a privately-held company focused on the development of drugs to treat endocrine
disorders, which developed and received regulatory approval for SOMAVERT, a growth hormone antagonist approved for the treatment of acromegaly, which is now marketed by Pfizer, Inc., and he served as Chairman of SDDC until 2000. In 1994, <FONT
STYLE="white-space:nowrap">Mr.&nbsp;Hawkins&nbsp;co-founded&nbsp;Corning</FONT> Biopro, a contract protein manufacturing firm, where he served on its board until Corning BioPro&#146;s sale to
<FONT STYLE="white-space:nowrap">Akzo-Nobel,&nbsp;N.V.,</FONT> a publicly-held producer of paints, coatings and specialty chemicals, in 2000. In September 2003 Mr.&nbsp;Hawkins founded LabNow, Inc., a privately held company that <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">develops&nbsp;lab-on-a-chip&nbsp;sensor</FONT></FONT></FONT> technology, where he served as the Chairman and Chief Executive Officer until October 2009.
Mr.&nbsp;Hawkins has served on the board of SciClone Pharmaceuticals, Inc., a publicly-held specialty pharmaceutical company, from October 2004 through December 2017. In February 2011, Mr.&nbsp;Hawkins became Chief Executive Officer, and is
currently Chief Executive Officer, president and chairman of Lumos Pharma, Inc. (NASDAQ: LUMO). He has also served on the Presidential Advisory Committee for the Center for Nano and Molecular Science and Technology at the University of Texas in
Austin, and was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas. Mr.&nbsp;Hawkins is a member of the National Ernst&nbsp;&amp; Young Entrepreneur of the Year Hall of Fame. Mr.&nbsp;Hawkins graduated cum
laude with a B.S. in Biology from Ohio University, where he later received the Ohio University Konneker Medal, the highest award given to a faculty member or former student for entrepreneurial excellence. We believe Mr.&nbsp;Hawkins&#146;s
qualifications to serve on our Board include his executive experience working with life sciences companies, his extensive experience in pharmaceutical research and development, his knowledge, understanding and experience in the regulatory
development and approval process, and his service on other public company boards and committees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Marc H. Hedrick,
M.D.</I> Dr.&nbsp;Hedrick joined the Company in October 2002 as Chief Scientific Officer. In May 2004, he was appointed as President of the Company and in April 2014 he was appointed as Chief Executive Officer. Dr.&nbsp;Hedrick has served as a
member of our Board since joining the Company in October 2002. Previously, Dr.&nbsp;Hedrick served in a number of executive leadership positions, including as President and Chief Executive Officer of Cytori Therapeutics, President and Chief
Executive Officer of StemSource, and Chief Scientific Officer and Medical Director of Macropore Biosurgery. Dr.&nbsp;Hedrick has also served as a board member for a number of public and private companies since 2000. Prior to his corporate career,
Dr.&nbsp;Hedrick was Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles. Dr.&nbsp;Hedrick&#146;s academic research received both NIH funding as well as private and public capitalization and was widely
acknowledged through scientific publications and the media. Dr.&nbsp;Hedrick has a medical degree from The University of Texas Southwestern Medical School and a Master of Business Administration from The UCLA Anderson School of Management and is a
trained general, vascular and plastic surgeon. We believe Dr.&nbsp;Hedrick&#146;s qualifications to serve on our Board include his executive, financial, governance and operational leadership experience in medical and pharmaceutical product
development. Furthermore, Dr.&nbsp;Hedrick has first-hand experience as a physician, practicing general, vascular and craniofacial surgery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Robert Lenk</I>. Dr.&nbsp;Lenk has served on our Board since April&nbsp;1, 2020. Since 2016, he has served as President of
Lenk Pharmaceuticals, LLC, consulting to clients in the pharmaceuticals industry. Dr.&nbsp;Lenk <FONT STYLE="white-space:nowrap">co-founded</FONT> the Liposome Company, in Princeton, New Jersey in 1981 which was later acquired by Elan
Pharmaceuticals. After the Liposome Company went public, he <FONT STYLE="white-space:nowrap">co-founded</FONT> Argus Pharmaceuticals in 1989 as Vice President of Research&nbsp;&amp; Development, which later merged with two other companies to become
Aronex Pharmaceuticals. In 1989, Dr.&nbsp;Lenk served as President and Chief Executive Officer of Therapeutics 2000, Inc. which was later sold to Coller Capital. Dr.&nbsp;Lenk joined Luna Innovations as President of the Nanoworks Division in 2004.
After the parent company went public, he joined MediVector, Inc. as Chief Science Officer until 2016 when he started Lenk Pharmaceuticals, LLC. He currently serves on the board of a PoP Biotechnology, a private company. Dr.&nbsp;Lenk received both
his PhD and BSc. from the Massachusetts Institute of Technology. We believe Dr.&nbsp;Lenk&#146;s broad experience in translating research candidates into products, especially in the fields of nanotechnology and liposomal drug products, brings
valuable implementation skills to the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Greg Petersen. </I>Greg Petersen has served on our Board since
February&nbsp;14, 2020. Mr.&nbsp;Petersen is an accomplished executive and board member with more than 25 years of strategy, operations, finance and compliance leadership experience. His 10 years of board of directors experience includes his current
roles as compensation committee chair and audit committee member of PROS Holdings, Inc. (NYSE: PRO), a software company, and as audit committee chair of Mohawk Group Holdings (NASDAQ: MWK), a consumer product manufacturing company. He previously
also served on the boards of publicly traded companies Diligent Corporation (NZX: DIL), a software as a service company, from 2013 to 2016, and Piksel, Inc. (OTC US: PIKL), a video management software and services company, from 2012 to 2017. During
his career, Mr.&nbsp;Petersen has served as Executive Vice Chairman of Diligent Corporation and as Chief Financial Officer of Lombardi Software (now part of IBM) and Activant Solutions (now part of Epicor). He has also held executive positions at
American Airlines and other corporations. Mr.&nbsp;Petersen has a BA from Boston College and an MBA from Duke University&#146;s Fuqua School of Business. We believe Mr.&nbsp;Petersen&#146;s extensive experience as an executive and a director,
including as a director on other public company boards, as well as his strategic, operations, finance, and compliance leadership experience, qualify him to serve on our Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 7
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The nominees will be elected by a plurality vote, which means that the six nominees receiving the most affirmative votes will
be elected. Only votes &#147;FOR&#148; or &#147;WITHHELD&#148; will affect the outcome. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR BOARD UNANIMOUSLY RECOMMENDS A VOTE &#147;FOR&#148; THE NOMINEES TO THE BOARD NAMED ABOVE. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers; Director Nominees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows information about our executive officers, continuing directors, and director nominees, and their ages
as of March&nbsp;31, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Executive Officers</I></B><I></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">President, Chief Executive Officer and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Financial Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Howard Clowes<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">An van <FONT STYLE="white-space:nowrap">Es-Johansson,</FONT> M.D.<SUP
STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Hawkins</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chairman of the Board</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lenk, PhD<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Petersen<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the governance and nominating committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following presents biographical information for each of our executive officers listed in the table above, other than
Dr.&nbsp;Hedrick whose information is presented above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Andrew Sims</I>.<I> </I>Mr.&nbsp;Sims<I> </I>joined us as Chief
Financial Officer in February 2020. Prior to his appointment as our Chief Financial Officer, Mr.&nbsp;Sims held roles at several private equity-backed companies. Between 2012 and 2017, Mr.&nbsp;Sims was Chief Financial Officer of Amplify LLC, an
advisory and management consulting services firm. Following his time at Amplify, Mr.&nbsp;Sims served as Chief Financial Officer of Verbatim Support Services LLC, a litigation support company. His focus has been on mergers and acquisitions,
integrations, corporate capitalization, and building out and managing teams to support global growth. Previously, Mr.&nbsp;Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm. Working from both the Oxford,
England and New York offices, Mr.&nbsp;Sims audited and advised global public clients, including a variety of healthcare companies, with average annual revenues in excess of $1&nbsp;billion. Further, he was the lead partner on over 50 acquisitions
ranging from $5&nbsp;million to $4&nbsp;billion in purchase price. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. Mr.&nbsp;Sims is a graduate of Buckingham University in the United Kingdom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are no family relationships among any of our directors or executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 8
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc41684_2"></A>CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended December&nbsp;31, 2020: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Board held 4 meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the audit committee held 5 meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the compensation committee held 2 meetings; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the governance and nomination committee held 1 meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each member of the Board attended at least seventy-five percent (75%) or more of the aggregate of (i)&nbsp;the total number of
Board meetings held during the period of such member&#146;s service and (ii)&nbsp;the total number of meetings of committees of the Board on which such member served, during the period of such member&#146;s service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All Board members are encouraged to attend our annual meetings of stockholders in person. However, in 2020, our stockholder
meeting was held virtually due to <FONT STYLE="white-space:nowrap">COVID-19</FONT> and thus only Dr.&nbsp;Hedrick, who is also our CEO, attended our 2020 Annual Meeting of Stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Board has determined that Mr.&nbsp;Clowes, Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson,</FONT> Mr.&nbsp;Hawkins, Dr.&nbsp;Lenk and Mr.&nbsp;Petersen are &#147;independent&#148; under the rules of the Nasdaq Stock Market and the SEC.
Under applicable SEC and Nasdaq rules, the existence of certain &#147;related person&#148; transactions above certain thresholds between a director and the Company are required to be disclosed and preclude a finding by the Board that the director is
independent. The Board has therefore deemed Dr.&nbsp;Hedrick, our President and Chief Executive Officer, as not independent, as a result of his employment with us during his tenure as one of our directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our bylaws and governance principles provide the Board with the flexibility to combine or separate the positions of Chairman
and Chief Executive Officer. Historically, these positions have been separate. Mr.&nbsp;Hawkins currently serves as the Chairman of our Board. Our Board believes that the separation of these positions strengthens the independence of our Board and
allows us to have a Chairman focused on the leadership of the Board while allowing our Chief Executive Officer to focus more of his time and energy on managing our operations. The Board currently believes this structure works well to meet the
leadership needs of the Board and of the Company. Dr.&nbsp;Hedrick, our President and Chief Executive Officer, has comprehensive industry expertise and is able to devote substantial time to the Company, and Mr.&nbsp;Hawkins, our Chairman, is able to
focus on longer term and strategic matters, and to provide related leadership to the Board. As a result, we do not currently intend to combine these positions; however a change in this leadership structure could be made if the Board determines it is
in the best long-term interests of stockholders based upon a departure of either our Chief Executive Officer or Chairman. For example, if the two roles were to be combined, we believe that the independence of the majority of our directors, and the
three fully independent Board committees, would provide effective oversight of our management and the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Board&#146;s Role in Risk Oversight
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board&#146;s role in risk oversight includes assessing and monitoring risks and risk management. The Board reviews
and oversees strategic, financial and operating plans and holds management responsible for identifying and moderating risk in accordance with those plans. The Board fulfills its risk oversight function by reviewing and assessing reports from members
of management on a regular basis regarding material risks faced by us and applicable mitigation strategy and activity. The reports cover the critical areas of operations, sales and marketing, development, regulatory and quality affairs, intellectual
property, clinical development, legal and financial affairs. The Board and its Committees (described below) consider these reports, discuss matters with management and identify and evaluate any potential strategic or operational risks, and
appropriate activity to address those risks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 9
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board has standing audit, compensation, and governance and nominating committees. All members of the compensation
committee, audit committee, and governance and nominating committee are independent directors under the applicable SEC and Nasdaq rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The compensation committee currently consists of Mr.&nbsp;Petersen and the compensation committee chair, Mr.&nbsp;Clowes. Each
of the members of our compensation committee is independent, as defined by Nasdaq, and is a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; as defined by rule <FONT STYLE="white-space:nowrap">16b-3(b)(3)(i)</FONT> of the
Exchange Act. The compensation committee chair is responsible for setting the compensation committee&#146;s calendar and meeting agenda. The charter of the compensation committee has been established and approved by the Board, and a copy of the
charter has been posted on our website at www.plustherapeutics.com under &#147;Investor Relations &#150; Governance.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The functions of the compensation committee include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and implementing compensation programs for our executive officers and other employees, subject to
the discretion of the full Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing base salary rates, benefits and other compensation matters for each of our officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity compensation plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the relationship between our performance and our compensation policies and assessing any risks
associated with such policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and advising the Board on director compensation matters and on regional and industry-wide
compensation practices and trends in order to assess the adequacy of our executive compensation programs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing compensation related disclosures with management and making a recommendation to the
Board regarding the inclusion of such disclosures in our annual proxy statement or Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as applicable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Chief Executive Officer attends some of the meetings of the compensation committee upon invitation, but does not
participate in the executive sessions of the compensation committee or in any discussions regarding Chief Executive Officer compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Audit Committee </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audit committee currently consists of Mr.&nbsp;Clowes, Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT>
and the audit committee chair, Mr.&nbsp;Petersen. The audit committee is comprised solely of independent directors, as defined by Nasdaq and applicable SEC rules, who meet the qualifications for audit committee membership under the Nasdaq rules. The
Board has determined that Mr.&nbsp;Petersen is an &#147;audit committee financial expert&#148; within the meaning of Item 407(d)(5) of SEC Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> The charter of the audit committee has been
established and approved by the Board, and a copy of the charter has been posted on our website at <U>www.plustherapeutics.com</U> under &#147;Investor Relations&#151;Governance.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The functions of the audit committee include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review management&#146;s and our independent auditor&#146;s report on their assessment of the effectiveness of
internal control over financial reporting as of the end of each fiscal year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting our auditors and reviewing the scope of the annual audit; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 10
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">resolving any disagreements between management and the auditor regarding financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving the audit fees and <FONT STYLE="white-space:nowrap">non-audit</FONT> fees to be paid to our
auditors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our financial accounting controls with the staff and the auditors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and monitoring management&#146;s enterprise risk management assessment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and the auditor, our audited financial statements including our
disclosures under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our earnings press releases as well as financial information and earnings guidance provided to
analysts and rating agencies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving our annual budget; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing all related person transactions which are required to be reported under applicable SEC regulations.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Governance and Nominating Committee </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our governance and nominating committee currently consists of Mr.&nbsp;Clowes, Dr.&nbsp;Lenk and the governance and nominating
committee chair, Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson.</FONT> The governance and nominating committee is comprised solely of independent directors, as defined by Nasdaq. The charter of the governance and nominating committee
has been established and approved by the Board, and a copy of the charter has been posted on our website at www.plustherapeutics.com under &#147;Investor Relations &#150; Governance.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The functions of the governance and nominating committee include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analyzing the expertise and experience of the Board and ensuring the membership of the Board consists of
persons with sufficiently diverse and independent backgrounds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting, evaluating and recommending to the Board individuals qualified to become members of
the Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the Board committee structure and recommending to the Board changes to such structure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and reassessing the adequacy of our Corporate Governance Guidelines and recommending any proposed
changes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the annual self-evaluations of the Board and Board committees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management disclosures in our annual proxy statement regarding director
independence; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing succession planning and processes for our Chief Executive Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the members of our compensation committee has ever been an executive officer or employee of ours. None of our executive
officers currently serve, or has served during the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one or more executive officers serving as a member of our Board or compensation
committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 11
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Nominations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Criteria for Board Membership </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The governance and nominating committee is responsible for annually reviewing the applicable skills and characteristics
required of Board nominees with the Board in the context of the current Board composition and our circumstances. In making its recommendations to the Board, the governance and nominating committee considers, among other things, the qualifications of
individual director candidates in light of the Board&#146;s membership criteria as set forth in our Corporate Governance Guidelines. The governance and nominating committee may utilize a variety of sources, including stockholder recommendations,
Board member recommendations, executive search firms, management recommendations or other reasonable means to identify director candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The governance and nominating committee considers candidates recommended by our Board and management, as well as candidates
submitted by our stockholders (as discussed below). Members of the Board or management who wish to recommend that a person be considered for Board membership are required to provide relevant qualifications and other information regarding the
prospective candidate to the governance and nominating committee along with their recommendations and reasons why they believe such person should be considered. The governance and nominating committee then reviews each of the proposed candidates and
determines whether or not to add such person to the proposed candidates list. In the event the Board determines to add an additional Board member, the Committee shall select candidates from this list in addition to candidates drawn from any search
firm that the Committee deems necessary to retain for this purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The criteria used in selecting Board candidates
include the candidate&#146;s integrity, business acumen, commitment, reputation among our various constituencies and communities, ability to make independent analytical inquiries, understanding of our business environment, and willingness to devote
adequate time to Board duties. The Board has also determined that gender and ethnic diversity of the Board will be an important factor in evaluation of candidates. There are no other <FONT STYLE="white-space:nowrap">pre-established</FONT>
qualifications, qualities or skills at this time that any particular director nominee must possess and nominees are not discriminated against on the basis of race, religion, national origin, sexual orientation, disability or any other basis
proscribed by law. The governance and nominating committee does not assign specific weights to any particular criteria, nor has it adopted specific requirements. Rather, the Board believes that the backgrounds and qualifications of the directors,
considered as a group, should provide a composite mix of experience, knowledge and abilities that will allow the Board to fulfill its responsibilities. The goal of the governance and nominating committee is to assemble a Board that brings a variety
of skills derived from high quality businesses and professional experience. The governance and nominating committee seeks to ensure that at least a majority of the directors are independent under Nasdaq rules, that members of the Company&#146;s
audit committee meet the financial literacy and sophistication requirements under the Nasdaq rules, and at least one of them qualifies as an &#147;audit committee financial expert&#148; under the rules of the SEC, and that members of the
compensation and governance and nominating committee meet applicable independence and other requirements under the Nasdaq rules and rules of the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stockholder Recommendations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The governance and nominating committee is responsible for the consideration of any director candidates recommended by security
holders. Any recommendations received from the security holders will be evaluated in the same manner that potential nominees suggested by Board members, management or other parties are evaluated. Any such recommendations should be submitted to the
governance and nominating committee c/o the Secretary of the Company and should include the following information: (a)&nbsp;all information relating to such recommended candidate as would be required to be disclosed for a director nominee pursuant
to Regulation 14A under the Exchange Act (including such person&#146;s written consent to being named in the proxy statement as a nominee and to serving as a director if elected) and as required for stockholder nominations of director candidates
pursuant to the Company&#146;s Amended and Restated Bylaws (&#147;Bylaws&#148;); (b) the names and addresses of the stockholders making the recommendation and the number of shares of the Company&#146;s common stock which are owned beneficially and
of record by such stockholders; and (c)&nbsp;other appropriate biographical information and a statement as to the qualification of the nominee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 12
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Communications with our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stockholders may contact an individual director, the Board as a group, or a specified Board committee or group, including the
independent directors as a group, by the following means: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mail:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chairman of the Board</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Plus Therapeutics, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4200
Marathon Blvd. Suite 200,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Austin, TX 78756</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CC: Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Email:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chairman@plustherapeutics.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each communication should specify the applicable addressee or addressees to be contacted as
well as the general topic of the communication. The Chairman of the Board will initially receive and process communications before forwarding them to the addressee. Communications also may be referred to other departments within the Company. The
Chairman of the Board generally will not forward to the directors a communication that he determines to be primarily commercial in nature or related to an improper or irrelevant topic, or that requests general information about us. Concerns about
questionable accounting or auditing matters or possible violations of the Plus Code of Business Conduct and Ethics should be reported pursuant to the procedures outlined in the Code of Business Conduct and Ethics, which is available on the
Company&#146;s website in the Investor Relations section under &#147;Corporate Governance Materials.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees,
including our principal executive officer, principal financial officer and principal accounting officer. This Code of Business Conduct and Ethics has been posted on our website at www.plustherapeutics.com. We intend to post amendments to this code,
or any waivers of its requirements, on our website at <U>www.plustherapeutics.com</U> under &#147;Investor Relations &#150; Governance,&#148; as permitted under SEC rules and regulations. To date, there have been no waivers under our Code of
Business Conduct and Ethics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, our Board believes that the level of director compensation should be based on time spent carrying out Board and
committee responsibilities and be competitive with comparable companies. In addition, the Board believes that a significant portion of director compensation should align director interests with the long-term interests of stockholders. The Board
makes changes in its director compensation practices only upon the recommendation of the compensation committee, and discussion and approval by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Board, following the compensation committee&#146;s recommendation, has approved the compensation of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors, as described below. The compensation of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors remains the same as in 2020. The compensation committee believes that our <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation remains aligned with director compensation practices at our peer companies while considering the ongoing cash constraints of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The cash component of our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation is as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$40,000 annual cash retainer for Board members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$30,000 annual cash retainer for the Chairman of the Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$25,000 annual cash retainer for the Chairman of the audit committee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$15,000 annual cash retainer for the Chairman of our compensation committee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$10,000 annual cash retainer for the Chairman of our governance and nominating committee; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$5,000 annual cash retainer for each <FONT STYLE="white-space:nowrap">non-Chairman</FONT> committee member.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 13
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each new director is also eligible for an initial option grant, upon
commencement of services, to purchase 40,000 shares of our common stock, vesting over two years in equal, annual installments as measured from the grant date. However, the grant of options for 40,000 shares to Messrs. Clowes and Lenk, and a portion
of the options granted to <FONT STYLE="white-space:nowrap">Mr.&nbsp;Es-Johansson</FONT> with respect to 34,000 shares were granted in June 2020 after the stockholders approved our 2020 Stock Incentive Plan because there were not enough shares
available under our 2014 Stock Incentive Plan prior to approval of the 2020 Stock Incentive Plan. Mr.&nbsp;Hawkins received an option grant to purchase 40,000 shares on June&nbsp;25, 2020 so that his outstanding equity incentives would be consistent
with the awards granted to the new directors. In addition, the options to purchase 40,000 shares granted to Messrs. Hawkins, Clowes and Lenk vest in equal monthly installments over the <FONT STYLE="white-space:nowrap">two-year</FONT> period
following grant, and the option to purchase 34,000 shares granted to <FONT STYLE="white-space:nowrap">Mr.&nbsp;Es-Johansson</FONT> vests in 19 equal monthly installments following grant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2020 Director Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes director compensation awarded to, earned by or paid to our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors who served on our Board during fiscal year 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Director
Name<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned</B><br><B>or&nbsp;Paid&nbsp;in&nbsp;Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Hawkins, Chairman<SUP STYLE="font-size:85%; vertical-align:top"> </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;84,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Howard Clowes<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">An van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lenk<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Petersen<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Hedrick is not included in this table as he is our chief executive officer and receives no extra
compensation for his service as a director. The compensation received by Dr.&nbsp;Hedrick in his capacity as our chief executive officer is set forth in the 2020 Summary Compensation Table and further described in the &#147;Narrative Disclosures to
Summary Compensation Table.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Amounts shown in this column represent the aggregate grant date fair value of stock option awards made
during 2020, calculated in accordance with Accounting Standards Codification, or ASC, Topic 718. See Note 2 to our consolidated financial statements appearing in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for a discussion
of the relevant assumptions used in calculating these amounts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The aggregate number of shares underlying outstanding option awards as of December&nbsp;31, 2020 was:
Mr.&nbsp;Hawkins, 40,000, shares; Mr.&nbsp;Clowes, 40,000 shares; Dr.&nbsp;van <FONT STYLE="white-space:nowrap">Es-Johansson,</FONT> 40,000 shares; Dr.&nbsp;Lenk, 40,000 shares; and Mr.&nbsp;Peterson, 40,000 shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Mr.&nbsp;Clowes and Dr.&nbsp;Lenk were appointed to the Board on April&nbsp;1, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Mr.&nbsp;Petersen was appointed to the Board on February&nbsp;14, 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 14
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc41684_3"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named executive officers, or NEOs, for fiscal year 2020 are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Marc H. Hedrick, M.D., our President and Chief Executive Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Andrew Sims, our Chief Financial Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investors are encouraged to read the compensation discussion below in conjunction with the compensation tables and related
notes, which include more detailed information about the compensation of our NEOs for 2020 and 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information concerning compensation earned during 2019 and 2020 for services rendered to us by
our NEOs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other</B><br><B>Compensation<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">294,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">322,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">838,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">867,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">348,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts in this column reflect the aggregate grant date fair value of stock options granted in the
applicable year. Pursuant to SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions computed in accordance with Topic 718. Assumptions used in the calculation of these amounts are
included in Note 13 to our consolidated financial statements included in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts in this column represent annual <FONT STYLE="white-space:nowrap">performance-based</FONT>
bonuses for 2020 and 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">This column includes life insurance premiums paid by the Company for each of the named executive officers.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Mr.&nbsp;Sims became our Chief Financial Officer on February&nbsp;6, 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the process of determining compensation for our NEOs, the compensation committee considers the current financial position of
the Company, the strategic goals of the Company, and the performance of each of our NEOs. The Committee retained Larry Setren&nbsp;&amp; Associates in February 2020, to perform an independent compensation review and to provide compensation research,
analysis and recommendations. In addition, from time to time, the compensation committee considers the various components (described below) of our compensation program for executives in relation to compensation paid by other public companies,
compensation data from Radford Global Life Sciences Survey and BIOCOM Total Rewards Survey, their historical review of all executive officer compensation, and recommendations from our Chief Executive Officer (other than for his own salary). The
compensation committee has the sole authority to select, compensate and terminate its external advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The compensation
committee utilizes the following components of compensation (described further below) to strike an appropriate balance between promoting sustainable and excellent performance and discouraging any excessive risk-taking behavior: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Base salary; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual bonuses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual long-term equity compensation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 15
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Personal benefits and perquisites; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Acceleration and severance agreements tied to changes in control of the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Base Salaries </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of our NEOs received base salary increases for 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Annual Bonuses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Target bonuses are reviewed annually and established as a percentage of the executives&#146; base salaries, generally based
upon seniority of the officer and targeted at or near the median of the peer group (with reference to our corporate compensation philosophy) and relevant survey data (including the Radford Global Life Sciences Survey and BIOCOM Total Rewards
Survey). Each year, the compensation committee establishes corporate and individual objectives and respective target percentages, taking into account recommendations from our Chief Executive Officer as it relates to executive positions other than
the Chief Executive Officer&#146;s compensation. Our Chief Executive Officer&#146;s target bonus is set by the compensation committee to align entirely with our overall corporate objectives. After each fiscal
<FONT STYLE="white-space:nowrap">year-end,</FONT> our Chief Executive Officer provides the compensation committee with a written evaluation showing actual performance as compared to corporate and/or individual objectives, and the compensation
committee uses that information, along with the overall corporate performance, to determine what percentage of each executive&#146;s bonus target will be paid out as a bonus for that year. Overall, the compensation committee seeks to establish the
corporate and individual functional goals to be highly challenging yet attainable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For 2020, the general corporate goals
approved by the Board (upon recommendation of the compensation committee for purposes of executive compensation) were determined by the compensation committee to account for 115% of the target cash bonus amount payable to Chief Executive Officer,
Dr.&nbsp;Hedrick, and 112.5% of the target cash bonus amount payable to Chief Financial Officer, Mr.&nbsp;Sims. The Company&#146;s general corporate objectives included clinical, financial and operational objectives (including the pipeline expansion
goals); the achievement of <FONT STYLE="white-space:nowrap">certain&nbsp;year-end&nbsp;cash</FONT> objectives, achievement of certain objectives regarding the Company&#146;s outstanding loan and the raising of capital; and various operational
objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Hedrick&#146;s target bonus for 2020 as a percentage of base salary was 55% (unchanged from 2019).
Mr.&nbsp;Sims&#146; target bonus for 2020 as a percentage of base salary was 30%. In February 2021, the compensation committee evaluated our achievement and results in 2020 as compared to the overall corporate and individual objectives for
Dr.&nbsp;Hedrick and Mr.&nbsp;Sims and the results are tabulated in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Officer and Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target&nbsp;Bonus</B><br><B>as a % of<BR>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of&nbsp;Target</B><br><B>Bonus<BR>Awarded</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus&nbsp;Awarded</B><br><B>as % of</B><br><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;of&nbsp;2020</B><br><B>Bonus Payable</B><br><B>in 2021<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">322,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President&nbsp;&amp; Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.38</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The 2020 bonus amounts are payable in 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The target bonus (as a percentage of base salary) for Dr.&nbsp;Hedrick for fiscal year 2021 remains unchanged from the 2020
target bonus described above. The target bonus for Mr.&nbsp;Sims for fiscal year 2021 increased to 35% from the 2020 target bonus described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Long-Term Equity Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We designed our long-term equity grant program to further align the interests of our executives with those of our stockholders
and to reward the executives&#146; longer-term performance. Historically, the compensation committee has granted stock options, although from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time,</FONT></FONT> to further
increase the emphasis on compensation tied to performance, the compensation committee may grant other equity awards as allowed by the 2020 Stock Incentive Plan. The compensation committee may grant stock options, restricted stock, restricted stock
units and similar equity awards permitted under our plans based on its judgment as to whether the complete compensation packages to our executives, including prior equity awards, are appropriate and sufficient to retain and incentivize the
executives and whether the grants balance long-term versus short-term compensation. The compensation committee also considers our overall performance as well as the individual performance of each of our NEOs, the potential dilutive effect of
restricted stock awards, the dilutive and overhang effect of the equity awards, and recommendations from the Chief Executive Officer (other than with respect to his own equity awards). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 16
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock options are granted with an exercise price equal to the fair market
value of our common stock on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the year ended December&nbsp;31, 2020, our Chief Executive Officer
was awarded a stock option covering 140,000 shares and our Chief Financial Officer was awarded a stock option covering 40,000 shares. No stock options were awarded to our NEOs during the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Personal Benefits and Perquisites </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of our executives are eligible to participate in our employee benefit plans, including medical, dental, vision, life
insurance, short-term and long-term disability insurance, flexible spending accounts, 401(k), and an Employee Stock Purchase Program (the &#147;ESPP&#148;). These plans are available to all full-time employees. In keeping with our philosophy to
provide total compensation that is competitive within our industry, we offer limited personal benefits and perquisites to executive officers. You can find more information on the amounts paid for these perquisites to or on behalf of our NEOs in our
2020 Summary Compensation Table. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outstanding Equity Awards at December&nbsp;31, 2020 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information regarding outstanding equity awards held by our NEOs as of December&nbsp;31, 2020.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Grant<BR>Date <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options</B><br><B>(#)</B><br><B>Exercisable<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of&nbsp;Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options</B><br><B>(#) Un-</B><br><B>Exercisable<SUP
STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Exercise</B><br><B>Price</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/26/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/26/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/31/2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/31/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/31/2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/31/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/11/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/11/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/21/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/21/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/30/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/30/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/04/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/04/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/08/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/08/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/25/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/25/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2/06/2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2.23</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2/06/2030</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For a better understanding of this table, we have included an additional column showing the grant date of
the stock options. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 17
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless otherwise provided, unvested stock options are subject to four-year vesting (from the grant date),
and all stock options have a contractual term of 10 years from the date of grant. Awards presented in this table contain one of the following two vesting provisions: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">With respect to an initial stock option grant to an employee, 25% of the shares subject to the award vest on
the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting start date, while an additional 1/48th of the remaining option shares vest at the end of each month thereafter for 36 consecutive months, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">With respect to stock option grants made to an employee after one full year of employment, 1/48th of the
shares subject to the award vest at the end of each month over a four-year period, as measured from the vesting start date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">We consummated a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-15</FONT></FONT>
reverse stock split in May 2016, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-10</FONT></FONT> reverse stock split in May 2018 and a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-50</FONT></FONT> reverse stock split in August 2019. The amounts set forth in this column reflect these three reverse stock splits. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Our Named Executive Officers and our Chief Financial Officer and Potential Payments Upon Termination or Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Below are descriptions of the employment agreements and offer letter agreements with our named executive officers and current
chief financial officer. The agreements with our current executive officers generally provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment and set forth the executive officer&#146;s initial base salary and eligibility for employee
benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with Marc H. Hedrick, M.D. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;11, 2020, we entered into an Executive Employment Agreement with Dr.&nbsp;Hedrick which was amended and restated
on May&nbsp;13, 2020 (the &#147;Hedrick Employment Agreement&#148;). Pursuant to the terms of the Hedrick Employment Agreement, Dr.&nbsp;Hedrick receives an initial annual base salary of $510,000 and is eligible to receive an initial annual target
bonus of 55% of his base salary. Dr.&nbsp;Hedrick is also eligible to participate in, subject to applicable eligibility requirements, all of our benefit plans and fringe benefits and programs that may be provided to our executives from time to time.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreement with Andrew Sims </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;11, 2020, we entered into an Executive Employment Agreement with Mr.&nbsp;Sims, which was amended and restated on
May&nbsp;13, 2020 (the &#147;Sims Employment Agreement&#148; and, together with the Hedrick Employment Agreement, the &#147;Executive Employment Agreements&#148;) with Mr.&nbsp;Sims. Pursuant to the terms of the Amended and Restated Sims Employment
Agreement, Mr.&nbsp;Sims receives an initial annual base salary of $260,000 and is eligible to receive an initial annual target bonus of 30% of his base salary. Mr.&nbsp;Sims is also eligible to participate in, subject to applicable eligibility
requirements, all of our benefit plans and fringe benefits and programs that may be provided to our executives from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential
Payments upon Termination or Change of Control </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Hedrick </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the terms of the Hedrick Employment Agreement, if Dr.&nbsp;Hedrick is terminated without cause or resigns for good
reason (each as defined in the Hedrick Employment Agreement), provided he signs and does not revoke a general release of claims in favor of the Company, Dr.&nbsp;Hedrick is eligible to receive an amount equal to twelve months of his base salary,
plus an amount equal to his target bonus for the year in which the termination occurs, plus the annual bonus earned for the prior calendar year if not yet paid as of the date of termination, plus an amount equal to twelve months of the premiums
Dr.&nbsp;Hedrick is required to pay under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;COBRA&#148;) to continue coverage for him and his eligible dependents under our group health plans, with the aggregate amount
paid in a lump sum within ten days following the effective date of the release of claims, and an additional twelve months of accelerated vesting of his outstanding equity awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 18
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If Dr.&nbsp;Hedrick is terminated without cause or resigns for good reason
within the period beginning on the date the Company and an acquiror formally or informally agree on the terms of a transaction which, if consummated, would constitute a change in control (as defined in the Hedrick Employment Agreement) and ending on
the closing date of the change in control, or within twelve months following a change in control, provided he signs and does not revoke a general release of claims in favor of the Company, Dr.&nbsp;Hedrick is eligible to receive the same payments
and benefits as set forth above, paid in a lump sum within ten days following the later of the effective date of the release and the date of the change in control, except the amount of the salary payment will be increased to 18 months of the greater
of his base salary in effect immediately prior to the date of termination and his base salary in effect on the date the terms of a transaction that results in a change in control are agreed to, the amount of the COBRA payment will be increased to 18
months of COBRA premiums, any remaining unvested equity incentive awards will become fully vested on the later of the date of termination and the date of the change in control and Dr.&nbsp;Hedrick will be eligible to exercise the equity incentive
awards granted to him on or after May&nbsp;13, 2020 until the latest of three months after Dr.&nbsp;Hedrick&#146;s termination of employment, three months following the change in control with respect to any equity incentive awards that become
exercisable upon a change in control due to this acceleration in connection with the change in control, and any longer period specified in Dr.&nbsp;Hedrick&#146;s award agreements (but not beyond the original expiration date of any equity incentive
award). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the vesting and exercisability of Dr.&nbsp;Hedrick&#146;s outstanding equity incentive awards will
be fully accelerated on the date of a change in control if he remains employed with the Company as of the closing of the change in control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Mr.&nbsp;Sims </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the terms of the Sims Employment Agreement, if Mr.&nbsp;Sims is terminated without cause or resigns for good reason
(each as defined in the Sims Employment Agreement), provided he signs and does not revoke a general release of claims in favor of the Company, Mr.&nbsp;Sims is eligible to receive an amount equal to twelve months of his base salary, plus an amount
equal to his target bonus for the year in which the termination occurs, plus the annual bonus earned for the prior calendar year if not yet paid as of the date of termination, plus an amount equal to twelve months of the COBRA premiums Mr.&nbsp;Sims
is required to pay to continue coverage for him and his eligible dependents under our group health plans, with the aggregate amount paid in a lump sum within ten days following the effective date of the release of claims, and an additional nine
months of accelerated vesting of his outstanding equity awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If Mr.&nbsp;Sims is terminated without cause or resigns
for good reason within the period beginning on the date the Company and an acquiror formally or informally agree on the terms of a transaction which, if consummated, would constitute a change in control (as defined in the Sims Employment Agreement)
and ending on the closing date of the change in control, or within twelve months following a change in control, provided he signs and does not revoke a general release of claims in favor of the Company, Mr.&nbsp;Sims is eligible to receive the same
payments and benefits as set forth above, paid in a lump sum within ten days following the later of the effective date of the release and the date of the change in control, except the amount of the salary payment will be based on the greater of his
base salary in effect immediately prior to the date of termination and his base salary in effect on the date the terms of a transaction that results in a change in control are agreed to, any remaining unvested equity incentive awards will become
fully vested on the later of the date of termination and the date of the change in control and Mr.&nbsp;Sims will be eligible to exercise the equity incentive awards granted to him on or after May&nbsp;13, 2020 until the latest of three months after
Mr.&nbsp;Sims&#146; termination of employment, three months following the change in control with respect to any equity incentive awards that become exercisable upon a change in control due to this additional acceleration in connection with the
change in control, and any longer period specified in Mr.&nbsp;Sims&#146; award agreements (but not beyond the original expiration date of any equity incentive award). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the vesting and exercisability of Mr.&nbsp;Sims&#146; outstanding equity incentive awards will be fully
accelerated on the date of a change in control if he remains employed with the Company as of the closing of the change in control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 19
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plan Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table gives information as of December&nbsp;31, 2020 about shares of our common stock that may be issued upon the
exercise of outstanding options, warrants and rights and shares remaining available for issuance under all of our equity compensation plans: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities<BR>to be Issued upon<BR>exercise of<BR>outstanding options,<BR>warrants and rights<BR>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise price of<BR>outstanding<BR>options, warrants<BR>and rights</B><br><B>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities<BR>remaining available<BR>for future issuance<BR>under equity<BR>compensation plans<BR>(excluding securities<BR>reflected
in<BR>column(a)) (c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">490,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">531,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">370,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents (i)&nbsp;options outstanding that were issued under the 2004 Stock Option and Stock Purchase Plan
which plan expired in August 2014, (ii) the 2015 New Employee Incentive Plan.. For more information, see &#147;Material Features of the Amended and Restated 2015 New Employee Incentive Plan and the 2020 Stock Incentive Plan&#148; provided in our
annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;22, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents awards outstanding under our 2014 Equity Incentive Plan and 2020 Stock Incentive Plan. See Notes
to the Consolidated Financial Statements included with our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on February&nbsp;22, 2021 for a description of our 2020 Stock Incentive Plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 20
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc41684_4"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information regarding ownership of our common stock as of February&nbsp;24, 2021 (or
earlier date for information based on filings with the SEC) by (a)&nbsp;each person known to us to own more than 5% of the outstanding shares of our common stock, (b)&nbsp;each director, (c)&nbsp;our Chief Executive Officer and our Chief Financial
Officer who constitute our named executive officers and (e)&nbsp;all current directors and executive officers as a group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe, based on information provided to us or based on filings with the SEC, that each of the stockholders listed below
has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. A total of 9,221,902 shares of our common stock were issued and
outstanding as of March&nbsp;22, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner <SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares of</B><br><B>Common<BR>Stock</B><br><B>Owned<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B><br><B>of Common Stock</B><br><B>Subject to</B><br><B>Awards/Warrants</B><br><B>Exercisable&nbsp;Within</B><br><B>60 Days
of<BR>March&nbsp;22, 2021<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Number<BR>of&nbsp;Shares
of</B><br><B>Common&nbsp;Stock</B><br><B>Beneficially</B><br><B>Owned<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B><br><B>Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Greater than 5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hudson Bay Capital Management LP<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">530,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">530,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Howard Clowes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">An van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Hawkins</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Petersen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert P. Lenk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All current executive officers and directors as a group (7 persons)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents beneficial ownership of less than one percent (1%) of the outstanding shares as of March&nbsp;22,
2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless otherwise indicated, the address of each of the individuals is c/o Plus Therapeutics, Inc., 4200
Marathon Blvd. Suite 200, Austin, TX 78756. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless otherwise indicated, represents shares of outstanding common stock owned by the named parties as of
March&nbsp;22, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Shares of common stock subject to stock options or warrants currently exercisable or exercisable within 60
days of March&nbsp;22, 2021 are deemed to be outstanding for computing the percentage ownership of the person holding such options and the percentage ownership of any group of which the holder is a member, but are not deemed outstanding for
computing the percentage of any other person or group. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts and percentages of common stock beneficially owned are reported on the basis of regulations of
the SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a &#147;beneficial owner&#148; of a security if that person has or shares &#147;voting power,&#148; which includes the
power to vote or to direct the voting of such security, or &#147;investment power,&#148; which includes the power to dispose of or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities for
which that person has a right to acquire beneficial ownership within 60 days. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Based solely on information reported on a Schedule 13G filed by Hudson Bay Capital Management LP and Sander
Gerber (together, &#147;Hudson&#148;) on February&nbsp;10, 2021. Mr.&nbsp;Gerber serves as the managing member of the general partner of Hudson Bay Capital Management LP. The principal business address of Hudson is 777 Third Avenue, 30th Floor, New
York, NY 10017. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 21
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc41684_5"></A>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have adopted a Related Person Transactions Policy that sets forth our policies and procedures regarding the identification,
review, consideration, and oversight of &#147;related person transactions.&#148; For purposes of our policy only, a &#147;related person transaction&#148; is a transaction, arrangement, or relationship (or any series of similar transactions,
arrangements or relationships) in which we or any of our subsidiaries are participants involving an amount that exceeds $120,000, in which any &#147;related person&#148; has a material interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Transactions involving compensation for services provided to us as an employee, consultant, or director are not considered
related person transactions under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than 5% of any class of our voting securities (including our common stock), including any of their
immediate family members and affiliates, including entities owned or controlled by such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the policy, the
related person in question or, in the case of transactions with a holder of more than 5% of any class of our voting securities, an officer with knowledge of the proposed transaction, must present information regarding the proposed related person
transaction to our audit committee (or, where review by our audit committee would be inappropriate, to another independent body of our Board) for review. To identify related person transactions in advance, we rely on information supplied by our
executive officers, directors, and certain significant stockholders. In considering related person transactions, our audit committee considers the relevant available facts and circumstances, which may include, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs, and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on a director&#146;s independence in the event the related person is a director, immediate family
member of a director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audit committee will approve only those transactions that it determines are fair to us and in our best interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following includes a summary of any related party transactions since January&nbsp;1, 2020 to which we have been a
party.&nbsp;We also describe below certain other transactions with our directors, executive officers and 5% stockholders. We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions
described below were comparable to terms available or the amounts that would be paid or received, as applicable, from unaffiliated third parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Director and Officer Indemnification </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation, as amended, and our amended and restated bylaws, as amended, provide
that we will indemnify each of our directors and officers to the fullest extent permitted by the Delaware General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 22
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Option Grants to Executive Officers and Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into employment agreements with our executive officers pursuant to which we pay our executive officers annual
salaries and bonuses as more fully described above under &#147;Executive Compensation.&#148; Further, we have granted stock options to our executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as more fully described
above under &#147;Director Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The information under the heading &#147;Board Independence&#148; in this
Proxy Statement is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 23
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc41684_6"></A>AUDIT MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report of the Audit Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The
following report of the audit committee does not constitute soliciting material and shall not be deemed filed or incorporated by reference into any other filing by Plus Therapeutics, Inc. under the Securities Act or the Exchange Act, whether made
before or after the date hereof and irrespective of any general incorporation language in any such filing. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The audit
committee is a committee of the Board comprised solely of independent directors as required by the listing standards of Nasdaq and rules and regulations of the SEC. The audit committee provides assistance to the Board in fulfilling its legal and
fiduciary obligations in matters involving the Company&#146;s accounting, auditing, financial reporting, internal control and legal compliance functions by approving the services performed by the Company&#146;s independent registered public
accountants and reviewing their reports regarding the Company&#146;s accounting practices and systems of internal accounting controls as set forth in a written charter adopted by the Board, which is available on the Company&#146;s website at
<I>www.plustherapeutics.com</I>. The composition and responsibilities of the audit committee, as reflected in its charter, are intended to be in accordance with applicable requirements. The audit committee reviews and assesses the adequacy of its
charter and the audit committee&#146;s performance on an annual basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s management is responsible for
preparing the Company&#146;s financial statements and the independent registered public accountants are responsible for auditing those financial statements. The audit committee is responsible for overseeing the conduct of these activities by the
Company&#146;s management and the independent registered public accountants. In this context, the audit committee has met and held discussions with management and the independent registered public accountants. Management represented to the audit
committee that the Company&#146;s consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles, and the audit committee has reviewed and discussed the consolidated financial statements with
management and the independent registered public accountants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The audit committee has discussed with the independent
registered public accountants matters required to be discussed by Auditing Standard No.&nbsp;1301, as adopted by the Public Company Accounting Oversight Board (&#147;PCAOB&#148;) and approved by the SEC. In addition, the independent registered
public accountants provided to the audit committee the written disclosures and letter from the independent registered public accountants as required by applicable requirements of the PCAOB regarding the independent registered public
accountants&#146; communications with the audit committee concerning independence and the audit committee has discussed with such accountants such accountants&#146; independence from the Company and its management. The audit committee has discussed
with management and the independent registered public accounts the procedures for selection of consultants, fully considered whether those services provided by the independent registered public accountants are compatible with maintaining such
accountants&#146; independence and have determined that the <FONT STYLE="white-space:nowrap">non-audit</FONT> services performed by the independent registered public accountant are compatible with maintaining their independence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The audit committee has discussed with the Company&#146;s management and its independent registered public accountants, with
and without management present, their evaluations of the Company&#146;s internal accounting controls and the overall quality of the Company&#146;s financial reporting. In reliance on the reviews and discussions with management and the independent
registered public accountants referred to above, the audit committee recommended to the Board, and the Board has approved, the inclusion of the audited financial statements in the Company&#146;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2020, for filing with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the audit committee has selected BDO USA, LLP as independent registered public accountants to audit the books,
records and accounts of the Company and its subsidiaries for the fiscal year ending December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Respectfully submitted, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Greg Petersen, Chairman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Howard Clowes </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An van <FONT STYLE="white-space:nowrap">Es-Johansson</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 24
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc41684_7"></A>PROPOSAL #2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audit committee has selected BDO USA, LLP (&#147;BDO&#148;), as our independent registered public accounting firm for the
fiscal year ending December&nbsp;31, 2021 and has further directed that we submit the selection of the independent registered public accounting firm for ratification by our stockholders at the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">BDO has served as our independent registered public accounting firm since July 2016. The selection of the independent
registered public accounting firm is not required to be submitted for stockholder approval. However, if the stockholders do not ratify this selection, the audit committee will reconsider its selection of BDO. Even if the selection is ratified, our
audit committee may direct the appointment of a different independent accounting firm at any time during the year if the audit committee determines that the change would be in the Company&#146;s best interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Representatives of BDO will be available at the Annual Meeting and will have an opportunity to make a statement if they desire
to do so and will be available to respond to appropriate questions from stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional information concerning
the audit committee and BDO can be found in the &#147;Audit Matters&#148; section of this Proxy Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal Accountant Fees and Services
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On July&nbsp;12, 2016, the audit committee appointed BDO USA, LLP, or BDO, as our independent registered public
accounting firm for the fiscal year ending December&nbsp;31, 2016, subject to completion of its standard client acceptance procedures (which were subsequently completed). Additionally, the audit committee appointed BDO as our independent public
accounting firm for the fiscal years ending December&nbsp;31, 2017, December&nbsp;31, 2018, December&nbsp;31, 2019, and December&nbsp;31, 2020. The decision to engage BDO as our independent registered public accounting firm was recommended by the
audit committee and approved by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The audit committee reviews and must
<FONT STYLE="white-space:nowrap">pre-approve</FONT> all audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services performed by our independent registered public accounting firm, as well as the fees charged by it for such services. No fees
charged by BDO during 2020 were approved under the Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> Rule 2.01(c)(7)(i)(C) exception to the <FONT STYLE="white-space:nowrap">pre-approval</FONT> requirement. In its review of <FONT
STYLE="white-space:nowrap">non-audit</FONT> service fees, the audit committee considers, among other things, the possible impact of the performance of such services on the accounting firm&#146;s independence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the aggregate fees paid or accrued by us for the audit and other services provided by BDO for fiscal
years ended December&nbsp;31, 2020 and 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">368,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">383,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Related Fees<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">402,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">417,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Audit fees consist of fees for professional services performed by BDO USA, LLP for the audit of the
financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and review of the financial statements included in our quarterly Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filings, reviews of
registration statements and issuances of consents, and services that are normally provided in connection with statutory and regulatory filings or engagements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Audit related fees consist of fees for assurance and related services, performed by BDO USA, LLP that are
reasonably related to the performance of the audit or review of our financial statements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Tax fees consist of fees for professional services performed by BDO USA, LLP with respect to tax compliance,
tax advice, tax consulting and tax planning. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 25
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The proposal to ratify the appointment of BDO requires the affirmative vote of a majority of the common stock present in person
or represented by proxy at the Annual Meeting. Abstentions are considered present and entitled to vote with respect to this proposal and will, therefore, be treated as votes against this proposal. Because brokers have discretionary authority to vote
on this proposal, we do not expect any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> in connection with this proposal. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR
BOARD UNANIMOUSLY RECOMMENDS A VOTE &#147;FOR&#148; THE RATIFICATION OF THE SELECTION OF BDO USA, LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR 2021</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 26
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc41684_8"></A>PROPOSAL #3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL TO APPROVE THE AMENDMENT AND RESTATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF THE 2020 STOCK INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;22, 2021, our Board approved the amended and restated 2020 Stock Incentive Plan (the &#147;Amended Plan&#148;),
subject to the approval of our stockholders at the Annual Meeting. We refer to the 2020 Stock Incentive Plan that was approved by our stockholders at our 2020 annual meeting of stockholders in this proposal as the &#147;Plan.&#148; The Board is
requesting stockholder approval of the Amended Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board believes that equity awards are a key element underlying
its ability to retain, recruit and motivate key personnel who are critical to our ability to execute successfully and implement our growth plans. After reviewing the Plan, the Board has determined that the current share reserve available for awards
under the Plan is insufficient and limits the Board&#146;s ability to provide equity incentives that align the interests of our directors, executives and employees with those of our stockholders and limits our ability to attract and retain talented
personnel. Approval of the Amended Plan by our stockholders will allow us to grant stock options, restricted stock unit awards and other awards at levels determined appropriate by our Board or Compensation Committee. The Amended Plan contains the
following material changes from the Plan: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common
stock that may be issued under the Amended Plan has been increased by 1,000,000 shares, from 650,781 shares to 1,650,781 shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subject to adjustment for certain changes in our capitalization, the number of shares of our common stock
issuable under the Amended Plan as incentive stock options (ISOs) has been increased to 4,952,343 shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Amended Plan extends the period during which ISOs can be granted through 10 years following the date the
Amended Plan was approved by the Board. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following summary of the principal features of the Amended
Plan is qualified by reference to the terms of the Amended Plan, a copy of which is available without charge upon stockholder request to Secretary, Plus Therapeutics, Inc., 4200 Marathon Blvd., Suite 200, Austin, TX 78756. The Amended Plan has also
been filed electronically with the Securities and Exchange Commission together with this Proxy Statement as Appendix A and can be accessed on the SEC&#146;s web site at http://www.sec.gov. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation and Governance Best Practices </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Amended Plan approved by our Board and submitted for stockholder approval includes an increase in the number of shares
available for issuance of equity incentive awards by the Company by 1,000,000 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Amended Plan contains the following important
compensation and governance best practices: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No single trigger accelerated vesting upon change in control. The Amended Plan does not provide for automatic
vesting of awards upon a change in control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No liberal change in control definition. The change in control definition in the Amended Plan is not a
&#147;liberal&#148; definition. A change in control transaction must actually occur in order for the change in control provisions in the Amended Plan to be triggered. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No discounted stock options or stock appreciation rights. All stock options and stock appreciation rights
granted under the Amended Plan must have an exercise or strike price equal to or greater than the fair market value of a share of our common stock on the date the stock option or stock appreciation right is granted. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 27
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Administration by independent committee. The Amended Plan will be administered by the members of the
compensation committee, all of whom are <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> under the Exchange Act and &#147;independent&#148; within the
meaning of the Nasdaq listing standards. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Material amendments require stockholder approval. Consistent with Nasdaq rules and regulations, the Amended
Plan requires stockholder approval of any material revisions to the Amended Plan. In addition, certain other amendments to the Amended Plan require stockholder approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Repricing not permitted. Repricing of stock options and cancellation of stock options with an exercise price
greater than the current fair market value of a share in return for cash or the grant of new stock options or other awards is prohibited without stockholder approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No liberal share recycling. Liberal share recycling is not allowed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Limitations on dividends and dividend equivalents. Dividends and dividend equivalents on shares and awards
that have not vested and accrued dividends are not paid under the Amended Plan until the underlying shares vest. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Awards subject to clawback. There is a robust clawback provision under the Amended Plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Limit on <FONT STYLE="white-space:nowrap">non-employee</FONT> director awards and other awards. The sum of any
cash compensation and the value of awards (calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting purposes) granted to <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors as compensation for services during any calendar year may not exceed $500,000, or $700,000 in the calendar year of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial service as a director).
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why We Are Asking Our Stockholders to Approve the Amended Plan </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Equity incentives are key to retaining key talent to drive our business forward. </I>The Board believes
that equity awards are a key element underlying our ability to retain, recruit and motivate key personnel who are critical to our ability to execute successfully through this time of transition for our Company and implement our business plan to
develop our pipeline of therapeutics. Equity awards align the interests of our key personnel with those of our stockholders and are a substantial contributing factor to our success and the future growth of our business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Current shares available for awards are inadequate. </I>We believe that the shares currently available for
grant under the Plan will be insufficient to meet our anticipated retention and recruiting needs. Awards may only be granted to new employees under the 2015 New Employee Incentive Plan as a material inducement to accepting an offer of employment. As
of March&nbsp;31, 2021, there were no shares available for future grant under the Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information regarding Equity Incentive
Program, Dilution and Overhang </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides certain information regarding our equity incentive program: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>March&nbsp;31,&nbsp;2021</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock subject to outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">691,263</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average exercise price of outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$7.82</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining term of outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9.33 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock subject to outstanding full value awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock available for grant under the Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock available for grant under the 2015 New Employee Incentive
Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">210,389</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total number of shares of common stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10,180,525</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Per-share</FONT> closing
price of common stock as reported on the Nasdaq Capital Market</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$2.40</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 28
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To provide the Company the flexibility to responsibly address our future
equity compensation needs, we are requesting that stockholders approve the Amended Plan to make an additional 1,000,000 shares available for grant. Grant levels for the preceding three fiscal years have averaged 178,382 shares per year. After giving
effect to a new grant authority of 1,000,000 shares, the pro forma overhang percentage (see footnote 3 below) as of March&nbsp;31, 2021 would be 15.7%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows our key dilution metrics over the last three years: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Key Equity Metrics</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Year<BR>Average</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Equity Burn Rate<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.96</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.06</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.87</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Overhang<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.05</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.79</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.82</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Net Equity Burn Rate is calculated by dividing the number of shares subject to equity awards granted during
the year, minus shares subject to awards that were cancelled or forfeited during the year, by the weighted average number of shares outstanding during the year. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Dilution is calculated by dividing the number of shares subject to equity awards outstanding at the end of
the year by the number of shares outstanding at the end of the year. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Overhang is calculated by dividing (a)&nbsp;the sum of (i)&nbsp;the number of shares subject to equity
awards outstanding at the end of the year and (ii)&nbsp;the number of shares available for future grants by (b)&nbsp;the sum of (i)&nbsp;the number of shares outstanding at the end of the year and (ii)&nbsp;the number of shares subject to equity
awards outstanding at the end of the year and (iii)&nbsp;the number of shares available for future grants. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">When considering the number of shares authorized for issuance under the Amended Plan, the compensation committee reviewed,
among other things, the potential dilution to the Company&#146;s current stockholders as measured by burn rate, dilution and overhang, projected future share usage and projected future forfeitures. The projected future usage of shares for long-term
incentive awards under the Amended Plan was reviewed under scenarios based on a variety of assumptions. The compensation committee is committed to effectively managing the number of shares reserved for issuance under the Amended Plan while
minimizing stockholder dilution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 29
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the 2020 Stock Incentive Plan, as amended and restated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purpose </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
purpose of the Amended Plan is to assist management in the recruitment, retention and motivation of employees, outside directors and consultants who are in a position to make material contributions to our
<FONT STYLE="white-space:nowrap">long-term</FONT> success and the creation of stockholder value. The Amended Plan offers a significant incentive to encourage our employees, outside directors and consultants by enabling those individuals to acquire
shares of our common stock, thereby increasing their proprietary interest in the growth and success of our Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Types of Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Amended Plan provides for the direct award or sale of shares of common stock (including restricted stock), the award of
stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock intended to qualify for preferential tax treatment under Section&nbsp;422 of the Internal Revenue Code of 1986 (the &#147;Code&#148;)
and nonstatutory stock options to purchase common stock that do not qualify for such treatment under the Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eligibility </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All employees (including officers) and directors of the Company or any subsidiary and any consultant who performs services for
the Company or a subsidiary are eligible to purchase shares of common stock and to receive awards of shares or grants of nonstatutory stock options, stock units and stock appreciation rights. Only employees are eligible to receive grants of
incentive stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, we (including our affiliates) had approximately 13 employees, 5
consultants and 5 <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Amended Plan is administered by the compensation committee of our Board. Subject to the limitations set forth in the
Amended Plan, the compensation committee has the authority to determine, among other things, to whom awards will be granted, the number of shares subject to awards, the term during which an option, stock unit or stock appreciation right may be
exercised and the rate at which the awards may vest or be earned, including any performance criteria to which they may be subject. The compensation committee also has the authority to determine the consideration and methodology of payment for
awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The compensation committee, our Board and any of their designees do not have the authority to: (i)&nbsp;amend the
terms of outstanding option or stock appreciation right to reduce its exercise price, or (ii)&nbsp;cancel outstanding options or stock appreciation rights with an exercise price above the then-current fair market value per share in exchange for
another option, stock appreciation right or other award, unless the stockholders of the Company have previously approved such an action or the action relates to a capitalization adjustment under the terms of the Amended Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shares Available for Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common stock that may be
issued under the Amended Plan will not exceed 1,650,781 shares, which is the sum of (i) 1,000,000 new shares, plus (ii) 550,000 shares approved at our 2020 Annual Meeting of stockholders plus (iii)&nbsp;the number of unallocated shares remaining
available for grant under the Plus Therapeutics, Inc. 2014 Equity Incentive Plan, as amended (the &#147;2014 Plan&#148;) as of the effective date of the Plan, plus (iv)&nbsp;the Predecessor Plan&#146;s Returning Shares (as defined below), as such
shares become available from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The term &#147;Predecessor Plan&#146;s Returning Shares&#148; refers to the
following shares of our common stock subject to any outstanding stock award granted under the 2014 Plan: (i)&nbsp;any shares subject to such stock award that are not issued because such stock award expires or otherwise terminates without all of the
shares covered by such stock award having been issued, and (ii)&nbsp;any shares issued pursuant to such stock award that are forfeited back to us because of a failure to vest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 30
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares that may be delivered in the aggregate pursuant to the
exercise of incentive stock options granted under the Amended Plan will not exceed 4,952,343 shares plus, to the extent allowable under Section&nbsp;422 of the Code, any shares that become available for issuance under the Plan discussed below as a
result of forfeiture or termination of awards. These limitations, and the terms of outstanding awards, shall be adjusted as appropriate and equitable in the event of a stock dividend, stock split, reclassification of stock or similar events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If stock units, options, or stock appreciation rights are forfeited or terminate for any other reason before being settled or
exercised, or if restricted shares are forfeited, then the corresponding shares will again become available for awards under the Amended Plan. If stock units are settled or stock appreciation rights are exercised, then only the number of shares
settled or exercised shall reduce the number of shares available under the Amended Plan.&nbsp;Shares withheld to satisfy the grant price or exercise price or tax withholding obligation pursuant to an award will not again become available for awards
under the Amended Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> Director Compensation Limit </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Amended Plan, the sum of any cash compensation, or other compensation, and the value (determined as of the grant date
in accordance with Financial Accounting Standards Board Accounting Standards Codification of Topic 718, or any successor thereto) of awards granted to any of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as compensation for
services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director during any calendar year of the Company may not exceed $500,000 (increased to $700,000 in the calendar year of his or her initial service). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
terms of any grants of stock options under the Amended Plan will be set forth in a stock option agreement to be entered into between the Company and the recipient. The compensation committee will determine the terms and conditions of such option
grants, which need not be identical. The compensation committee may modify, extend or renew outstanding options but the compensation committee may not modify outstanding options to lower the exercise price or cancel options in exchange for cash or
for options or stock appreciation rights with a lower exercise price, other than in connection with a corporate transaction, without stockholder approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The exercise price of each option will be set by the compensation committee, subject to the following limits. The exercise
price of an incentive stock option cannot be less than 100% of the fair market value of a share of common stock on the date the option is granted, and in the event an option recipient is deemed to be a 10% owner of our Company or one of our
subsidiaries, the exercise price of an incentive stock option cannot be less than 110% of the fair market value of a share of common stock on the date the option is granted. The exercise price of a nonstatutory stock option cannot be less than 100%
of the fair market value of a share of the Company&#146;s common stock on the date the option is granted. The maximum period in which an option may be exercised will be fixed by the compensation committee and included in each stock option agreement
and cannot exceed ten years in the case of an incentive stock option (and in the event an option recipient is deemed to be a 10% owner of our Company or one of our subsidiaries, the maximum period for an incentive stock option granted to that person
cannot exceed five years). In addition, no option recipient may be granted incentive stock options that are exercisable for the first time in any calendar year for our common stock having a total fair market value (determined as of the option grant)
in excess of $100,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The exercise price for the exercise of a stock option may be paid in cash or, to the extent that
the stock option agreement so provides, by surrendering shares of common stock, by a broker-assisted cashless exercise procedure, by a net exercise arrangement, by delivering a full-recourse promissory note, or in any other form that is consistent
with applicable laws, regulations and rules. Options generally will be nontransferable except in the event of the option recipient&#146;s death, but the compensation committee may allow the transfer of nonstatutory stock options through a gift or
domestic relations order to the option recipient&#146;s family members. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 31
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock options granted under the Amended Plan generally must be exercised by
the optionee before the earlier of the expiration of such option or 90 days after termination of the optionee&#146;s employment, except that the period may be extended on certain events including death and termination of employment due to
disability. Each stock option agreement will set forth the extent to which the option recipient will have the right to exercise the option following the termination of the recipient&#146;s service with us, and the right to exercise the option of any
executors or administrators of the award recipient&#146;s estate or any person who has acquired such options directly from the award recipient by bequest or inheritance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The terms of any awards of restricted shares under the Amended Plan will be set forth in a restricted share agreement to be
entered into between the Company and the recipient. The compensation committee will determine the terms and conditions of the restricted share agreements, which need not be identical. A restricted share award may be subject to vesting requirements
or transfer restrictions or both. Restricted shares may be issued for such consideration as the compensation committee may determine, including cash, cash equivalents, <FONT STYLE="white-space:nowrap">full-recourse</FONT> promissory notes, past
services and future services. Award recipients who are granted restricted shares generally have all of the rights of a stockholder with respect to those shares.&nbsp;Holders of restricted shares must invest any cash dividends received in additional
restricted shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Units </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The terms of any awards of restricted stock units under the Amended Plan (referred to as &#147;stock units&#148; in the Amended
Plan document) will be set forth in a restricted stock unit agreement to be entered into between the Company and the recipient. The compensation committee will determine the terms and conditions of the restricted stock unit agreements, which need
not be identical. Restricted stock units give an award recipient the right to acquire a specified number of shares of common stock or, at the compensation committee&#146;s discretion, cash, or a combination of common stock and cash, at a future date
upon the satisfaction of certain vesting conditions based upon a vesting schedule or performance criteria established by the compensation committee. Restricted stock units may be granted in consideration of a reduction in the award recipient&#146;s
other compensation, but no cash consideration is typically required of the award recipient. Unlike restricted shares, the stock underlying restricted stock units will not be issued until the stock units have vested, and recipients of restricted
stock units generally will have no voting or dividend rights prior to the time of issuance of any common stock upon settlement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Appreciation
Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The terms of any awards of stock appreciation rights under the Amended Plan will be set forth in an
agreement to be entered into between the Company and the recipient. The compensation committee will determine the terms, conditions and restrictions of any such agreements, which need not be identical. A stock appreciation right generally entitles
the award recipient to receive a payment upon exercise equal to the amount by which the fair market value of a share of common stock on the date of exercise exceeds the value of a share of common stock on the date of grant. The amount payable upon
the exercise of a stock appreciation right may be settled in cash or by the issuance of shares of common stock. The compensation committee may not modify outstanding stock appreciation rights to lower the exercise price or cancel stock appreciation
rights in exchange for cash or for options or stock appreciation rights with a lower exercise price, other than in connection with a corporate transaction, without stockholder approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 32
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance Criteria </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An award may be made subject to the attainment of performance goals for a specified period of time relating to performance
criteria including, but not limited to one or more of the following performance criteria, either individually, alternatively or in any combination, applied to either us as a whole or to a business unit or subsidiary, either individually,
alternatively or in any combination, and measured either annually or cumulatively over a period of years, on an absolute basis or relative to a <FONT STYLE="white-space:nowrap">pre-established</FONT> target, to previous years&#146; results or to a
designated comparison group or index, in each case as specified by the compensation committee in the award: (a)&nbsp;cash flow, (b)&nbsp;earnings per share, (c)&nbsp;earnings before interest, taxes and amortization, (d)&nbsp;return on equity,
(e)&nbsp;total stockholder return, (f)&nbsp;share price performance, (g)&nbsp;return on capital, (h)&nbsp;return on assets or net assets, (i)&nbsp;revenue, (j) income or net income, (k)&nbsp;operating income or net operating income,
(l)&nbsp;operating profit or net operating profit, (m)&nbsp;operating margin or profit margin, (n)&nbsp;return on operating revenue, (o)&nbsp;return on invested capital, (p)&nbsp;market segment shares, (q)&nbsp;costs, (r) expenses,
(s)&nbsp;achievement of target levels of discovery and/or development of products or services, including but not limited to research or regulatory achievements, (t)&nbsp;third party coverage and/or reimbursement objectives, (u)&nbsp;test volume
metrics, (v)&nbsp;objective customer indicators (including, without limitation, customer satisfaction), (w) improvements in productivity, (x)&nbsp;attainment of objective operating goals, (y)&nbsp;objective employee metrics, or (z)&nbsp;any other
measures of performance selected by the compensation committee. The compensation committee will appropriately adjust any evaluation of performance under a qualifying performance criteria for a performance period: (i)&nbsp;to exclude asset <FONT
STYLE="white-space:nowrap">write-downs,</FONT> (ii)&nbsp;to exclude litigation or claim judgments or settlements, (iii)&nbsp;to exclude the effect of changes in tax law, accounting principles or other such laws or provisions affecting reported
results, (iv)&nbsp;to exclude accruals for reorganization and restructuring programs, (v)&nbsp;to exclude any extraordinary nonrecurring items as determined under generally accepted accounting principles and/or in managements&#146; discussion and
analysis of financial condition and results of operations appearing in our annual report to stockholders for the applicable year, (vi)&nbsp;to exclude the dilutive and/or accretive effects of acquisitions or joint ventures, (vii)&nbsp;to assume that
any business divested by the Company achieved performance objectives at targeted levels during the balance of a performance period following the divestiture, (viii)&nbsp;to exclude the effect of any change in the outstanding shares of our common
stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any
distributions to our common stockholders other than regular cash dividends, (ix)&nbsp;to exclude the effects of stock based compensation, (x)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required
to be expensed under generally accepted accounting principles, and (xi)&nbsp;to make other appropriate adjustments selected by the compensation committee.&nbsp;If applicable, the compensation committee will establish the goals before results are
substantially certain and will determine and certify, for each award recipient, the extent to which the qualifying performance criteria have been met. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment and Termination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board may amend or terminate the Amended Plan at any time, but an amendment will not become effective without the approval
of our stockholders to the extent required by applicable laws, regulations or rules.&nbsp;No amendment or termination of the Amended Plan will affect an award recipient&#146;s rights under outstanding awards without the award recipient&#146;s
consent. No incentive stock options may be granted under the Amended Plan after the tenth anniversary of the date the Amended Plan is adopted by the Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forfeiture Events and Clawback / Recoupment Policy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The compensation committee may specify in an award agreement that a participant&#146;s rights, payments, and benefits with
respect to an award will be subject to reduction, cancellation, forfeiture, or recoupment upon the occurrence of specified events, in addition to any otherwise applicable vesting or performance conditions of an award, including termination of
service for cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that we are required to prepare restated financial results due to the material
noncompliance of the Company, as a result of misconduct, with any financial reporting requirement under the securities laws, at the discretion of the compensation committee any participant who knowingly or through gross negligence engaged in the
misconduct, or who knowingly or through gross negligence failed to prevent the misconduct, and any participant who is subject to automatic forfeiture under Section&nbsp;304 of the Sarbanes-Oxley Act of 2002, will reimburse the Company for
(i)&nbsp;the amount of any payment in settlement of an award during the twelve month period following the first public issuance or filing with the Securities and Exchange Commission of the financial document embodying the financial reporting
requirement and (ii)&nbsp;any profits realized by the participation from the sale of securities of the Company during the twelve month period. In addition, to the extent claw-back or similar provisions applicable to awards are required by applicable
law, listing standards and/or policies adopted by the Company, awards granted under the Amended Plan shall be subject to such provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 33
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effect of Certain Corporate Events </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of a subdivision of the outstanding common stock or a combination or consolidation of the outstanding common stock
(by reclassification or otherwise) into a lesser number of shares, a recapitalization, a <FONT STYLE="white-space:nowrap">spin-off</FONT> or a similar occurrence, a declaration of a dividend payable in common stock or a declaration of a dividend
payable in a form other than shares in an amount that has a material effect on the price of the shares, the compensation committee will make appropriate adjustments in the number and class of shares covered by outstanding awards and the exercise
price of outstanding options and stock appreciation rights, the number and class of shares that may be issued pursuant to the exercise of incentive stock options, and the number and class of shares available under the Amended Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of a merger or other reorganization, subject to any acceleration provisions in the agreement relating to an
award, outstanding awards will be treated in the manner provided in the agreement of merger or reorganization.&nbsp;That agreement may provide for the assumption of outstanding awards by the surviving corporation or its parent, for their
continuation by the Company (if the Company is the surviving corporation), for the substitution by the surviving corporation or its parent of its own awards, or for the acceleration of the exercisability of awards followed by the cancellation of
those awards.&nbsp;The agreement of merger or reorganization may also provide for the full exercisability or vesting and accelerated expiration of outstanding awards, cancellation of outstanding awards to the extent not vested or exercised prior to
the effective time of the merger or reorganization in exchange for such cash consideration, if any, as the compensation committee may consider appropriate, or settlement of the intrinsic value of the outstanding awards in cash or cash equivalents or
equity, followed by cancellation of the awards.&nbsp;The Company need not take the same action or actions with respect to all awards or portions thereof or with respect to all participants, and the Company may take different actions with respect to
the vested and unvested portions of an award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In its discretion, the compensation committee may provide in the award
agreement governing an award or at any other time may take any action as it deems appropriate to provide for acceleration of the exercisability, vesting and/or settlement in connection with a change in control of the Company of each or any
outstanding award or portion thereof upon such conditions, including termination of the participant&#146;s service prior to, upon or following the change in control. In the absence of such provision in an award agreement or any action taken by the
compensation committee, no acceleration will occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of the Amended Plan, a change in control generally means
the occurrence of any of the following events: (i)&nbsp;a change in the composition of the Board occurs, as a result of which fewer than <FONT STYLE="white-space:nowrap">one-half</FONT> of the incumbent directors are directors who either had been
directors on the date that is 24 months prior to the date that the change in control could be deemed to occur, or were elected or nominated to the Board with the affirmative votes of at least a majority of the directors who had been directors on the
date that was 24 months prior to the date the change in control cold be deemed to occur and are still in office at the time of election or nomination, (ii)&nbsp;any person who, through the acquisition or aggregation of securities, becomes the
beneficial owner of securities of the Company representing 50% or more of the combined voting power of the Company&#146;s then outstanding securities ordinarily having the right to vote at elections of directors (subject to certain exceptions set
forth in the Amended Plan); (iii) the consummation of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if persons who were not stockholders of the Company immediately prior to the merger,
consolidation or other reorganization own immediately after the merger, consolidation or other reorganization 50% or more of the voting power of the outstanding securities of each of the continuing or surviving entity and any direct or indirect
parent corporation of such continuing or surviving entity; or (iv)&nbsp;the sale, transfer or other disposition of all or substantially all of the Company&#146;s assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Federal Income Tax Aspects of Awards Under the Amended Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This is a brief summary of the federal income tax aspects of awards that may be made under the Amended Plan based on existing
U.S. federal income tax laws. This summary provides only the basic tax rules. It does not describe a number of special tax rules, including the alternative minimum tax and various elections that may be applicable under certain circumstances. It also
does not reflect provisions of the income tax laws of any municipality, state or foreign country in which a holder may reside, nor does it reflect the tax consequences of a holder&#146;s death. The tax consequences of awards under the Amended Plan
depend upon the type of award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 34
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incentive Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The recipient of an incentive stock option generally will not be taxed upon grant of the option. Federal income taxes are
generally imposed only when the shares of common stock from exercised incentive stock options are disposed of, by sale or otherwise. The amount by which the fair market value of the common stock on the date of exercise exceeds the exercise price is,
however, included in determining the option recipient&#146;s liability for the alternative minimum tax. If the incentive stock option recipient does not sell or dispose of the shares of common stock until more than one year after the receipt of the
shares and two years after the option was granted, then, upon sale or disposition of the shares, the difference between the exercise price and the market value of the shares of common stock as of the date of exercise will be treated as a capital
gain, and not ordinary income. If a recipient fails to hold the shares for the minimum required time the recipient will recognize ordinary income in the year of disposition generally in an amount equal to any excess of the market value of the common
stock on the date of exercise (or, if less, the amount realized or disposition of the shares) over the exercise price paid for the shares. Any further gain (or loss) realized by the recipient generally will be taxed as
<FONT STYLE="white-space:nowrap">short-term</FONT> or <FONT STYLE="white-space:nowrap">long-term</FONT> gain (or loss) depending on the holding period. Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code
and the satisfaction of our tax reporting obligation, we will generally be entitled to a tax deduction at the same time and in the same amount as ordinary income is recognized by the option recipient. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nonstatutory Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The recipient of stock options not qualifying as incentive stock options generally will not be taxed upon the grant of the
option. Federal income taxes are generally due from a recipient of nonstatutory stock options when the stock options are exercised. The excess of the fair market value of the common stock purchased on such date over the exercise price of the option
is taxed as ordinary income. Thereafter, the tax basis for the acquired shares is equal to the amount paid for the shares plus the amount of ordinary income recognized by the recipient. Subject to the requirement of reasonableness, the provisions of
Section&nbsp;162(m) of the Code and the satisfaction of our tax reporting obligation, we will generally be entitled to a tax deduction at the same time and in the same amount as ordinary income is recognized by the option recipient by reason of the
exercise of the option. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Recipients who receive restricted stock unit awards will generally recognize ordinary income when they receive shares upon
settlement of the awards, in an amount equal to the fair market value of the shares at that time.&nbsp;Recipients who receive awards of restricted shares subject to a vesting requirement will generally recognize ordinary income at the time vesting
occurs, in an amount equal to the fair market value of the shares at that time minus the amount, if any, paid for the shares. However, a recipient who receives restricted shares which are not vested may, within 30 days of the date the shares are
transferred, elect in accordance with Section&nbsp;83(b) of the Code to recognize ordinary compensation income at the time of transfer of the shares rather than upon the vesting dates. Recipients who receive stock appreciation rights will generally
recognize ordinary income upon exercise in an amount equal to the excess of the fair market value of the underlying shares of common stock on the exercise date and cash received, if any, over the exercise price. Subject to the requirement of
reasonableness, the provisions of Section&nbsp;162(m) of the Code and the satisfaction of our tax reporting obligation, we will generally be entitled to a tax deduction at the same time and in the same amount as ordinary income is recognized by the
recipient. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Plan Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No new grants have been made under the Amended Plan requiring stockholder approval. With respect to future grants under the
Amended Plan, it is not possible to determine specific amounts and types of awards that may be awarded in the future under the Amended Plan, because the grant and actual settlement of awards will be discretionary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aggregate Past Grants Under the Amended Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with SEC rules, the following table sets forth summary information with respect to the number of shares of common
stock subject to stock option awards made under the Plan to the Company&#146;s named executive officers, all current executive officers as a group, directors, associates of such executive officers, directors and nominees, each other person who
received or is to receive 5% of such stock options and all employees (other than executive officers) as a group as of March&nbsp;31, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 35
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Individual or Group</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Underlying Stock<BR>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark H. Henrick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President, Chief Executive Officer and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Howard Clows</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">An van <FONT STYLE="white-space:nowrap">Es-Johansson,</FONT> M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Hawkins</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chairman of the Board</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lenk, PhD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Petersen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers as a group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">334,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current directors who are not executive officers as a group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All nominees for election as a director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Each associate of any such director, executive officer or nominees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Each other person who received or is to receive 5% of such awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All employees, including current officers who are not executive officers as a group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The proposal to approve the Plus Therapeutics Inc. 2020 Stock Incentive Plan, as amended and restated, requires the affirmative
vote of a majority of the common stock present in person or represented by proxy at the Annual Meeting.&nbsp;Abstentions are considered present and entitled to vote with respect to this proposal and will, therefore, be treated as votes against this
proposal. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR BOARD UNANIMOUSLY RECOMMENDS A VOTE &#147;FOR&#148; THE APPROVAL OF THE PLUS THERAPEUTICS, INC. 2020 STOCK INCENTIVE
PLAN, AS AMENDED AND RESTATED. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 36
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc41684_9"></A>PROPOSAL #4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-BINDING</FONT> ADVISORY VOTE ON EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act, enacted in July 2010, and related SEC regulations,
we are required to provide our stockholders with the opportunity to cast an advisory vote on the compensation of our named executive officers as disclosed in this Proxy Statement in accordance with the compensation disclosure rules of the Securities
and Exchange Commission. Our stockholders previously expressed a preference that we hold advisory votes on executive compensation on an annual basis, and our board of directors accordingly determined to hold such votes every year until the next
required advisory vote on the frequency of future votes on executive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our executive compensation programs
are designed to reward our named executive officers for the achievement of short-term and long-term strategic and operational goals, while at the same time avoiding the encouragement of unnecessary or excessive risk taking. Stockholders are
encouraged to read the Executive Compensation section of this Proxy Statement for a more detailed discussion of how our compensation programs reflect our objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board believes the Company&#146;s executive compensation programs use appropriate structures and sound pay practices that
are effective in achieving our core objectives. Accordingly, the Board recommends that you vote in favor of the following resolution: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;RESOLVED, that the Company&#146;s stockholders approve, on an advisory basis, the compensation of the named executive
officers, as described in the Company&#146;s proxy statement for the Annual Meeting of Stockholders pursuant to Item 402 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> and other compensation disclosure rules of the Securities and Exchange
Commission.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The vote on this proposal is advisory and therefore not binding on us or our Board. Although the vote
is <FONT STYLE="white-space:nowrap">non-binding,</FONT> the Board will review the voting results, seek to determine the cause or causes of any significant negative voting, and take them into consideration when making future decisions regarding
executive compensation programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The proposal to approve, on an advisory basis, the compensation of our named executive officers requires the affirmative vote
of a majority of the common stock present in person or represented by proxy at the Annual Meeting. Abstentions are considered present and entitled to vote with respect to this proposal and will, therefore, be treated as votes &#147;against&#148;
this proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>OUR BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE &#147;FOR&#148; THE APPROVAL, ON AN
ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 37
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc41684_10"></A>OTHER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of the time of preparation of this Proxy Statement, neither the Board nor management intends to bring before the meeting
any business other than the matters referred to in the Notice of Annual Meeting and this Proxy Statement. If any other business should be properly brought before the meeting, or any adjournment or postponement thereof, the designated proxy holders
will vote on such matters according to their best judgment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholders Sharing the Same Address </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stockholders who hold their shares through a bank, broker or other holder of record (a &#147;street-name stockholder&#148;) and
share a single address, may receive only one copy of the Proxy Materials is being delivered to that address unless contrary instructions from any stockholder at that address were received. This practice, known as &#147;householding,&#148; is
intended to reduce our printing and postage costs. However, any such street-name stockholder residing at the same address who wishes to receive a separate copy of this Proxy Statement or accompanying Annual Report to Stockholders may request a copy
by contacting us by telephone at: (737) <FONT STYLE="white-space:nowrap">255-7194.</FONT> Please contact your bank, broker or other holder of record if you wish to start or stop householding of our proxy materials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Proposals for the 2022 Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stockholders interested in submitting a proposal for consideration at our 2022 Annual Meeting must do so by sending such
proposal to our Corporate Secretary at Plus Therapeutics, Inc., 4200 Marathon Blvd. Suite 200, Austin, TX 78756, Attention: Corporate Secretary. Under the SEC&#146;s proxy rules, the deadline for submission of proposals to be included in our proxy
materials for the 2022 Annual Meeting is December&nbsp;6, 2021. Accordingly, for a stockholder proposal to be considered for inclusion in our proxy materials for the 2022 Annual Meeting, any such stockholder proposal must be received by our
Corporate Secretary on or before December&nbsp;6, 2021 and comply with the procedures and requirements set forth in Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our bylaws require advance notice of business to be brought before a stockholders&#146; meeting (other than
proposals presented under Rule <FONT STYLE="white-space:nowrap">14a-8),</FONT> including nominations of persons for election as directors. To be timely, notice to our Corporate Secretary must be received at our principal executive offices not less
than 120 days prior to the anniversary date of the preceding year&#146;s proxy statement and must contain specified information concerning the matters to be brought before such meeting, including nominations, if applicable, and concerning the
stockholder proposing such matters. Any stockholder proposal or nomination received after December&nbsp;6, 2021 will be considered untimely, and we will not entertain any proposals or nominations at the annual meeting that do not meet the
requirements set forth in our bylaws. However, in the event we hold the 2022 Annual Meeting of stockholders more than 30 days before or after the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary date of the Annual Meeting, a proposal
must be received by us a reasonable time before the proxy solicitation is made. If the stockholder does not also comply with the requirements of Rule <FONT STYLE="white-space:nowrap">14a-4(c)(2)</FONT> under the Exchange Act, we may exercise
discretionary voting authority under proxies that we solicit to vote in accordance with our best judgement on any such stockholder proposal or nomination. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By Order of the Board,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g41684g07d97.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MARC H. HEDRICK</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>President and Chief Executive Officer</I></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement | Page 38
</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 STOCK INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Adopted by the Board of Directors on April&nbsp;30, 2020 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Approved by the Stockholders on June&nbsp;16, 2020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amended and Restated by the Board of Directors on March&nbsp;22, 2021 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Approved by the Stockholders on
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ESTABLISHMENT AND PURPOSE.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DEFINITIONS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Affiliate&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Award&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(c)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Award Agreement&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(d)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Board of Directors&#148; or &#147;Board&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(e)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Cause&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(f)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Change in Control&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(g)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Code&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(h)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Committee&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(i)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Company&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(j)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Consultant&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(k)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Disability&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(l)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Effective Date&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(m)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Employee&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(n)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Exchange Act&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(o)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Exercise Price&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(p)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Fair Market Value&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(q)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;ISO&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(r)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Nonstatutory Option&#148; or &#147;NSO&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(s)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Offeree&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(t)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Option&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(u)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Optionee&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(v)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Outside Director&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(w)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Parent&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(x)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Participant&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(y)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Plan&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(z)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Purchase Price&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(aa)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Restricted Share&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(bb)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Restricted Share Agreement&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(cc)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;SAR&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(dd)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;SAR Agreement&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(ee)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Service&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(ff)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Share&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(gg)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Stock&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(hh)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Stock Option Agreement&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(ii)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Stock Unit&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(jj)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Stock Unit Agreement&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(kk)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>&#147;Subsidiary&#148;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ADMINISTRATION.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Committee Composition</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Committee for <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Grants</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(c)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Committee Procedures</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(d)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Committee Responsibilities</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(e)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Cancellation and <FONT STYLE="white-space:nowrap">Re-Grant</FONT> of Stock Awards</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ELIGIBILITY.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>General Rule</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Limit on Grants to Outside Directors</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(c)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I><FONT STYLE="white-space:nowrap">Ten-Percent</FONT> Stockholders</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(d)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Attribution Rules</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(e)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Outstanding Stock</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>STOCK SUBJECT TO PLAN.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Basic Limitation</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Additional Shares</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(c)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Substitution and Assumption of Awards</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>RESTRICTED SHARES.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Restricted Stock Agreement</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Payment for Awards</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(c)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Vesting</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(d)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Voting and Dividend Rights</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(e)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Restrictions on Transfer of Shares</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>TERMS AND CONDITIONS OF OPTIONS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Stock Option Agreement</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Number of Shares</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(c)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Exercise Price</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(d)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Withholding Taxes</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(e)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Exercisability and Term</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(f)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Exercise of Options</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(g)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>No Rights as a Stockholder</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(h)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Modification or Extension of Options</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(i)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Restrictions on Transfer of Shares</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(j)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Buyout Provisions</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PAYMENT FOR SHARES.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>General Rule</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Surrender of Stock</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(c)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Services Rendered</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(d)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Cashless Exercise</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(e)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Exercise/Pledge</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(f)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Net Exercise</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(g)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Promissory Note</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(h)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Other Forms of Payment</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(i)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Limitations under Applicable Law</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>STOCK APPRECIATION RIGHTS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>SAR Agreement</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Number of Shares</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(c)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Exercise Price</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(d)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Exercisability and Term</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(e)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>No Rights as a Stockholder</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(f)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Exercise of SARs</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(g)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Modification, Extension or Assumption of SARs</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(h)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Buyout Provisions</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>STOCK UNITS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Stock Unit Agreement</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Payment for Awards</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(c)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Vesting Conditions</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(d)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Voting and Dividend Rights</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(e)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Form and Time of Settlement of Stock Units</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(f)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Death of Recipient</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(g)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Creditors&#146; Rights</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ADJUSTMENT OF SHARES.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Adjustments</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Dissolution or Liquidation</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(c)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Reorganizations</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(d)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Reservation of Rights</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(e)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Change in Control</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DEFERRAL OF AWARDS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Committee Powers</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>General Rules</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>AWARDS UNDER OTHER PLANS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>LEGAL AND REGULATORY REQUIREMENTS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>WITHHOLDING TAXES.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Withholding Taxes</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Share Withholding</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>OTHER PROVISIONS APPLICABLE TO AWARDS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Transferability</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Performance Criteria</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>NO EMPLOYMENT RIGHTS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SECTION 409A.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DURATION AND AMENDMENTS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(a)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Term of the Plan</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(b)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Right to Amend or Terminate the Plan</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>(c)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><I>Effect of Termination</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;20.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>AWARDS TO <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> PARTICIPANTS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;21.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FORFEITURE, CANCELLATION OR CLAWBACK OF AWARDS.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;22.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>GOVERNING LAW.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 STOCK INCENTIVE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 1.
ESTABLISHMENT AND PURPOSE. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) The Plan was adopted by the Board of Directors on April&nbsp;30, 2020 and approved by
the Company&#146;s stockholders on June&nbsp;16, 2020. The Plan was amended and restated by the Board of Directors on March&nbsp;22, 2021, subject to approval of the Company&#146;s stockholders. The Plan was initially effective upon approval by the
stockholders of the Company on the Effective Date. The Plan is a successor to the 2014 Equity Incentive Plan of Plus Therapeutics, Inc. (the &#147;Predecessor Plan&#148;). From and after 12:01 a.m. Central time on the Effective Date, no additional
stock awards will be granted under the Predecessor Plan. All Awards granted on or after the Effective Date will be granted under the Plan as in effect on the date of grant of each Award. All stock awards granted under the Predecessor Plan will
remain subject to the terms of the Predecessor Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) Any Shares that would otherwise remain available
for future grants under the Predecessor Plan as of 12:01 a.m. Central Time on the Effective Date (the &#147;Predecessor Plan&#146;s Available Reserve&#148;) will cease to be available under the Predecessor Plan at such time. Instead, that number of
Shares equal to the Predecessor Plan&#146;s Available Reserve will be added to the Absolute Share Limit (as further described in Section&nbsp;5(a) below) and be then immediately available for grants and issuance pursuant to Awards hereunder, up to
the maximum number set forth in Section&nbsp;5(a) below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) In addition, from and after 12:01 a.m.
Central time on the Effective Date, with respect to the aggregate number of Shares subject, at such time, to outstanding stock options and stock awards granted under the Predecessor Plan that (i)&nbsp;expire or terminate for any reason prior to
exercise or settlement; or (ii)&nbsp;are forfeited because of the failure to meet a contingency or condition required to vest such Shares or otherwise return to the Company (such Shares the &#147;Predecessor Plan Returning Shares&#148;) will
immediately be added to the Absolute Share Limit (as further described in Section&nbsp;5(a) below) as and when such a Share becomes a Predecessor Plan Returning Share, up to the maximum number set forth in Section&nbsp;3(a) below. For the avoidance
of doubt, Predecessor Plan Returning Shares will not include any Shares subject to outstanding stock options or stock awards granted under the Predecessor Plan that are reacquired, withheld (or not issued) to satisfy (i)&nbsp;a tax withholding
obligation in connection with an award or (ii)&nbsp;the purchase price or exercise price of an award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> The
purpose of the Plan is to promote the long-term success of the Company and the creation of stockholder value by (a)&nbsp;encouraging Employees, Outside Directors and Consultants to focus on critical long-range objectives, (b)&nbsp;encouraging the
attraction and retention of Employees, Outside Directors and Consultants with exceptional qualifications and (c)&nbsp;linking Employees, Outside Directors and Consultants directly to stockholder interests through increased stock ownership. The Plan
seeks to achieve this purpose by providing for Awards in the form of restricted shares, stock units, options (which may constitute incentive stock options or nonstatutory stock options) or stock appreciation rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 2. DEFINITIONS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a)</I> <I>&#147;</I><I>Affiliate</I><I>&#148;</I> shall mean any entity other than a Subsidiary, if the Company and/or one
or more Subsidiaries own not less than 50% of such entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> <I>&#147;</I><I>Award</I><I>&#148;</I> shall mean
any award of an Option, a SAR, a Restricted Share or a Stock Unit under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(c)</I> <I>&#147;</I><I>Award
Agreement</I><I>&#148;</I><I> </I>shall mean a Stock Option Agreement, SAR Agreement, Restricted Share Agreement or Stock Unit Agreement, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(d)</I> <I>&#147;</I><I>Board of Directors</I><I>&#148;</I><I> </I>or <I>&#147;</I><I>Board</I>&#148;<I> </I>shall mean the
Board of Directors of the Company, as constituted from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(e)</I> &#147;<I>Cause</I>&#148; shall mean,
unless such term or an equivalent term is otherwise defined by the applicable Award Agreement or other written agreement between a Participant and the Company, a Subsidiary or an Affiliate applicable to an Award, any of the following: (i)&nbsp;the
Participant&#146;s theft, dishonesty, willful misconduct, breach of fiduciary duty for personal profit, or falsification of any documents or records of the Company, a Subsidiary or any Affiliate; (ii)&nbsp;the Participant&#146;s material failure to
abide by a code of conduct or other policies of the Company, a Subsidiary or an Affiliate (including, without limitation, policies relating to confidentiality and reasonable workplace conduct); (iii) the Participant&#146;s unauthorized use,
misappropriation, destruction or diversion of any tangible or intangible asset or corporate opportunity of the Company, a Subsidiary or an Affiliate (including, without limitation, the Participant&#146;s improper use or disclosure of confidential or
proprietary information of the Company, a Subsidiary or an Affiliate); (iv) any intentional act by the Participant which has a material detrimental effect on the reputation or business of a Company, a Subsidiary or an Affiliate; (v)&nbsp;the
Participant&#146;s repeated failure or inability to perform any reasonable assigned duties after written notice from the Company, a Subsidiary or an Affiliate of, and a reasonable opportunity to cure, such failure or inability; (vi)&nbsp;any
material breach by the Participant of any employment, service, <FONT STYLE="white-space:nowrap">non-disclosure,</FONT> <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation</FONT> or other similar
agreement between the Participant and the Company, a Subsidiary or an Affiliate, which breach is not cured pursuant to the terms of such agreement; or (vii)&nbsp;the Participant&#146;s conviction (including any plea of guilty or nolo contendere) of
any criminal act involving fraud, dishonesty, misappropriation or moral turpitude, or which impairs the Participant&#146;s ability to perform his or her duties with the Company, a Subsidiary or an Affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(f)</I> <I>&#147;</I><I>Change in Control</I><I>&#148;</I> shall mean the occurrence of any of the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) A change in the composition of the Board of Directors occurs, as a result of which fewer than <FONT
STYLE="white-space:nowrap">one-half</FONT> of the incumbent directors are directors who either: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(A) Had
been directors of the Company on the &#147;look-back date&#148; (as defined below) (the &#147;original directors&#148;); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(B) Were elected, or nominated for election, to the Board of Directors with the affirmative votes of at least a
majority of the aggregate of the original directors who were still in office at the time of the election or nomination and the directors whose election or nomination was previously so approved (the &#147;continuing directors&#148;); or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) Any &#147;person&#148; (as defined below) who by the
acquisition or aggregation of securities, is or becomes the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), directly or indirectly, of securities of the Company representing 50%
or more of the combined voting power of the Company&#146;s then outstanding securities ordinarily (and apart from rights accruing under special circumstances) having the right to vote at elections of directors (the &#147;Base Capital Stock&#148;);
except that any change in the relative beneficial ownership of the Company&#146;s securities by any person resulting solely from a reduction in the aggregate number of outstanding shares of Base Capital Stock, and any decrease thereafter in such
person&#146;s ownership of securities, shall be disregarded until such person increases in any manner, directly or indirectly, such person&#146;s beneficial ownership of any securities of the Company; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) The consummation of a merger or consolidation of the Company with or into another entity or any other
corporate reorganization, if persons who were not stockholders of the Company immediately prior to such merger, consolidation or other reorganization own immediately after such merger, consolidation or other reorganization 50% or more of the voting
power of the outstanding securities of each of (A)&nbsp;the continuing or surviving entity and (B)&nbsp;any direct or indirect parent corporation of such continuing or surviving entity; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) The sale, transfer or other disposition of all or substantially all of the Company&#146;s assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of subsection 2(f)(i) above, the term &#147;look-back&#148; date shall mean the date 24 months prior to the date
of the event that may constitute a Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of subsection 2(f)(iii)) above, the term
&#147;person&#148; shall have the same meaning as when used in Sections 13(d) and 14(d) of the Exchange Act but shall exclude (1)&nbsp;a trustee or other fiduciary holding securities under an employee benefit plan maintained by the Company or a
Parent or Subsidiary and (2)&nbsp;a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any other provision of this Section&nbsp;2(f) notwithstanding, a transaction shall not constitute a Change in Control if its
sole purpose is to change the state of the Company&#146;s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#146;s securities immediately before such
transaction, and a Change in Control shall not be deemed to occur if the Company files a registration statement with the United States Securities and Exchange Commission for the offering of securities or debt to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(g)</I> <I>&#147;</I><I>Code</I><I>&#148;</I> shall mean the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(h)</I> <I>&#147;</I><I>Committee</I><I>&#148;</I> shall mean the Compensation Committee as designated by the Board of
Directors, which is authorized to administer the Plan, as described in Section&nbsp;3 hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(</I><I>i</I><I>)</I> <I>&#147;</I><I>Company</I><I>&#148;</I> shall mean
Plus Therapeutics, Inc., a Delaware corporation, or any successor corporation thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(j)</I>
<I>&#147;</I><I>Consultant</I><I>&#148;</I> shall mean an individual who is a consultant or advisor and who provides bona fide services to the Company, a Parent, a Subsidiary or an Affiliate as an independent contractor (not including service as a
member of the Board of Directors) or a member of the board of directors of a Parent or a Subsidiary, in each case who is not an Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(k)</I> <I>&#147;</I><I>Disability</I><I>&#148;</I> shall mean any permanent and total disability as defined by section
22(e)(3) of the Code </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(l)</I> <I>&#147;</I><I>Effective Date</I>&#148; shall mean the effective date of this Plan
document, which is the date of the annual meeting of stockholders of the Company held in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(m)</I>
<I>&#147;</I><I>Employee</I><I>&#148;</I> shall mean any individual who is a <FONT STYLE="white-space:nowrap">common-law</FONT> employee of the Company, a Parent, a Subsidiary or an Affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(n)</I> <I>&#147;</I><I>Exchange Act</I><I>&#148;</I> shall mean the Securities Exchange Act of 1934, as amended, and the
rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(o)</I> <I>&#147;</I><I>Exercise Price</I><I>&#148;</I> shall mean, in
the case of an Option, the amount for which one Share may be purchased upon exercise of such Option, as specified in the applicable Stock Option Agreement. &#147;Exercise Price,&#148; in the case of a SAR, shall mean an amount, as specified in the
applicable SAR Agreement, which is subtracted from the Fair Market Value of one Share in determining the amount payable upon exercise of such SAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(p)</I> <I>&#147;</I><I>Fair Market Value</I><I>&#148;</I> with respect to a Share, shall mean the market price of one
Share, determined by the Committee as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) If the Stock was traded
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> on the date in question, then the Fair Market Value shall be equal to the last transaction price quoted for such date by the OTC Bulletin Board or, if
not so quoted, shall be equal to the mean between the last reported representative bid and asked prices quoted for such date by the principal automated inter-dealer quotation system on which the Stock is quoted or, if the Stock is not quoted on any
such system, by the Pink Sheets LLC; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) If the Stock was traded on any established stock exchange (such
as The Nasdaq Global Market, The Nasdaq Global Select Market or the New York Stock Exchange) or national market system on the date in question, then the Fair Market Value shall be equal to the closing price reported for such date by the applicable
exchange or system; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) If none of the foregoing provisions is applicable, then the Fair Market Value
shall be determined by the Committee in good faith on such basis as it deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In all cases, the determination of Fair Market
Value by the Committee shall be conclusive and binding on all persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(q)</I> <I>&#147;</I><I>ISO</I><I>&#148;</I> shall mean an employee
incentive stock option described in Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(r)</I> <I>&#147;</I><I>Nonstatutory</I><I>
Option</I><I>&#148;</I> or <I>&#147;</I><I>NSO</I><I>&#148;</I> shall mean an employee stock option that is not an ISO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(s)</I> <I>&#147;</I><I>Offeree</I><I>&#148;</I> shall mean an individual to whom the Committee has offered the right to
acquire Shares under the Plan (other than upon exercise of an Option or SAR). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(t)</I>
<I>&#147;</I><I>Option</I><I>&#148;</I> shall mean an ISO or Nonstatutory Option granted under the Plan and entitling the holder to purchase Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(u)</I> <I>&#147;</I><I>Optionee</I><I>&#148;</I> shall mean the holder of an Option or SAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(v)</I> <I>&#147;</I><I>Outside Director</I><I>&#148;</I> shall mean a member of the Board of Directors who is not a <FONT
STYLE="white-space:nowrap">common-law</FONT> employee of, or paid consultant to, the Company, a Parent or a Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(w)</I> <I>&#147;</I><I>Parent</I><I>&#148;</I> shall mean any corporation (other than the Company) in an unbroken chain of
corporations ending with the Company, if each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that
attains the status of a Parent on a date after the adoption of the Plan shall be a Parent commencing as of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(x)</I> <I>&#147;</I><I>Participant</I><I>&#148;</I> shall mean the holder of an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(y)</I> <I>&#147;</I><I>Plan</I><I>&#148;</I> shall mean this 2020 Stock Incentive Plan of Plus Therapeutics, Inc., as
amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(z)</I> <I>&#147;</I><I>Purchase Price</I><I>&#148;</I> shall mean the consideration for
which one Share may be acquired under the Plan (other than upon exercise of an Option or SAR), as specified by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(aa)</I> <I>&#147;</I><I>Restricted Share</I><I>&#148;</I> shall mean a Share awarded under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(bb)</I> <I>&#147;</I><I>Restricted Share Agreement</I><I>&#148;</I> shall mean the agreement between the Company and the
recipient of a Restricted Share which contains the terms, conditions and restrictions pertaining to such Restricted Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(cc)</I> <I>&#147;</I><I>SAR</I><I>&#148;</I> shall mean a stock appreciation right granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(</I><I>dd</I><I>)</I> <I>&#147;</I><I>SAR Agreement</I><I>&#148;</I> shall mean the agreement between the Company and an
Optionee which contains the terms, conditions and restrictions pertaining to his or her SAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(</I><I>ee</I><I>)</I>
<I>&#147;</I><I>Service</I><I>&#148;</I> shall mean service as an Employee, Consultant or Outside Director, subject to such further limitations as may be set forth in the Plan or the applicable Stock Option Agreement, SAR Agreement, Restricted Share
Agreement or Stock Unit Agreement, and as determined in the sole discretion of the Committee. Service does not terminate when an Employee goes on a bona fide leave of absence, that was approved by the Company in writing, if the terms of the leave
provide for continued Service crediting, or when continued service crediting is required by applicable law. However, for purposes of determining whether an Option is entitled to ISO status, an Employee&#146;s Service will be treated as terminating
three months after such Employee went on leave, unless such Employee&#146;s right to return to active work is guaranteed by law or by a contract. Service terminates in any event when the approved leave ends, unless such Employee immediately returns
to active work. The Company determines which leaves count toward Service, and when Service terminates for all purposes under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(</I><I>ff</I><I>)</I> <I>&#147;</I><I>Share</I><I>&#148;</I> shall mean
one share of Stock, as adjusted in accordance with Section&nbsp;11 (if applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(gg)</I>
<I>&#147;</I><I>Stock</I><I>&#148;</I> shall mean the Common Stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(</I><I>hh</I><I>)</I>
<I>&#147;</I><I>Stock Option Agreement</I><I>&#148;</I> shall mean the agreement between the Company and an Optionee that contains the terms, conditions and restrictions pertaining to such Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(ii)</I> <I>&#147;</I><I>Stock Unit</I><I>&#148;</I> shall mean a bookkeeping entry representing the Company&#146;s
obligation to deliver one Share (or distribute cash) on a future date in accordance with the provisions of a Stock Unit Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(</I><I>jj</I><I>)</I> <I>&#147;</I><I>Stock Unit Agreement</I><I>&#148;</I> shall mean the agreement between the Company
and the recipient of a Stock Unit which contains the terms, conditions and restrictions pertaining to such Stock Unit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(</I><I>kk</I><I>)</I> <I>&#147;</I><I>Subsidiary</I><I>&#148;</I> shall mean any corporation, if the Company and/or one or
more other Subsidiaries own not less than 50% of the total combined voting power of all classes of outstanding stock of such corporation. A corporation that attains the status of a Subsidiary on a date after the adoption of the Plan shall be
considered a Subsidiary commencing as of such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 3. ADMINISTRATION. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a)</I> <I>Committee Composition</I>. The Plan shall be administered by a Committee appointed by the Board of Directors, or
by the Board of Directors acting as the Committee. The Committee shall consist of two or more directors of the Company. In addition, the composition of the Committee shall satisfy such requirements as the Securities and Exchange Commission may
establish for administrators acting under plans intended to qualify for exemption under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> (or its successor) under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> <I>Committee for <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Grants</I>. The Board of Directors may also
appoint one or more separate committees of the Board, each composed of one or more directors of the Company who need not satisfy the requirements of Section&nbsp;3(a), who may administer the Plan with respect to Employees who are not considered
officers or directors of the Company under Section&nbsp;16 of the Exchange Act, may grant Awards under the Plan to such Employees and may determine all terms of such grants. Within the limitations of the preceding sentence, any reference in the Plan
to the Committee shall include such committee or committees appointed pursuant to the preceding sentence. To the extent permitted by applicable law, the Board of Directors may also authorize one or more officers of the Company to designate
Employees, other than officers under Section&nbsp;16 of the Exchange Act, to receive Awards and/or to determine the number of such Awards to be received by such persons; provided, however, that the Board of Directors shall specify the total number
of Awards that such officers may so award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(c)</I> <I>Committee Procedures</I>. The Board of Directors shall
designate one of the members of the Committee as chairman. The Committee may hold meetings at such times and places as it shall determine. The acts of a majority of the Committee members present at meetings at which a quorum exists, or acts reduced
to or approved in writing (including via email) by all Committee members, shall be valid acts of the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(d)</I> <I>Committee Responsibilities</I>. Subject to the provisions of the Plan, the Committee shall have full authority
and discretion to take the following actions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) To interpret the Plan and to apply its provisions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) To adopt, amend or rescind rules, procedures and forms relating to the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) To adopt, amend or terminate <FONT STYLE="white-space:nowrap">sub-plans</FONT> established for the
purpose of satisfying applicable foreign laws including qualifying for preferred tax treatment under applicable foreign tax laws; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) To authorize any person to execute, on behalf of the Company, any instrument required to carry out the
purposes of the Plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) To determine when Awards are to be granted under the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi) To select the Offerees, Optionees and Participants; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vii) To determine the type of Award and number of Shares or amount of cash to be made subject to each Award;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(viii) To prescribe the terms and conditions of each Award, including (without limitation) the Exercise
Price and Purchase Price, and the vesting or duration of the Award (including accelerating the vesting of Awards, either at the time of the Award or thereafter, without the consent of the Participant), to determine whether an Option is to be
classified as an ISO or as a Nonstatutory Option, and to specify the provisions of the agreement relating to such Award; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ix) To amend any outstanding Award Agreement, subject to applicable legal restrictions and to the consent of
the Participant if the Participant&#146;s rights or obligations would be materially impaired; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(x) To
prescribe the consideration for the grant of each Award or other right under the Plan and to determine the sufficiency of such consideration; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xi) To determine the disposition of each Award or other right under the Plan in the event of a
Participant&#146;s divorce or dissolution of marriage; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xii) To determine whether Awards under the Plan will be
granted in replacement of other grants under an incentive or other compensation plan of an acquired business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xiii) To correct any defect, supply any omission, or reconcile any inconsistency in the Plan or any Award
Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xiv) To establish or verify the extent of satisfaction of any performance goals or other
conditions applicable to the grant, issuance, exercisability, vesting and/or ability to retain any Award; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xv) To take any other actions deemed necessary or advisable for the administration of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the requirements of applicable law, the Committee may designate persons other than members of the Committee to carry out its
responsibilities and may prescribe such conditions and limitations as it may deem appropriate, except that the Committee may not delegate its authority with regard to the selection for participation of or the granting of Awards under the Plan to
persons subject to Section&nbsp;16 of the Exchange Act. All decisions, interpretations and other actions of the Committee shall be final and binding on all Offerees, all Optionees, all Participants and all persons deriving their rights from an
Offeree, Optionee or Participant. No member of the Committee shall be liable for any action that he has taken or has failed to take in good faith with respect to the Plan, any Award, or any right to acquire Shares under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(e)</I> <I>Cancellation and <FONT STYLE="white-space:nowrap">Re-Grant</FONT> of Stock Awards</I>. Notwithstanding any
contrary provision of the Plan, neither the Committee nor its designees shall have the authority to: (i)&nbsp;amend the terms of outstanding Options or SARs to reduce the Exercise Price thereof, or (ii)&nbsp;cancel outstanding Options or SARs with
an Exercise Price above the current Fair Market Value per Share in exchange for another Option, SAR or other Award, unless the stockholders of the Company have previously approved such an action or such action relates to an adjustment pursuant to
Section&nbsp;11. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 4. ELIGIBILITY. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a)</I> <I>General Rule</I>. Only <FONT STYLE="white-space:nowrap">common-law</FONT> employees of the Company, a Parent or a
Subsidiary shall be eligible for the grant of ISOs. Only Employees, Consultants and Outside Directors shall be eligible for the grant of Restricted Shares, Stock Units, Nonstatutory Options or SARs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> <I>Limit on Grants to Outside Directors</I>. Notwithstanding any other provision of the Plan to the contrary, the
Board of Directors may establish compensation for Outside Directors from time to time, subject to the limitations in the Plan. The Board of Directors will from time to time determine the terms, conditions and amounts of all such Outside Director
compensation in its discretion and pursuant to the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation, or
other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification of Topic 718, or any successor thereto) of Awards granted to Outside Directors as
compensation for services as an Outside Director during any calendar year of the Company may not exceed $500,000 (increased to $700,000 in the calendar year of his or her initial service as an Outside Director). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(c)</I> <I><FONT STYLE="white-space:nowrap">Ten-Percent</FONT>
Stockholders</I>. An Employee who owns more than 10% of the total combined voting power of all classes of outstanding stock of the Company, a Parent or Subsidiary shall not be eligible for the grant of an ISO unless such grant satisfies the
requirements of Section&nbsp;422(c)(5) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(d)</I> <I>Attribution Rules</I>. For purposes of
Section&nbsp;4(c) above, in determining stock ownership, an Employee shall be deemed to own the stock owned, directly or indirectly, by or for such Employee&#146;s brothers, sisters, spouse, ancestors and lineal descendants. Stock owned, directly or
indirectly, by or for a corporation, partnership, estate or trust shall be deemed to be owned proportionately by or for its stockholders, partners or beneficiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(e)</I> <I>Outstanding Stock</I>. For purposes of Section&nbsp;4(c) above, &#147;outstanding stock&#148; shall include all
stock actually issued and outstanding immediately after the grant. &#147;Outstanding stock&#148; shall not include shares authorized for issuance under outstanding options held by the Employee or by any other person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 5. STOCK SUBJECT TO PLAN. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a)</I> <I>Basic Limitation</I>. Shares offered under the Plan shall be authorized but unissued Shares or treasury Shares.
Subject to Section&nbsp;5(b) below, the maximum aggregate number of Shares authorized for issuance as Awards under the Plan shall not exceed 1,650,781 Shares, which is the sum of (i) 550,000 Shares approved at the Company&#146;s 2020 annual meeting
of stockholders, <I>plus </I>(ii) 1,000,000 Shares approved at the Company&#146;s 2021 annual meeting of stockholders, <I>plus</I> (ii)&nbsp;the number of shares subject to the Predecessor Plan&#146;s Available Reserve, <I>plus</I> (iii)&nbsp;the
number of shares that are Predecessor Plan Returning Shares, as such shares become available from time to time (the &#147;Absolute Share Limit&#148;). The number of Shares that may be delivered in the aggregate pursuant to the exercise of ISOs
granted under the Plan shall not exceed 4,952,343 Shares plus, to the extent allowable under Section&nbsp;422 of the Code and the Treasury Regulations promulgated thereunder, any Shares that become available for issuance under the Plan pursuant to
Section&nbsp;5(b). The limitations of this Section&nbsp;5(a) shall be subject to adjustment pursuant to Section&nbsp;11. The number of Shares that are subject to Options or other Awards outstanding at any time under the Plan shall not exceed the
number of Shares which then remain available for issuance under the Plan. The Company shall at all times reserve and keep available sufficient Shares to satisfy the requirements of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> <I>Additional Shares</I>. If Restricted Shares are forfeited, then such Shares shall again become available for
Awards under the Plan. If Stock Units, Options or SARs are forfeited or terminate for any reason before being exercised or settled, then the corresponding Shares shall again become available for Awards under the Plan. If Stock Units are settled,
then only the number of Shares (if any) actually issued in settlement of such Stock Units shall reduce the number available in Section&nbsp;5(a) and the balance shall again become available for Awards under the Plan. The full number of Options
exercised shall be counted against the number of Shares available for Awards under the Plan, regardless of the number of Shares actually issued upon exercise of such Options. The full number of SARs settled shall be counted against the number of
Shares available for Awards under the Plan, regardless of the number of Shares actually issued in settlement of such SARs. For the avoidance of doubt, any Shares withheld to satisfy the exercise price or tax withholding obligation pursuant to any
Award shall not be added to the Shares available for Awards under the Plan. Notwithstanding the foregoing provisions of this Section&nbsp;5(b), Shares that have actually been issued shall not again become available for Awards under the Plan, except
for Restricted Shares that are forfeited and do not become vested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(c)</I> <I>Substitution and Assumption of Awards</I><I>. </I>The
Committee may make Awards under the Plan by assumption, substitution or replacement of stock options, stock appreciation rights, stock units or similar awards granted by another entity (including a Parent or Subsidiary), if such assumption,
substitution or replacement is in connection with an asset acquisition, stock acquisition, merger, consolidation or similar transaction involving the Company (and/or its Parent or Subsidiary) and such other entity (and/or its affiliate). The terms
of such assumed, substituted or replaced Awards shall be as the Committee, in its discretion, determines is appropriate, notwithstanding limitations on Awards in the Plan. Any such substitute or assumed Awards shall not count against the Absolute
Share Limit set forth in Section&nbsp;5(a) (nor shall Shares subject to such Awards be added to the Shares available for Awards under the Plan as provided in Section&nbsp;5(b) above), except that Shares acquired by exercise of substitute ISOs will
count against the maximum number of Shares that may be issued pursuant to the exercise of ISOs under the Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 6. RESTRICTED SHARES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a)</I> <I>Restricted Stock Agreement</I>. Each grant of Restricted Shares under the Plan shall be evidenced by a Restricted
Stock Agreement between the recipient and the Company. Such Restricted Shares shall be subject to all applicable terms of the Plan and may be subject to any other terms that are not inconsistent with the Plan. The provisions of the various
Restricted Stock Agreements entered into under the Plan need not be identical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> <I>Payment for Awards</I>.
Restricted Shares may be sold or awarded under the Plan for such consideration as the Committee may determine, including (without limitation) cash, cash equivalents, full-recourse promissory notes, past services and future services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(c)</I> <I>Vesting</I>. Each Award of Restricted Shares may or may not be subject to vesting. Vesting shall occur, in full
or in installments, upon satisfaction of the conditions specified in the Restricted Stock Agreement. A Restricted Stock Agreement may provide for accelerated vesting in the event of the Participant&#146;s death, Disability or retirement or other
events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(d)</I> <I>Voting and Dividend Rights</I>. The holders of Restricted Shares awarded under the Plan shall have
the same voting, dividend and other rights as the Company&#146;s other stockholders. Holders of Restricted Shares must invest any cash dividends received in additional Restricted Shares. Such additional Restricted Shares shall be subject to the same
conditions and restrictions (including without limitation, any forfeiture conditions) as the Award with respect to which the dividends were paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(e)</I> <I>Restrictions on Transfer of Shares</I>. Restricted Shares shall be subject to such rights of repurchase, rights
of first refusal or other restrictions as the Committee may determine. Such restrictions shall be set forth in the applicable Restricted Stock Agreement and shall apply in addition to any general restrictions that may apply to all holders of Shares.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 7. TERMS AND CONDITIONS OF OPTIONS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a)</I> <I>Stock Option Agreement</I>. Each grant of an Option under the Plan shall be evidenced by a Stock Option Agreement
between the Optionee and the Company. Such Option shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions which are not inconsistent with the Plan and which the Committee deems
appropriate for inclusion in a Stock Option Agreement. The Stock Option Agreement shall specify whether the Option is an ISO or an NSO. The provisions of the various Stock Option Agreements entered into under the Plan need not be identical. Options
may be granted in consideration of a reduction in the Participant&#146;s other compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> <I>Number of
Shares</I>. Each Stock Option Agreement shall specify the number of Shares that are subject to the Option and shall provide for the adjustment of such number in accordance with Section&nbsp;11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(c)</I> <I>Exercise Price</I>. Each Stock Option Agreement shall specify the Exercise Price. The Exercise Price of an ISO
shall not be less than 100% of the Fair Market Value of a Share on the date of grant, except as otherwise provided in 4(c), and the Exercise Price of an NSO shall not be less 100% of the Fair Market Value of a Share on the date of grant.
Notwithstanding the foregoing, Options may be granted with an Exercise Price of less than 100% of the Fair Market Value of a Share on the date of grant pursuant to a transaction described in, and in a manner consistent with, Section&nbsp;424(a) of
the Code. Subject to the foregoing in this Section&nbsp;7(c), the Exercise Price under any Option shall be determined by the Committee at its sole discretion. The Exercise Price shall be payable in one of the forms described in Section&nbsp;8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(d)</I> <I>Withholding Taxes</I>. As a condition to the exercise of an Option, the Optionee shall make such arrangements as
the Committee may require for the satisfaction of any federal, state, local or foreign withholding tax obligations that may arise in connection with such exercise. The Optionee shall also make such arrangements as the Committee may require for the
satisfaction of any federal, state, local or foreign withholding tax obligations that may arise in connection with the disposition of Shares acquired by exercising an Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(e)</I> <I>Exercisability and Term</I>. Each Stock Option Agreement shall specify the date when all or any installment of
the Option is to become exercisable. The Stock Option Agreement shall also specify the term of the Option; provided that the term of an ISO shall in no event exceed 10 years from the date of grant (five years for Employees described in
Section&nbsp;4(c)). A Stock Option Agreement may provide for accelerated exercisability in the event of the Optionee&#146;s death, Disability, or retirement or other events and may provide for expiration prior to the end of its term in the event of
the termination of the Optionee&#146;s Service. Options may be awarded in combination with SARs, and such an Award may provide that the Options will not be exercisable unless the related SARs are forfeited. Subject to the foregoing in this
Section&nbsp;7(e), the Committee at its sole discretion shall determine when all or any installment of an Option is to become exercisable and when an Option is to expire. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(f)</I> <I>Exercise of Options</I>. Each Stock Option Agreement shall set
forth the extent to which the Optionee shall have the right to exercise the Option following termination of the Optionee&#146;s Service with the Company and its Subsidiaries, and the right to exercise the Option of any executors or administrators of
the Optionee&#146;s estate or any person who has acquired such Option(s) directly from the Optionee by bequest or inheritance. Such provisions shall be determined in the sole discretion of the Committee, need not be uniform among all Options issued
pursuant to the Plan, and may reflect distinctions based on the reasons for termination of Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(g) No Rights as a
Stockholder</I><I>.</I><I> </I>An Optionee, or a transferee of an Optionee, shall have no rights (including voting, dividend and other rights) as a stockholder with respect to any Shares covered by his Option until such person has satisfied all of
the terms and conditions to receive such Shares, has satisfied any applicable withholding or tax obligations relating to the Award and the Shares have been issued (as evidenced by an appropriate entry on the books of the Company or a duly authorized
transfer agent of the Company). The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustments shall be made for a dividend or other right for which the record date is prior to the date the Shares
are issued, except as provided in Section&nbsp;11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(h)</I> <I>Modification or Extension of Options</I>. Within the
limitations of the Plan, the Committee may modify or, extend outstanding Options or may accept the cancellation of outstanding Options (to the extent not previously exercised), whether or not granted hereunder, in return for the grant of new Options
for the same or a different number of Shares and at the same or a different Exercise Price; provided, however, that other than in connection with an adjustment of Awards pursuant to Section&nbsp;11, the Committee may not modify outstanding Options
to lower the Exercise Price nor may the Committee assume or accept the cancellation of outstanding Options in return for cash or the grant of new Options or SARs with a lower Exercise Price, unless such action has been approved by the Company&#146;s
stockholders. The foregoing notwithstanding, no modification of an Option shall, without the consent of the Optionee, materially impair his or her rights or obligations under such Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(</I><I>i</I><I>)</I> <I>Restrictions on Transfer of Shares</I>. Any Shares issued upon exercise of an Option shall be
subject to such special forfeiture conditions, rights of repurchase, rights of first refusal and other transfer restrictions as the Committee may determine. Such restrictions shall be set forth in the applicable Stock Option Agreement and shall
apply in addition to any general restrictions that may apply to all holders of Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(j)</I> <I>Buyout
Provisions</I>. Except with respect to an Option whose Exercise Price exceeds the Fair Market Value of the Shares subject to the Option, the Committee may at any time (a)&nbsp;offer to buy out for a payment in cash or cash equivalents an Option
previously granted or (b)&nbsp;authorize an Optionee to elect to cash out an Option previously granted, in either case at such time and based upon such terms and conditions as the Committee shall establish. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 8. PAYMENT FOR SHARES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a)</I> <I>General Rule</I>. The entire Exercise Price or Purchase Price of Shares issued under the Plan shall be payable in
lawful money of the United States of America at the time when such Shares are purchased, except as provided in Section&nbsp;8(b) through Section&nbsp;8(h) below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> <I>Surrender of Stock</I>. To the extent that a Stock Option Agreement so provides, payment may be made all or in
part by surrendering, or attesting to the ownership of, Shares which have already been owned by the Optionee or his representative. Such Shares shall be valued at their Fair Market Value on the date when the new Shares are purchased under the Plan.
The Optionee shall not surrender, or attest to the ownership of, Shares in payment of the Exercise Price if such action would cause the Company to recognize compensation expense (or additional compensation expense) with respect to the Option for
financial reporting purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(c)</I> <I>Services Rendered</I>. At the discretion of the Committee, Shares may be
awarded under the Plan in consideration of services rendered to the Company or a Subsidiary prior to the award. If Shares are awarded without the payment of a Purchase Price in cash, the Committee shall make a determination (at the time of the
Award) of the value of the services rendered by the Offeree and the sufficiency of the consideration to meet the requirements of Section&nbsp;6(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(d)</I> <I>Cashless Exercise</I>. To the extent that a Stock Option Agreement so provides, payment may be made all or in
part by delivery (on a form prescribed by the Committee) of an irrevocable direction to a securities broker to sell Shares and to deliver all or part of the sale proceeds to the Company in payment of the aggregate Exercise Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(e)</I> <I>Exercise/Pledge</I>. To the extent that a Stock Option Agreement so provides, payment may be made all or in part
by delivery (on a form prescribed by the Committee) of an irrevocable direction to a securities broker or lender to pledge Shares, as security for a loan, and to deliver all or part of the loan proceeds to the Company in payment of the aggregate
Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(f)</I> <I>Net Exercise</I>. To the extent that a Stock Option Agreement so provides, payment may be
made by a &#147;net exercise&#148; arrangement pursuant to which the number of Shares issuable upon exercise of the Option shall be reduced by the largest whole number of Shares having an aggregate Fair Market Value that does not exceed the
aggregate Exercise Price (plus tax withholdings, if applicable) and any remaining balance of the aggregate Exercise Price (and/or applicable tax withholdings) not satisfied by such reduction in the number of whole Shares to be issued shall be paid
by the Optionee in cash or other form of payment permitted under the Stock Option Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(g)</I> <I>Promissory
Note</I>. To the extent that a Stock Option Agreement or Restricted Stock Agreement so provides, payment may be made all or in part by delivering (on a form prescribed by the Company) a full-recourse promissory note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(h)</I> <I>Other Forms of Payment</I>. To the extent that a Stock Option Agreement or Restricted Stock Agreement so
provides, payment may be made in any other form that is consistent with applicable laws, regulations and rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(</I><I>i</I><I>)</I> <I>Limitations under Applicable Law</I>.
Notwithstanding anything herein or in a Stock Option Agreement or Restricted Stock Agreement to the contrary, payment may not be made in any form that is unlawful, as determined by the Committee in its sole discretion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 9. STOCK APPRECIATION RIGHTS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a) SAR Agreement.</I> Each grant of a SAR under the Plan shall be evidenced by a SAR Agreement between the Optionee and the
Company. Such SAR shall be subject to all applicable terms of the Plan and may be subject to any other terms that are not inconsistent with the Plan. The provisions of the various SAR Agreements entered into under the Plan need not be identical.
SARs may be granted in consideration of a reduction in the Participant&#146;s other compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> <I>Number of
Shares</I>. Each SAR Agreement shall specify the number of Shares to which the SAR pertains and shall provide for the adjustment of such number in accordance with Section&nbsp;11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(c)</I> <I>Exercise Price</I>. Each SAR Agreement shall specify the Exercise Price. The Exercise Price of a SAR shall not
be less than 100% of the Fair Market Value of a Share on the date of grant. Notwithstanding the foregoing, SARs may be granted with an Exercise Price of less than 100% of the Fair Market Value of a Share on the date of grant pursuant to a
transaction described in, and in a manner consistent with, Section&nbsp;424(a) of the Code. Subject to the foregoing in this Section&nbsp;9(c), the Exercise Price under any SAR shall be determined by the Committee in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(d)</I> <I>Exercisability and Term</I>. Each SAR Agreement shall specify the date when all or any installment of the SAR is
to become exercisable. The SAR Agreement shall also specify the term of the SAR. A SAR Agreement may provide for accelerated exercisability in the event of the Participant&#146;s death, Disability or retirement or other events and may provide for
expiration prior to the end of its term in the event of the termination of the Participant&#146;s service. SARs may be awarded in combination with Options, and such an Award may provide that the SARs will not be exercisable unless the related
Options are forfeited. A SAR may be included in an ISO only at the time of grant but may be included in an NSO at the time of grant or thereafter. A SAR granted under the Plan may provide that it will be exercisable only in the event of a Change in
Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(e)</I> <I>No Rights as</I> a <I>Stockholder</I><I>. </I>A Participant, or a transferee of a Participant,
shall have no rights (including voting, dividend and other rights) as a stockholder with respect to any Shares pertaining to his SAR until the date such person has satisfied all of the terms and conditions to receive such Shares, has satisfied any
applicable withholding or tax obligations relating to the Award and any Shares have been issued pursuant to the SAR (to the extent the SAR is settled in Shares and as evidenced by an appropriate entry on the books of the Company or a duly authorized
transfer agent of the Company). No adjustments shall be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section&nbsp;11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(f)</I> <I>Exercise of SARs</I>. Upon exercise of a SAR, the Optionee (or any person having the right to exercise the SAR
after his or her death) shall receive from the Company (a)&nbsp;Shares, (b) cash or (c)&nbsp;a combination of Shares and cash, as the Committee shall determine. The amount of cash and/or the Fair Market Value of Shares received upon exercise of SARs
shall, in the aggregate, be equal to the amount by which the Fair Market Value (on the date of surrender) of the Shares subject to the SARs exceeds the Exercise Price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(g)</I> <I>Modification, Extension or Assumption of SARs</I>. Within the
limitations of the Plan, the Committee may modify, extend or assume outstanding SARs or may accept the cancellation of outstanding SARs (whether granted by the Company or by another issuer) in return for the grant of new SARs for the same or a
different number of Shares and at the same or a different Exercise Price; provided, however, that other than in connection with an adjustment of Awards pursuant to Section&nbsp;11, the Committee may not modify outstanding SARs to lower the Exercise
Price nor may the Committee assume or accept the cancellation of outstanding SARs in return for cash or the grant of new Options or SARs with a lower Exercise Price, unless such action has been approved by the Company&#146;s stockholders. The
foregoing notwithstanding, no modification of a SAR shall, without the consent of the holder, materially impair his or her rights or obligations under such SAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(h)</I> <I>Buyout Provisions</I>. Except with respect to a SAR whose Exercise Price exceeds the Fair Market Value of the
Shares subject to the SAR, the Committee may at any time (a)&nbsp;offer to buy out for a payment in cash or cash equivalents a SAR previously granted, or (b)&nbsp;authorize an Optionee to elect to cash out a SAR previously granted, in either case at
such time and based upon such terms and conditions as the Committee shall establish. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 10. STOCK UNITS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a)</I> <I>Stock Unit Agreement</I>. Each grant of Stock Units under the Plan shall be evidenced by a Stock Unit Agreement
between the recipient and the Company. Stock Units shall be subject to all applicable terms of the Plan and may be subject to any other terms that are not inconsistent with the Plan. The provisions of the various Stock Unit Agreements entered into
under the Plan need not be identical. Stock Units may be granted in consideration of a reduction in the Participant&#146;s other compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> <I>Payment for Awards</I>. To the extent that an Award is granted in the form of Stock Units, no cash consideration
shall be required of the Award recipients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(c)</I> <I>Vesting Conditions</I>. Each Award of Stock Units may or may not
be subject to vesting. Vesting shall occur, in full or in installments, upon satisfaction of the conditions specified in the Stock Unit Agreement. A Stock Unit Agreement may provide for accelerated vesting in the event of the Participant&#146;s
death, Disability or retirement or other events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(d)</I> <I>Voting and Dividend Rights</I>. The holders of Stock Units
shall have no voting rights. Prior to settlement or forfeiture, any Stock Unit awarded under the Plan may, at the Committee&#146;s discretion, carry with it a right to dividend equivalents. Such right entitles the holder to be credited with an
amount equal to all cash dividends paid on one Share while the Stock Unit is outstanding. Dividend equivalents may be converted into additional Stock Units. Settlement of dividend equivalents may be made in the form of cash, in the form of Shares,
or in a combination of both. Dividend equivalents shall not be distributed prior to settlement of the Stock Unit to which the dividend equivalents pertain. Prior to distribution, any dividend equivalents which are not paid shall be subject to the
same conditions and restrictions (including without limitation, any forfeiture conditions) as the Stock Units to which they attach. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(e)</I> <I>Form and Time of Settlement of Stock Units</I>. Settlement of
vested Stock Units may be made in the form of (a)&nbsp;cash, (b) Shares or (c)&nbsp;any combination of both, as determined by the Committee. The actual number of Stock Units eligible for settlement may be larger or smaller than the number included
in the original Award, based on predetermined performance factors. Methods of converting Stock Units into cash may include (without limitation) a method based on the average Fair Market Value of Shares over a series of trading days. Vested Stock
Units may be settled in a lump sum or in installments. The distribution may occur or commence when all vesting conditions applicable to the Stock Units have been satisfied or have lapsed, or it may be deferred to any later date, subject to
compliance with Section&nbsp;409A of the Code. The amount of a deferred distribution may be increased by an interest factor or by dividend equivalents. Until an Award of Stock Units is settled, the number of such Stock Units shall be subject to
adjustment pursuant to Section&nbsp;11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(f)</I> <I>Death of Recipient</I>. Any Stock Units Award that becomes payable
after the recipient&#146;s death shall be distributed to the recipient&#146;s beneficiary or beneficiaries. Each recipient of a Stock Units Award under the Plan shall designate one or more beneficiaries for this purpose by filing the prescribed form
with the Company. A beneficiary designation may be changed by filing the prescribed form with the Company at any time before the Award recipient&#146;s death. If no beneficiary was designated or if no designated beneficiary survives the Award
recipient, then any Stock Units Award that becomes payable after the recipient&#146;s death shall be distributed to the recipient&#146;s estate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(g)</I> <I>Creditors</I><I>&#146;</I><I> Rights</I>. A holder of Stock Units shall have no rights other than those of a
general creditor of the Company. Stock Units represent an unfunded and unsecured obligation of the Company, subject to the terms and conditions of the applicable Stock Unit Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 11. ADJUSTMENT OF SHARES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a)</I> <I>Adjustments</I>. In the event of a subdivision of the outstanding Stock, a declaration of a dividend payable in
Shares, a declaration of a dividend payable in a form other than Shares in an amount that has a material effect on the price of Shares, a combination or consolidation of the outstanding Stock (by reclassification or otherwise) into a lesser number
of Shares, a recapitalization, a <FONT STYLE="white-space:nowrap">spin-off</FONT> or a similar occurrence, the Committee shall make appropriate and equitable adjustments in: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) The class(es) and maximum number of securities available for future Awards under Section&nbsp;5; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) The class(es) and number of securities that may be issued pursuant to the exercise of ISOs pursuant to
Section&nbsp;5; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) The class(es) and number of securities covered by each outstanding Option and SAR;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) The Exercise Price under each outstanding Option and SAR; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) The classes and number of securities subject to any
outstanding Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Committee will make such adjustments, and its determination will be final, binding and conclusive. Except as
provided in this Section&nbsp;11, a Participant shall have no rights by reason of any issue by the Company of stock of any class or securities convertible into stock of any class, any subdivision or consolidation of shares of stock of any class, the
payment of any stock dividend or any other increase or decrease in the number of shares of stock of any class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I>
<I>Dissolution or Liquidation</I>. To the extent not previously exercised or settled, Options, SARs and Stock Units shall terminate immediately prior to the dissolution or liquidation of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(c)</I> <I>Reorganizations</I>. In the event that the Company is a party to a merger or other reorganization, outstanding
Awards shall be subject to the agreement of merger or reorganization. Subject to compliance with Section&nbsp;409A of the Code, such agreement shall provide for: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) The continuation of the outstanding Awards by the Company, if the Company is a surviving corporation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) The assumption of the outstanding Awards by the surviving corporation or its parent or subsidiary; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) The substitution by the surviving corporation or its parent or subsidiary of its own awards for the
outstanding Awards; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) Full exercisability or vesting and accelerated expiration of the outstanding
Awards, provided, however, that the Committee may require Participants to complete and deliver to the Company a notice of exercise before the effective date of the merger or reorganization, which exercise is contingent upon the effectiveness of such
merger or reorganization; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) Cancellation of the Award, to the extent not vested or not exercised prior
to the effective time of the merger or reorganization, in exchange for such cash consideration, if any, as the Committee, in its sole discretion, may consider appropriate; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi) Settlement of the intrinsic value of the outstanding Awards (whether or not then vested or exercisable) in
cash or cash equivalents or equity (including cash or equity subject to deferred vesting and delivery consistent with the vesting restrictions applicable to such Awards or the underlying Shares) followed by cancellation of such Awards (and, for the
avoidance of doubt, if as of the date of the occurrence of the transaction the Committee determines in good faith that no amount would have been attained upon the exercise of such Award or realization of the Participant&#146;s rights, then such
Award may be terminated by the Company without payment, and such amount may be delayed to the same extent that payment of consideration to the holders of Common Stock in connection with the merger or reorganization is delayed as a result of escrows,
earnouts, holdbacks or other contingencies); in each case without the Participant&#146;s consent. Any acceleration of payment or an amount that is subject to Section&nbsp;409A of the Code will be delayed, if necessary, until the earliest time that
such payment would be permissible under Section&nbsp;409A of the Code without triggering any additional taxes applicable under Section&nbsp;409A of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company need not take the same action or actions with respect to all Awards or portions
thereof or with respect to all Participants. The Company may take different actions with respect to the vested and unvested portions of an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(d)</I> <I>Reservation of Rights</I>. Except as provided in this Section&nbsp;11, an Optionee, Offeree or Participant shall
have no rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend or any other increase or decrease in the number of shares of stock of any class. Any issue by the Company of shares of stock of
any class, or securities convertible into shares of stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number or Exercise Price of Shares subject to an Award. The grant of an Award pursuant
to the Plan shall not affect in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure, to merge or consolidate or to dissolve, liquidate, sell or transfer
all or any part of its business or assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(e)</I> <I>Change in Control</I>. In its discretion, the Committee pay
provide in the Award Agreement governing an Award or at any other time may take such action as it deems appropriate to provide for acceleration of the exercisability, vesting and/or settlement in connection with a Change in Control of each or any
outstanding Award or portion thereof and shares acquired pursuant thereto upon such conditions, including termination of the Participant&#146;s Service prior to, upon or following such Change in Control, and to such extent as the Committee shall
determine. In the absence of such provision in an Award Agreement or any such action taken by the Committee, no acceleration will occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 12.
DEFERRAL OF AWARDS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a)</I> <I>Committee Powers</I>. Subject to compliance with Section&nbsp;409A of the Code, the
Committee (in its sole discretion) may permit or require a Participant to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) Have cash that otherwise
would be paid to such Participant as a result of the exercise of a SAR or the settlement of Stock Units credited to a deferred compensation account established for such Participant by the Committee as an entry on the Company&#146;s books; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) Have Shares that otherwise would be delivered to such Participant as a result of the exercise of an Option
or SAR converted into an equal number of Stock Units; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) Have Shares that otherwise would be
delivered to such Participant as a result of the exercise of an Option or SAR or the settlement of Stock Units converted into amounts credited to a deferred compensation account established for such Participant by the Committee as an entry on the
Company&#146;s books. Such amounts shall be determined by reference to the Fair Market Value of such Shares as of the date when they otherwise would have been delivered to such Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> <I>General Rules</I>. A deferred compensation account established under this Section&nbsp;12&nbsp;may be credited
with interest or other forms of investment return, as determined by the Committee. A Participant for whom such an account is established shall have no rights other than those of a general creditor of the Company. Such an account shall represent an
unfunded and unsecured obligation of the Company and shall be subject to the terms and conditions of the applicable agreement between such Participant and the Company. If the deferral or conversion of Awards is permitted or required, the Committee
(in its sole discretion) may establish rules, procedures and forms pertaining to such Awards, including (without limitation) the settlement of deferred compensation accounts established under this Section&nbsp;12. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 13. AWARDS UNDER OTHER PLANS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company may grant awards under other plans or programs. Such awards may be settled in the form of Shares issued under this
Plan. Such Shares shall be treated for all purposes under the Plan like Shares issued in settlement of Stock Units and shall, when issued, reduce the number of Shares available under Section&nbsp;5. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 14. LEGAL AND REGULATORY REQUIREMENTS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares shall not be issued under the Plan unless the issuance and delivery of such Shares complies with (or is exempt from) all
applicable requirements of law, including (without limitation) the Securities Act of 1933, as amended, the rules and regulations promulgated thereunder, state securities laws and regulations and the regulations of any stock exchange on which the
Company&#146;s securities may then be listed, and the Company has obtained the approval or favorable ruling from any governmental agency which the Company determines is necessary or advisable. The Company shall not be liable to a Participant or
other persons as to: (a)&nbsp;the <FONT STYLE="white-space:nowrap">non-issuance</FONT> or sale of Shares as to which the Company has not obtained from any regulatory body having jurisdiction the authority deemed by the Company&#146;s counsel to be
necessary to the lawful issuance and sale of any Shares under the Plan; and (b)&nbsp;any tax consequences expected, but not realized, by any Participant or other person due to the receipt, exercise or settlement of any Award granted under the Plan.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 15. WITHHOLDING TAXES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a)</I> <I>Withholding Taxes</I>. To the extent required by applicable federal, state, local or foreign law, a Participant
or his or her successor shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise in connection with the Plan. The Company shall not be required to issue any Shares or make any cash
payment under the Plan until such obligations are satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> <I>Share Withholding</I>. The Committee may
permit a Participant to satisfy all or part of his or her withholding or income tax obligations by having the Company withhold all or a portion of any Shares that otherwise would be issued to him or her or by surrendering all or a portion of any
Shares that he or she previously acquired. Such Shares shall be valued at their Fair Market Value on the date when taxes otherwise would be withheld in cash. In no event may a Participant have Shares withheld that would otherwise be issued to him or
her in excess of the number necessary to satisfy the maximum legally required tax withholding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 16. OTHER PROVISIONS APPLICABLE TO AWARDS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a)</I> <I>Transferability</I>. Unless the agreement evidencing an Award (or an amendment thereto authorized by the
Committee) expressly provides otherwise, no Award granted under this Plan, nor any interest in such Award, may be sold, assigned, conveyed, gifted, pledged, hypothecated or otherwise transferred in any manner (prior to the vesting and lapse of any
and all restrictions applicable to Shares issued under such Award), other than by will or the laws of descent and distribution; provided, however, that an ISO may be transferred or assigned only to the extent consistent with Section&nbsp;422 of the
Code. Any purported assignment, transfer or encumbrance in violation of this Section&nbsp;16(a) shall be void and unenforceable against the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> <I>Performance Criteria</I>. The number of Shares or other benefits granted, issued, retainable and/or vested under
an Award may be made subject to the attainment of performance goals. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) The Committee may utilize
performance criteria including, but not limited to any of the following performance criteria: (a)&nbsp;cash flow (including operating cash flow), (b) earnings per share, (c)&nbsp;earnings before any combination of interest, taxes, depreciation or
amortization, (d)&nbsp;return on equity, (e)&nbsp;total stockholder return, (f)&nbsp;share price performance, (g)&nbsp;return on capital, (h)&nbsp;return on assets or net assets, (i)&nbsp;revenue, (j) income or net income, (k)&nbsp;operating income
or net operating income, (l)&nbsp;operating profit or net operating profit, (m)&nbsp;operating margin or profit margin (including as a percentage of revenue), (n) return on operating revenue, (o)&nbsp;return on invested capital, (p)&nbsp;market
segment shares, (q)&nbsp;costs, (r) expenses, (s)&nbsp;achievement of target levels of discovery and/or development of products or services, including but not limited to research or regulatory achievements, (t)&nbsp;third party coverage and/or
reimbursement objectives, (u)&nbsp;test volume metrics, (v)&nbsp;objective customer indicators (including, without limitation, customer satisfaction), (w) improvements in productivity, (x)&nbsp;attainment of objective operating goals,
(y)&nbsp;objective employee metrics or (z)&nbsp;any other measures of performance selected by the Committee (&#147;Qualifying Performance Criteria&#148;), any of which may be measured either individually, alternatively or in any combination, applied
to either the individual, the Company as a whole or to a business unit or subsidiary of the Company, either individually, alternatively or in any combination, and measured either annually or cumulatively over a period of years, or on the basis of
any other specified period, on an absolute basis or relative to a <FONT STYLE="white-space:nowrap">pre-established</FONT> target, to previous years&#146; results or to a designated comparison group or index, and subject to specified adjustments, in
each case as specified by the Committee in the Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) Unless specified otherwise by the Committee at
the time the performance goals are established, the Committee shall appropriately adjust the method of evaluating performance under a Qualifying Performance Criteria for a performance period as follows: (a)&nbsp;to exclude asset write-downs,
(b)&nbsp;to exclude litigation or claim judgments or settlements, (c)&nbsp;to exclude the effect of changes in tax law, accounting principles or other such laws or provisions affecting reported results, (d)&nbsp;to exclude accruals for
reorganization and restructuring programs, (e)&nbsp;to exclude any extraordinary nonrecurring items as determined under generally accepted accounting principles and/or described in managements&#146; discussion and analysis of financial condition and
results of operations appearing in the Company&#146;s annual report to stockholders for the applicable year, (f)&nbsp;to exclude the dilutive and/or accretive effects of acquisitions or joint ventures, (g)&nbsp;to assume that any business divested
by the Company achieved performance objectives at targeted levels during the balance of a performance period following such divestiture, (h)&nbsp;to exclude the effect of any change in the outstanding shares of common stock of the Company by reason
of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to
common stockholders other than regular cash dividends, (i)&nbsp;to exclude the effects of stock based compensation; (j)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under
generally accepted accounting principles and (k)&nbsp;to make other appropriate adjustments selected by the Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Committee shall establish in writing the applicable performance goals (and any variation
to the adjustments specified in the preceding subparagraph (ii)), and an objective method for determining the Award earned by a Participant if the goals are attained, while the outcome is substantially uncertain, and shall determine and certify in
writing, for each Participant, the extent to which the performance goals have been met prior to payment or vesting of the Award. The Committee may reserve the right, in its sole discretion, to reduce the amount of compensation otherwise payable
under the Plan upon the attainment of the <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 17. NO EMPLOYMENT RIGHTS.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No provision of the Plan, nor any right or Award granted under the Plan, shall be construed to give any person any
right to become, to be treated as, or to remain an Employee, Consultant or Outside Director. The Company and its Subsidiaries and Affiliates reserve the right to terminate any person&#146;s Service at any time and for any reason, with or without
notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 18. SECTION 409A. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Plan is intended to comply with Section&nbsp;409A of the Code to the extent subject thereto, and, accordingly, to the
maximum extent permitted, the Plan shall be interpreted and administered to be in compliance therewith. Notwithstanding the foregoing, neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment of
any additional tax or penalty on any Participant under Section&nbsp;409A of the Code and neither the Company nor the Committee will have any liability to any Participant for such additional tax or penalty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each Award that provides for &#147;nonqualified deferred compensation&#148; within the meaning of Section&nbsp;409A of the
Code shall be subject to such additional rules and requirements as specified by the Committee from time to time in order to comply with Section&nbsp;409A of the Code. If any amount under such an Award is payable upon a &#147;separation from
service&#148; (within the meaning of Section&nbsp;409A of the Code) to a Participant who is then considered a &#147;specified employee&#148; (within the meaning of Section&nbsp;409A of the Code), then no such payment shall be made prior to the date
that is the earlier of (i)&nbsp;six months and one day after the Participant&#146;s separation from service, or (ii)&nbsp;the Participant&#146;s death, but only to the extent such delay is necessary to prevent such payment from being subject to
interest, penalties and/or additional tax imposed pursuant to Section&nbsp;409A of the Code. In addition, the settlement of any such Award may not be accelerated except to the extent permitted by Section&nbsp;409A of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 19. DURATION AND AMENDMENTS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(a)</I> <I>Term of the Plan</I>. The Plan, as set forth herein, shall become effective on the Effective Date. No Award may
be granted hereunder prior to the Effective Date. The Board of Directors may suspend or terminate the Plan at any time. No ISOs may be granted after the tenth anniversary of the earlier of (i)&nbsp;the date the Plan, as amended and restated herein,
is adopted by the Board of Directors, or (ii)&nbsp;the date the Plan, as amended and restated herein is approved the stockholders of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(b)</I> <I>Right to Amend or Terminate the Plan</I>. The Board of Directors may amend or terminate the Plan at any time and
from time to time. Rights and obligations under any Award granted before amendment of the Plan shall not be materially impaired by such amendment, except with consent of the Participant. An amendment of the Plan shall be subject to the approval of
the Company&#146;s stockholders only to the extent required by applicable laws, regulations or rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>(c)</I>
<I>Effect of Termination</I>. No Awards shall be granted under the Plan after the termination thereof. The termination of the Plan shall not affect Awards previously granted under the Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 20. AWARDS TO <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> PARTICIPANTS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Awards may be granted to Participants who are <FONT STYLE="white-space:nowrap">non-United</FONT> States nationals or employed
or providing services outside the United States, or both, on such terms and conditions different from those applicable to Awards to Participants who are employed or providing services in the United States as may, in the judgment of the Committee, be
necessary or desirable to recognize differences in local law, currency or tax policy or custom. The Committee also may impose conditions on the exercise, vesting or settlement of Awards in order to minimize the Company&#146;s obligation with respect
to tax equalization for Participants on assignments outside their home country. The Committee may, in its sole discretion, adjust the value of any Awards or any amounts due to Participants hereunder to reflect any foreign currency conversions or
fluctuations in foreign currency exchange rates; provided, however, that none of the Company or any Parent, Subsidiary or Affiliate shall be liable for any foreign exchange rate fluctuations between a Participant&#146;s local currency and the United
States Dollar that may affect the value of any Awards or of any amounts due to a Participant hereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 21. FORFEITURE, CANCELLATION OR
CLAWBACK OF AWARDS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) The Committee may specify in an Award Agreement that the Participant&#146;s rights, payments,
and benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture, or recoupment upon the occurrence of specified events, in addition to any otherwise applicable vesting or performance conditions of an Award. Such events
may include, but shall not be limited to, termination of Service for Cause or any act by a Participant, whether before or after termination of Service, that would constitute Cause for termination of Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company, as a
result of misconduct, with any financial reporting requirement under the securities laws, at the discretion of the Committee, any Participant who knowingly or through gross negligence engaged in the misconduct, or who knowingly or through gross
negligence failed to prevent the misconduct, and any Participant who is one of the individuals subject to automatic forfeiture under Section&nbsp;304 of the Sarbanes-Oxley Act of 2002, shall reimburse the Company for (i)&nbsp;the amount of any
payment in settlement of an Award received by such Participant during the twelve (12) month period following the first public issuance or filing with the United States Securities and Exchange Commission (whichever first occurred) of the financial
document embodying such financial reporting requirement, and (ii)&nbsp;any profits realized by such Participant from the sale of securities of the Company during such twelve- (12)&nbsp;month period. In addition, to the extent claw-back or similar
provisions applicable to Awards are required by applicable law, listing standards and/or policies adopted by the Company, Awards granted under the Plan shall be subject to such provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION 22. GOVERNING LAW. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Plan, each Award Agreement and each Award and all disputes or controversies arising out of or relating thereto and all
other matters shall be governed by, and construed in accordance with, the internal laws of the State of Delaware as to matters within the scope thereof, without regard to the laws of any other jurisdiction that might be applied because of the
conflicts of laws principles of any state. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">PLUS THERAPEUTICS, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">2020 STOCK INCENTIVE PLAN </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Appendix A | 23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g41684g89m19.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g41684g01v01.jpg" ALT="LOGO">
 </P> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">VOTE BY INTERNET&#151;www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic
delivery of information up until 11:59 P.M. ET on 05/16/2021. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. During The
Meeting&#151;Go to www.virtualshareholdermeeting.com/PSTV2021 PLUS THERAPEUTICS, INC. C/O Broadridge You may attend the meeting via the Internet and vote during the meeting. Have the P.O. Box 1342 information that is printed in the box marked by the
arrow available and follow the Brentwood, NY 11717 instructions. VOTE BY <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PHONE&#151;1-800-690-6903</FONT></FONT></FONT> 1 Use any touch-tone telephone
to transmit your voting instructions up until 11:59 P.M. ET Investor Address Line 1 on 05/16/2021. Have your proxy card in hand when you call and then follow the Investor Address Line 2 instructions. Investor Address Line 3 1 1 OF Investor Address
Line 4 VOTE BY MAIL Investor Address Line 5 Mark, sign and date your proxy card and return it in the postage-paid envelope we have John Sample provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. 1234
ANYWHERE STREET 2 ANY CITY, ON A1A 1A1 CONTROL # &acirc;&#134;&#146; NAME THE COMPANY NAME INC.&#151;COMMON SHARES 123,456,789,012.12345 THE COMPANY NAME INC.&#151;CLASS A 123,456,789,012.12345 THE COMPANY NAME INC.&#151;CLASS B
123,456,789,012.12345 THE COMPANY NAME INC.&#151;CLASS C 123,456,789,012.12345 THE COMPANY NAME INC.&#151;CLASS D 123,456,789,012.12345 THE COMPANY NAME INC.&#151;CLASS E 123,456,789,012.12345 THE COMPANY NAME INC.&#151;CLASS F 123,456,789,012.12345
THE COMPANY NAME INC.&#151;401 K 123,456,789,012.12345 PAGE 1 OF 2 TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: x KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION
ONLY For Withhold For All To withhold authority to vote for any All All Except individual nominee(s), mark &#147;For All Except&#148; and write the number(s) of the The Board of Directors recommends you vote FOR 0 nominee(s) on the line below. 2 the
following: 0 0 0 1. Election of Directors Nominees 0000000000 01) Richard J. Hawkins 02) Marc H. Hedrick, M.D. 03) An Van Es-Johansson 04) Greg Petersen 05) Howard Clowes 06) Robert Lenk The Board of Directors recommends you vote FOR proposals 2, 3
and 4. For Against Abstain 2. Ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the 0 0 0 2021 fiscal year. 3. Approval of the amendment and restatement of the Plus Therapeutics, Inc. 2020 Stock
Incentive Plan. 0 0 0 4. <FONT STYLE="white-space:nowrap">Non-binding</FONT> advisory vote on compensation of our named executive officers. 0 0 0 NOTE: Transact such other business as may be properly brought before the meeting or any adjournment or
postponement thereof. Investor Address Line 1 Investor Address Line 2 Investor Address Line 3 Investor Address Line 4 Investor Address Line 5 Please sign exactly as your name(s) appear(s) hereon. When signing as John Sample attorney, executor,
administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must 1234 ANYWHERE STREET sign. If a corporation or partnership, please sign in full corporate or ANY CITY, ON A1A 1A1
partnership name by authorized officer. SHARES CUSIP # JOB # SEQUENCE # Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date 0000504378_1 R1.0.0.177 </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g41684g02v02.jpg" ALT="LOGO">
 </P> <P ALIGN="justify" STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Combined Document is
available at www.proxyvote.com . PLUS THERAPEUTICS, INC. PROXY SOLICITED BY THE BOARD OF DIRECTORS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY&nbsp;17, 2021 The undersigned hereby appoints each of Marc H. Hedrick, M.D. and Andrew Sims,
or either of them, as proxy holders each with full power of substitution, to appear on behalf and to vote all shares of common stock of Plus Therapeutics, Inc. (the &#147;Company&#148;) that the undersigned is entitled to vote at the Annual Meeting
of Stockholders of the Company to be held virtually via live webcast at www.virtualshareholdermeeting.com/PSTV2021 on May&nbsp;17, 2021, and at any postponement thereof. When properly executed, this proxy will be voted as directed. If properly
executed and no instructions are specified, this proxy will be voted FOR the election of the listed Nominees as Directors under Proposal 1, FOR Proposals 2, 3 and 4, and at the discretion of the proxies with respect to such other business as may
properly come before the meeting. The proxies, in their discretion, are further authorized to vote (a)&nbsp;for the election of a person to the Board of Directors if any nominee named herein becomes unable to serve or for good cause will not serve,
(b)&nbsp;on any matter which the Board of Directors did not know would be presented at the Annual Meeting of Stockholders by a reasonable time before the proxy solicitation was made, and (c)&nbsp;on other matters which may properly come before the
Annual Meeting of Stockholders and any adjournments or postponements thereof. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of
Director&#146;s recommendations. PLEASE COMPLETE, DATE AND SIGN THIS PROXY AND RETURN IT IN THE ACCOMPANYING ENVELOPE. Continued and to be signed on reverse side 0000504378_2 R1.0.0.177 </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g41684g01v01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g41684g01v01.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0./:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z13 R-3 X1#<Y-#4S,3%%0CE&-CA%1#8U-C<Q
M.#%#-#@B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z13 R-3 X1#8Y-#4S
M,3%%0CE&-CA%1#8U-C<Q.#%#-#@B('AM<#I#<F5A=&]R5&]O;#TB07-P;W-E
M($QT9"XB/B \>&UP34TZ1&5R:79E9$9R;VT@<W12968Z:6YS=&%N8V5)1#TB
M=75I9#HX.&1B-C5D-2TU,C4R+31A,#DM8C0R-"TP.#=B-C<S,3AD.3 B('-T
M4F5F.F1O8W5M96YT240](G5U:60Z-39D,C Q864M8F-C-BTT9C,P+3DV9&4M
M93DU-S8S-3(W,C0T(B\^(#QD8SIC<F5A=&]R/B \<F1F.E-E<2\^(#PO9&,Z
M8W)E871O<CX@/&1C.G1I=&QE/B \<F1F.D%L="\^(#PO9&,Z=&ET;&4^(#PO
M<F1F.D1E<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP
M86-K970@96YD/2)R(C\^_^X #D%D;V)E &3      ?_; (0  0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @("
M P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\  $0@#Z ,% P$1  (1
M 0,1 ?_$ *\  0 " P$! 0$!           '" 4&"00# @$* 0$
M            $   !@(! 00#!! 1!P<* 0T" P0%!@<  0@1$A,4"2$5%E87
MUQ@QT2+2DU24U+4V5Y=8>)C805&Q(U-T595VEM8W=[<XN!EA,R2TU5F9<9$R
MLC6V>8&A0E)RLS0E.0KP0],FP7-$)UKQ8H*2*!$!
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M,!@1;<_\WB_^%%8_UJ0G E4S_.&?^V+_ *V\#\8# 8# C%1_/<R_T-RW_O\
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M0=LI+9L.5*3-%$A&9LM.E(&:8+IT 6 0M]-:WO DXS_.#_\ ;%^KO _& P&
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MZ;\^%/ ?$\XY^X:1_?IOSX4\!\3SCG[AI']^F_/A3P'Q/..?N&D?WZ;\^%/
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MN-%,*+U3ZU0L_P#HRG2U;WRKQC@7^M]G7S'7?7T=,"\OLLV?^LJ^B@__ #6
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MNDG#LJ-NLN7UZ^*>2T+B#A'55<,\_J'V2O1H:X$Y60W,TI7-?(99"WRJ0*E
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M 8'^7;SY_P"?2AOZ)I#_ -\,#M_Y>7]B#C!_1#%O]5%@7*P/\>/G5?VVY/\
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M!@10[_\ :B_]LC_4#@8[ 8# 8# 8# 8# 8# KW9']I#A/_2)=_\ =ZF^!>S
M8# 8# 8%1^97*1%Q(K9ALQPCCI+4:N3OK0='F;;62XNVF2H[2LO3>F7O#DVH
M&LY>*OM$ 4#V< !AH=#!H AFEA0][\TFQ&*YU\5=*1CK1%6*+2N.NC&[6;&F
ME=NZX5.K\22XA79[V<VQ%K@B&O>.KFJ9A"0"7/3JYITYH4)91YI82$3YHJI[
M''5D.XS3-]CTR>W9OBJYRL&&1EZ5M39<U*T 6ZN\=<BQF,2I59=[-)>T0U!A
MQ+<D6J!BT:6G3*@C"=^<8V(!1R-02G4ZV?RA@:3@()58*!&Q12:I7".JYQ$)
MDZM#0L1MB-EA[DK6(EP5(E:L9:8PQN(1J0*L#:TWFV1TI #NJ@D,I5GO)$"9
MP(YA!6&0/EG*R(D]IVQ3"U+NXN4<KP<=FR,)<K/.,0G.H!I.Y#WA!QH7"1<Q
M8^33%9V_+8>NB!,WO4/'R1,Z^1L9Z2"35';TFI)^<%TGV)*U.<9;YI%%'AU0
M0D&+$QI(NZ*-,V4$(8XF^91$.5\^9H<PUJZ1END["\NL;?#9M%),N.51N TU
M8KR4_P 68S!.T89#6.[FPMN<U&Q$KU2<X/9* 8B,5ABI;YF\<;Y6DKJ!5,YV
M%9"R66A$=Q0NP8C'MM2VKK,OFO'!1)%BL*XYB(>4]!.+HC"8G$:8G5D@T'8M
M#%H-&H;S)99>EPUO"$\&C\88K"M.0-#8 Y=IZ=3*G!7]G2^(O3F8C=B?9RQ7
M!1$D/C6_9*Y 4D,,$4>9LTL0 LS9E^WI&KTNNK8E%*G7-<3XB[O&JE$B?Y<E
M7OD]32F01]T26 I;6120PQ%+X)-X=,W)W!8I[!HQJB.] 40$%V9S3M^-TWQ;
MM5(163"TV'6\8MVXU!:N-O\ +=14RLH?+Y,AK"K95:E;O+JM)?):$LLE(N?W
M+20LL):4\]02$0;WP\Y>6+>\HO2-3=ECQ:BMF%KE12F-,#JUL,7<GBP;MA!U
M7*),LDTA0V4KCJ2I4ZT<C;RVQ*NVY# %&0(G8 A#-1\Q.63]Q#NOD/.(M$D!
MC7Q';+OIV12JKGNK&!SMQ=64TG3M"=1!1;DTD5@5M'2VUG5@>B%3$<N2JCRB
M@B& 9J<))XB\V;%Y#W@\P62QV'1N&1NA8<>]F(T[L3(2>3\<FCI".1$-*6+W
M@Y#N(PB5C3LB$CPVUNW)O7",4&!V L ?%IMJT6OEE8?&"J$=?U=4-<#A2%C)
M9*BA"]J3/EG0-YL)R<7H\[D56[^G/42Y=L[9#/#W$*H1@MFJ>^4&FIPD6G.1
M-CQ[B-:7)GD(^1N>!K\R^'DQJJFNU<$&"-T?-)[#SDA*616/-25KJ_E0?Q8E
M!ZU"D2"4B"9L))>SL",8'YF*69V@CK4ZCG9&!FL.NJILZ9,=F0F6Q2*S>VI3
M/(E BX@N; D&65'5;G"M:<%R<*(3:)2,DP@2A*>3H,+R-YL7)6-P6I"8.JH_
MNHGM7 HK!I^I!'9*LDKEQ>E5^L5W/\W>;$C4;::B:)8RD1A<E4HDA)AFCS/7
M!!O8)T$5RCD[)I]6[U<!574+9]B\4'R!L$@FEL5^E;U4-LF2\B7"#3K=9G1B
M46@W@41N$Q1"N0;;I%I,X*W! M-6D;3#0X&Z1_GW<3_;%O5UMLK!@4ALJ:0B
MFT4C3!T4V,U.WE-ZZM&96<\L5FO#BW,A=;U^NDY07)HC)Y9(MC3!<$A1IX0C
MY#YAM]@%$E@)'Q[ED0<G1M?X=-T44D<83<GZ_D-O493A&ZP8E-JOZZOA,[W9
M;NM2.:DQ_P!O;.F9W$+>F2.6C!A+L)YD\@7>%P.:(EW'NUH'+.8]/T@1;T-2
M2R-1Z9U58A<:8Y#)ZPB(I3-3W8+593JM;&9]7O"1 \LZ'3HG1GDG)Q* N!R;
MON0TJR4R^PB*&V1[X=]P>KG*/L 6I<_.+')FZ4GN!L4-=I5$H\![1*&0L?>+
M%P4X" '=0C,[ <"C"#S7PM3O7\*DU)R!ZL*?2ZY8_J&QQW9D4OC*F)V1R98J
MXC#W'"W"4,P9#((IQR6%JC=OI0%+L=KU<2J([_:0)9@'F;0*S;WKBH(;5L]>
M8U9R5N=HW;"7N-Q=PBDP-M8VKYVVIS4I.U\.G;+4*]>$X2@E8F3+D(@I5 1*
MQ(PW"Z.?;%4-F2.G?>R>WZ?,;Q"D  *Y,R16)@8[3=JZB-63J12QW*,2QN%S
M*P9HYL@5&R5*@M7%'0)9!Y@4Y1X0B#S<JW=(S&5\5JR0ODTF4Z8J]C=>*9O"
M6IZ6O$AA5/25O>C%FUBY)[#GO=OIVTEY(TH1JBT8U:?9I1Q(!!87DWSC:.,,
MVKJ&R:O%<@%+80XS^1JVN:1QO6L#(U6-5-7+$<5C[P%([V3(MR2W$)A:%" D
MPQ&G.%UTH&F3* KVD\UUE V-SL_T>X1\E=7K9-S$*JV:^&])5,CH*3<GXNWB
M:CAHS36!=3\8, J?M"]6(Y0<!JT(XL!Z\D)YH#GO$^0,LK*',%=2MC=[6@/O
MT,"9T<F10J:J0/0.9"6<2M*@/.$POZ">)4T6>8\,0W!D?E6TZC?4@WH$'W#Y
ML$#J%KMAW7UVG<05[-+'B,?8=VQ"4\^FA=+KK+;K4=CJU;RGR=Q-*@/JQP.9
MC%2 U&Z(3B%2E2W$=^(@,+/?-(<RFQF-@-/)F\,ILMNCL8D4_GD92I'6!H.3
M56\<91)4482+D;BZR4Y_GQHDK*D6'*$R8DM4>(0C4R)4$R\FN?GQ;[7DU>%5
M6^66..5,&XG<#6^QR+ 983&XM<4XG;J4O>5AYCZZDQVK#"T+<%,FT<M-* )0
M HPTY,&P<EN9CUQVM^M&4V#)I;4LBJUWGE@/B9U1LLFAA&[NH&HV>0(PNRTE
M \M2/WY#%*Q!W91XRDVS J2]EA(4!6>,><-$Y@)\]G*+DKVGAQKU(9JY-D[C
MNVMKJEI8Z*DQ4[8%+FVM1LN<7!BOA ,EN2E!2GFHCMIG!0F,(5&!8CCGS9D7
M(>4<B_9^MD6X[5U55A85;1EKF$=>I]-3YT[W\A U2O3<YJ&Z R5TU5"(@#(N
M* I:E)YNE!YVA="0KD]^9!&GV6,LVXW\?T\TDSS.BZ_LB1R?U!")!*JN9Z@O
M^XZS QRT\P2P*61H:_<'MJTM J3HT0U!0TQ2A<6:6&<BGFW,5F/?J"J^.5ER
M59(9?&836JB1OC#!FR4O3PXF-#L%_<'5.J(BQ#2M+V<0--MXTN0 &=KN3>Z3
MG!(_!.Q&FWZEGUL,*-P;F2SN05J6 TMSL%,!U;V^8$15_2H'(*-0K1^/1$K]
M%';)--*V8#>P#$'IO870P& P& P*Z\F_M+K;\:CAO_>GJ/ OE@,!@,!@,!@,
M!@,!@4OOK^U%P[_:?);^J]MP)HP&!SH\UCRWY9YE=$5!6,1M*.54LKVS#Y^J
M=I)&7*4)G-,.,R*.:;4R5L=FDU,HT:\!-[P0QA[(-A[/7?70?YB^87_V\%I<
M/N-%N\E7_DW7TW:*DCB>1+8HSUM(F9R>RU#VU,VDJ5T62E<F1&!&Z:,[8R3-
M;T#IT]/704N\L;RKIGYFRJYDL0N&+5,*FR8,<O%)8D[2G3[J<CE(4VD>FMY:
M/ ^K_98?>=OO.\[X/3IV=]0_TK>6IY!UF\#^7L%Y+R3D; [%:(A&Y^Q'Q1BK
MV01]R6FS*+K&!.H)=%\E<DI($)JG1@PB)%L8==-;UOTX'7[C)Y>5#\99G)K2
M:$[E-[8E#Q)'0V=RWPIJB/$2=T6N+@U0]J2DE-\?3& 6=P:?K1JX\K6P#/[L
M6R\"1.=']C;D[_0C8G_=M=@<!_(?_M*W!_07O_O]%<#_ %28# _S1>?=$G$F
M=<=)YW0]M"^*SF';/UK>RRG1M=69\*(&+Y 1J4;D8(&M_P#2T2+I_P!'>!U$
M\J>TH]9/"6H4#2M3FO%:-BFMI8V@&#Q+4ZQQ:H"@\03H>S %.C >D5E#WK6A
MA-WTZ]G?0.C.!_BX\T:<-EX<ZK&200X#Z2W;AM0-AZ#85!;K)&=*6UN2=&,H
M0PJ.YE#J>C#L.]Z$,G?3 _V10QD'&H?%(X8+0S(_&F)D,&'?:T,;2UI4 Q:W
MZ>NA"3]<#"P^SZWLA9,&B$S.,RY?!7]5$9LVLKHC<E,<?TP-;5-#TE)&,Q*>
M'0MAWV]=@0@C#K>Q 'K00+;7 [B+=A:P<ZHF"#=5@3>W)8TUAADH <;K?57Z
M^BHFA>H4!%OM:V>(T.]Z^:#O7HP/\FW._CJCX3\FE4)KB8O"YN;&F,V9 WE6
MJ)!*XN-4L7FMR-P7-Y:4LQT9'5D$80J 64(TG98A!T+M=0_V@5')G&:U16,R
M>"PE.\MKR%R9T*"#N@EN+]&VUU7%A+UK6BP@4JA:T'IZ.G3 D+ BAW_[47_M
MD?Z@<#'8# 8# 8# 8# 8# 8%>[(_M(<)_P"D2[_[O4WP+V8# 8# 8# A*];.
MJ.JXRU/=SE(O9->ZNZ$A<ZL('YI0.3=!)E*SMK@FD*2T W*/1MP1)1B#K:M8
MI*0@V(U666,*HD\R^%T[=S84^0Q<,<M','IJ3S:E#R6BQ$]3(K,G$]D3,)U:
M34[X37TEK-\3JS3P@/*?.Z&2$8%J=2<$E6QRJXQ4W&:6G\]0A11N]5C"KAL@
M*A:4\"(N;/T'=4CY(.] 0L0>(E$D95:@L@"EPVI#XON!!1GGD!&2+E-P\DRY
MC6IZ6D[F?/FAY.:WLWC:X'EOU&,QC*@=KE$Y&L AK*$3'60D*-6[V,98'08S
M$@2=GC"&H0+S". =@/$"5PUC"K=K'?4M5QQZ#4B-'HQJ1D1BP8RG.D)B8M(9
M'W0$J;G5J:$ZA0["4;.&%N >A6Z3!)BCF'Q_GO$"9\A(A6;S:54-DH0L;E6A
MD0CQ#V^O3Y/8RC/&KASTH&@2N!;Q+2796F<@IW%.<$W2H@E: 900J[6/F$<#
MZ89WZP7JM'BA+"M*2*GR2L@(2XN3W*F5 =,HF*:Q=\$B;_7]<LS91R_6TC<
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MQY2F6QQ]V&N].+.N:SJ^"P+3&4NNP022JV%HK5 W%F/3.YB5I#5(UWBU1WB
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M$:T7KLE:.[H'IV$.M[WU#.8%=>3?VEUM^-1PW_O3U'@7RP& P& P& P& P&
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MZMKTV'F*B27%I7)7% <<A5GH%I12M&:<G,,1KDQA)H="WLLTL0!=!!WK09+
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M:YITI(=C#2NZ,&7O6_F1>C8RQ%"$'?I /98_F@=L&];Z;_0W@?/IK]+7_-K
M=-?I:_YM8#IK]+7_ #:P'37Z6O\ FU@.FOTM?\VL#^X# 8# 8# 8# 8# 8#
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MCQ U;/.8NO@+:@AC3;VI<V<_VME1BY()N[]M&&=*/>W%W'_R!6TMXA>#[(A
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MM^-G%3?/ZG.(\$B7*CD['..P]P9'&7)9*)#:_*V85D0=!W4F+EMK^[*$TDF
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ML26VW(:?A[Y94\889%IG,'0AQ6N<CC5=2AEFT$8G(HYP$W":XI,(ZB<T9("
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MVG3;V+8DR86QG%*![$F(%LQ21HO1"DS>R][,4)]% [LS?48.P'L[UV== ^N
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MD3^UI7UN3JUZ5,XE(UP-&:)//)%OYHLPP&PCV$Q8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# H/QL_S'(C\<#D']F63 LA@,!@,!@5UY-_:76WXU'#?^]/4>!?+
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M U=4YJ (>=_+^M6&0@Z;4M<:>4WY(RWC6[,;%IB4#A,)/<E:/$3M:9+Y!/\
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M+<MQQ&;TQ;D4JM<K<U-.16.Q>,)A'H2$+=M$8B*;P)#B$"-2H#Q59P?Y7L%
M^8^R,4$D]#V+R8HCCQ7]+@<^7#Q;\X#959U],8W9$S#=)TA<WV"$O$IDFUC:
M8!P+-Z'"6[*1JE!Z8D+4\R>']IK^-$.ICB-*+/(8&;D*FLFQ(4JNAX43V;52
M[(IJI?JSA]DVE+DAB9E:)X^-+RE971^1H3$;:8D"J!K910PBWDUQ<YB22A.%
ML5JYWLFQK6I&%&(9FOF_(-'%V>13W;-!DC*]7\XPJ451)IPI936=8$$LB;P:
MZ-9VU)I;*[Z<A;)"8>05'\FI-SMX^W962%X<ZUBA%;-$Z"^70K8ZI8(\WRB;
MKK0=66N8Y*H3,D]D.#!($Q)&SVV9QV6 3(DKDE:0H/$&AT^1F@(6)3A]=%DJ
M2#1[UKKOL%FA&+IK7R=]G6!SDX#PCD!5=2AXT7E0 X7%X>JN\]!;K7<T!E#/
M/D-AWA/YFU-[7%(BXAG\35JHI.M&B4JM)Q)34XB]"";LL6PC8/#J]4/"U1QF
M12"9-;EKG&7-FY6FOF>ES%)P^WSD2VB&+$7"HE1]B!/'QF"-M\&)U$OV6+:#
MO.UO B2\N'/,EXXMQ>EJ[F$X&SP;F9>\L-@T<NKN;"EW$1\=+:^+]"6RTK!E
MK=M6=7)\GCS@)J?7\@TM*V!+\08<C3IS ZW4U&I/#*@JJ'S61R"7S**5Q"8Y
M*Y5+'-N>Y5(Y$RQQN;WAYDSVT(VYK>Y O7IQF+%J=.22L4;&<$ =#Z8%+++K
M#DI97.*OGZ=5#()MP]I]VKN:TXKBEKUK$8>Q7,G8) "7W?=T'<32[2LY_KM>
MXIT$19D8P,B'NS'(Q.K7"3FHPZ-X# 8# 8# 8# 8# 8%:+@_M \+?X?WU_=I
ML3 LO@,!@8QZ>&^/,KQ('8T9#4PM+D]N9Q90SS2F]I1'KU@RB"^IAYP4Z<78
M 'YH8N@=>G>!7^!W79KS*6-GLSCQ)*DCLV&I)@DI5SN(3+9[B2UJWU)'IRQ1
M\05T'D#JRMZ@X@';7)N^(&G&<$WL:&'CYK?V2>0G]&SI_KC?@;USA>>2;!5L
M>=.+$;]I;,32N0#T0)NV\)VY("F;:,8W-8T"?8^E=4H;" QD"3GFC*-VHT'8
M0BV$XH.?]OS/S3@^W-;1YOG#LB55_P G(?%;'@-=P6-RD;RRF6T945N*79Q&
MYQ/;LN:VZ,I$;4D''U UROQ1"1R+//"TA)"&W_,ACZ-D".N)#8#M8SBF/B!;
ME7,7C;-!DS/RE5QMP:K/5H'I&NBB%[XPEM[N)6I <H$YJU@DP "("B*"(133
MS/%[Q#9HS1JU9<\;K82,4!L.LX75]?F6RV/L>?7XYU31.Q#G!,TLS@Y*&5F<
M%ZQO3O+4E.WL*LLL#NL"262QO,[<E0G=I:WL^'Q<V+&1D$_HV&1N;7"BDEIP
M6)2HRP(FBG36&!*:_B[U)'%&F0+6L;DB9D*H\PL!YNE(7*X0V)R#FM1HB>3T
M.E4?M5*ZR$"AY=XPECC3)V1"H;"T;V@;432QF1HI4M7J$Z9L<4A#EHE",WM+
M$XB'!6%T,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@4'XV
M?YCD1^.!R#^S+)@33)"IN;X/V-<(<A[/?^L?:QD?GCO>O=>%\!ZDD3#X?L=!
M]YWG>]KJ'L]GIOJ&K^%N[W04]_$J=_"'@/"W=[H*>_B5._A#P-T8 24M!L,L
M5QY:Z^(-WHZ,MKHU-GA-Z!W -I7AW>U?B@B[7;'WW8%K>N@==-]0S>!77DW]
MI=;?C4<-_P"]/4>!?+ 8# 8# 8# 8# 8# I??7]J+AW^T^2W]5[;@31@,#F5
MYKDUC4'X[5LND%GV356W#E?Q=;!/E63>U8'(U\,57'%4]S-ZYWJ)2ED)T9(I
M90_JG L\?ABB$^U ?](()$$-<Y><E^6-7W/-O>2!"UU,U!0/&BYG2-O%0R6:
M22X'BW^2TMJ260UCGC=+&8$/(9*Y9D[J$PEN<5R9684>:':81I1H2*]<BN1+
M?S^1\.DT5:S8H[RMIO!!:@H,^&1Y%PV;:G>FF;QI;( +M, KJ!RE:T30D-V8
M$W4>>"U'@A]SLW815Q!Y><J[GY9\D:TMF*UA$:WK-1=R-J@*=!(TEQ0/WO;6
M)A]2OCV22F6[E<9N2 !,?AJ1]R,\2A*)F >F[\( QG#SE'R;Y3<>>6J5[E$>
M27I 8CHNOI_6-0C][)OF,KKF1O#<U5\H>9@>XV(YQR1-  &,TB;(O*X^-4E3
MO"09YQ8]AAH!RHNMC\N[AQ:*^\&&62RPI/4M=\CN4$QI=U,;>/2%Q@3NNL!]
MGU9I'9!MRDL2LAC1PUQ=W%0F;4[P\;7+R@ )&1@;JGY"\U;2JS@.7 ?>]I^T
M>3*SD"19,PF]'S25Q!J:*LKFP9/54S35XX3",R* LUT+(PS.>T;FO.6(FMZ&
ME*V-4 HS0=5TGB](T>G#:43AI(ETXB0!. @$X:(+TN$@ I$-2!")5V]DA-$(
MS179T+>Q==X'(5@N3D,I\VQS-7,%ND\.'73APG:W<]X:]TX5=,5J1HY'G3A)
M!/6HI6EE2R0B>XJ9*AM@&12G(3H KA'AT3@5RI'EIRELKE'.9^[E"G,XK'@1
MSHD.N)$7JVR*^357=4*ORKTE6T;.Y.\O#DSV=8,K8(H7X%Q(3(W U,N5*D9>
MVYQ1] \5*\L>2)]8>:CR0B]E,?(&P8)Q\XF2BFW5'1EFP&JRK'%6MD.<LA+;
M4C_)U[D[JXG)G4")]"V+TZLT2<E(M[IP2G] NSS-O#F'Q.XU0Y[2/]46)8[_
M ,ADL!F%XE5POB%>5?3#ZBFCXP3N8PA?*)$U,[V4N96J,JEZAPVPEK74M2/1
M>QA#@13R:YN\GZ9H3A99O9JMFEMJP@V57E&X= 93:+K)GY.S056@CO'N.2QZ
MK5!)T[ZH?EIPF%0]-\V5D&)@LY"P29=T"8N0?+&X*MYW<?:095$>.IVS"*T;
M76*,U;.TPMU:^SN4SAF>WMU,=)##2FNMHPV-38<>]1GVA/C(P+CI"W%I#$0]
MAU"0A )<C"9H(B]JTX3-#Z;!L&S@:'H77T;#L/R>OZ&!S \MSDTQVW2*&HGB
MW%[_ ,I(.X7^9/F69MLK=)E%DZ'D+9;-$760^TB% D>&YF9%[*4G3:7;[Q#H
MDL&PD]D80B6O['Y.U9P0<3XD=&U%^!\PN64&*7R*MK#?HJNC4Y\PM54$EMX=
M9/UFOTF1MBB!ORI^3("))IE;@]@*01#<464 -7O3FSS*JWBY&9,W-%>ZL=#S
M/OGC%95ZR:OW*-5JP5_4+K;:&#7 Z098^.C=$R[>7PQD; G'N*AF*5.@M)3-
M&*480!UMIF1S&84_5,NL1MCS-/Y36\)D4W:HBI=5D302QZCC<XOZ:,*7Y&WO
MAL> YJ#/!>-()5Z3[!HX.C-"P.3/*]M@(?,ZX:RR%2%9*;58I]%F6U^/D7<.
M0S+-'YGES$I:8O?CV\LCX?2AM/4!$._=7)E6M*9O>EF]^-<A+R$:$T.U^ P&
M P& P& P& P&!5#D"_-D6N+B1)WLT\AFCLIY$O;L>E0KG-22VMG&"R%BPU.V
MMB=6Y.!X$Y0MA)3E&G&B^9 $0MZU@;)5O*>HKFFBB$5\LE;@N2QA3)SG![@$
M[AK;W21S1MQS:0=,8VQ:5..@+@'Z"5L?ZUH6_1L.\"7IW.8W6L2>9Q+U2Y%&
MV I.>Z*FUD>I&N)+5K4S>1LAECJ!T>EPA*E9>MZ(3F""'>QBUH(1;T$;5!R,
MK.\W>6-5>*)*K#$43"M6+W^&2^'$+@/HW(KL-I$O8F-6J$VG-V@J-@ (.MGE
M]-^G?0)?D*=.KCT@2*V8<C2JF)Y3*HZ7LD)D@3'MJDH]B*&I.3IP&O!0]I@B
M,,+!H1NMB&'746@YNT&J?$5TQQCG$.YD@1QUP41N%H;VLNI)7 :L?7BOG:2-
MJ;P\*=#I1*'Y7!4ZA*@7.0W(:,@X8=F!,&(S LUS6_LD\A/Z-G3_ %QOP.@^
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P*#\;
M/\QR(_' Y!_9EDP)JD4UAL/\'[6RV,Q;UAW^T'M$^MC+X[PW=>)\'ZQ5)O$^
M'[\';['7L=L/7IUU@:S[]5-_=:K/^/48_P!IX#WZJ;^ZU6?\>HQ_M/ W)ADD
M=E2#;I%W]EDC9I0:DVXL+HB=T&E1&@"/3;5H#E!&E!(30[$#M=H.A:ZZ].L#
M-8%=>3?VEUM^-1PW_O3U'@7RP& P& P& P& P& P*7WU_:BX=_M/DM_5>VX$
MT8# J7S/NFZ*$JB)S6C4E9KI4_WYQ]J!Q3VJGFRB/DLMYVS%JA];) 0-X97;
M;HP/$Q2+NR8:(@Y,G.*[/>C+$$-9OKGG ..MLJJIE5=W)(BXS JNM6R;'A+7
M"U-?59![CMQXHR*/\H,?I['Y8Y*#9TR&:4HF1K=EQ;;H:K18P$FZ"&V+>9-;
M-]Z&\9CV:>>^SJ^8U2">*EMK4("\4FHEVY!IK@1F;?0A,I]N@D?<4JMS$ *P
MIY0FHM)1#[&Q!H5"^8W0_)._+-XX5R58"J0U9[Y/62+FMF40N4'4].D]:60E
M8 LDD>9.QKF68J=D("7UK9S7Y.4<I;=*22ABT'YJ7S (ER&H*]KVJRM+)>#Z
M-89"Y[KB3OM4-DXD:]HB2^6IHXK0MEER$%92792 1+DSRT3$\M)^A!.2]KIV
M@],*YR+GCC-QCY 3*B[4CMD\J1UJP5=0;$]UQ))M*9A8]?+K);B&65BGJ& M
ML.W"V)U>-.#V[M9Z9J0[\8F3K1Z1[#RO_F#0!/7/'ZP8-4U_7 NY-N%LM$(K
M6OXU$??*0/U$1Z7R6V8_+VB6SR,,R5]B!L!=V[2=(X+Q.#NF G1[/\00,87F
M2*0K4:-: E4G M1I5@$ZY,8C7)@JTY:@*=<C.UHY&N(T9V#B1_-%&:$'?IU@
M<^6GGNV.WF</?E\EBK[:5NH\B1I',N9 %:1]OIVM@LIUAZN#;5_Z/715.RE&
MX)W/9.MC=B5"?M[T7V=!HL3\S9JG-T:*]BYQ".)K-P]Y0\I-W%/F-IUNQ6+C
MG;%=0)7-*O21F<R)Z20TME=GQ0-N?6=J>UA8FU404$A1K0@_43\REU-1\Y[3
MMVF+:K*JN(E.\=KB9H4_L\05WB_QZW83.ID[JR"8U:$J@[J-S3L;>!K1Z<F]
M4B5>*2+]%J"]Z"$O7%S_ ()QRI)@NFYJMNFKW:56\KHZ,U)*TU=,-A/$X3DR
M9S">F?5=CDU07"G"*1)<\)WL<C"@/1%Z+"+:H6D^P\-@>9)35=5MQBMH4=M=
MWB?+AO)=X L\%#(!ME2F(&)P&W3]SMJ>5]&V:;FZD02D$=+7JGEY.2K--Y"G
M288MA)-A\RH%6/)NL^)CS'YT;,K89VMZ99$6I@L?@HR'MTDK.E2-@IG.8M)K
M#=FY5%#AO"*+-;XL9$JE$>L)++5%[T%M$I.E"E,G%O80GGDDB%KIU#HTP(-[
MUUZZZZT+ K5Q5OZ3\BN-D1NU_C@43J_.%M)-Q"-+5!R4X=;6Q8E=-:%G/D"T
M)0')^;X629U4GED 5*A=1EDZZA"NL"YXJ4'$=7R6MB"6.[OY/)J5<;!59"H/
M$V*RT<S6\IEG&>#5X8P#N:90A>],3\L0M[H[D2O;:X[).7DEI2C I"P6-YHM
M'5'1T4NZ8QBU&9VE-UV)QN35"HW7+?8[3;]/GS@FSHD[OCC8Z.J"$4335TY'
M!<"9(>A<0>&+1C..4EEX%XJTL..6[7,!M>'F.AL3LR&QJ>QH;XU+&)[]1RQH
M2/C:!Z9'$ %[.[E)5H0*DIVN\(/"(&^N]==A3Z3\\:_CG/.+<,7.S*WBY:B!
MM)+HQ2!VUJ=S6^+32/DUJ:N(:W!=2"VML:ZGK9_?'E<K2FD*UCNPMR8T"M3W
M1H7WP& P& P& P& P& P*TV]O8>0?"P0=["(-@7SL(M;WK>MZXU6)O6];UZ=
M;UO LV,\\S79,.-,#UZ]D9@Q:ZZ^1OH+>]=?3@?@(Q %H0!" +7R!!WL(M==
M=-]-ZWK>NNMX'Z,..-Z:--,,UKTZT8,0^G7Y/3M;WTP/G@?+:=/LSO=IT^SM
M&!.[[9!6S>^ 2). [O=@[?? 3BV7H77M:+WL.M]G>]8%9>:W]DGD)_1LZ?ZX
MWX&W<ZN4+_P\KJL+P,01,VFF_D%4D)Y-2.4[<B=UM1UH/1U=K;3:5R%>E3(1
M0.P9)'UCF8L)5)@L&EXNP$P)9H XZO'G"\TE5;V1<<>JSB?#HIQRXB0_GY<$
M)N"26-'+ M'C]=\]N1RI" 4R:W.JALBUAET76"$3P_NY#LUJ9R^IVDAL2E=H
MT(9F]/,L\QNF?CZRS;)Q ?8+Q9B?&"45]'4-,\AE=HR#7,NQ&Y@JIJD[.ANP
MX#T_5[&C3P/C>U)DZE]=ME 0>$UO96PLC9//;EU4WEB23E?(H7$7#D,5<U=5
MM'(H\<3^353(--5B\A:_I=$I6<:IO8:R^W^0)VZ6*%B)*B>"1/AP4^D@-!,[
M(@KQ%O-HYN.-)5]/ \?ZGF\WL'DE=7 $F.(X]9=,NL*Y?AD+/KC',K=K&TI>
MIGU5TU+(D:X*9C'U9BR3,X"VY6E6&DN6B$P3'YA_FIW)P1Y)TY3(H#7$ZBD^
MXJ67-7B2;:I<B=C^38UY4&X\0QD2I96I3MD#M6W34S$>0H K7DF.B?L+0[ +
MO0@"F//9ETKN3RUJRLN/T0P)>3M)4:^<GQLSK)DDI@5W<JPV U4%':E87*0N
M8#H65+*W[B2;<S5RM&FEC&8 W7;,V,+W>6-Y@UE\VU$V3V7$J^AXXU1W&FSF
M\$. _IS%3Y=4CY&,LB;5 ']]>-B;FHFG$ D00=D[0U*CO1F:V7HL.MV P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P*#\;/\QR(_' Y!_9EDP+&
MB++'T[998^G7IVP!'TZ_)Z=K6^G7I@?GN"/V CZ"5\[@.X(_8"/H)7SN!^PA
M"#70 0@U\GH (0ZZ_I] ZUKK@?K KKR;^TNMOQJ.&_\ >GJ/ OE@,!@,!@,!
M@,!@,!@4OOK^U%P[_:?);^J]MP)HP&!0SS$">/ J7A*CDQ6%\VQ! WO3[3&X
M[Q\D4[CLL16S)Y>@CU1/3F; +3J5R/;TMB+VXM$,]>H)1/)R-2$D)A03R0V2
M[&3@RLL0Z"W[+*B:K7O& U15H85/;=*BLZL6#0>RWZ95.Q-4<52]K>'/2:U%
M+@-*L2%>*<''8TIIQ_0).!NB^'\45/)1-R5<#ZXWR98TNN)!,V-F@29&WN$F
M "RT],F1H+Z6R!L-T:E_K)*2-!M_]3*1Z)'I":,(@PM/0SB-';ENYHIB7QE5
M:QRA]<+HJ*.WK)92UP=PGK][0S%W,H0V>.L+JEVF\I4;6/"MN9&P]6XGC$>/
M1IYFC T&F". =05OR(M.H[&KZ3UZT,1*+DA8BR]GZ_ML\1K:*/*=EADQEDQG
M,^=FF*1.(.RXII9O$%)-)EAO<%CV<(0@U""-WESR_@[64ABED,2?AM'5L2GE
M3V:[\@[#85M5R-. A+#"(A<SU82>R*RED.(>-,2)F2/*4]I3F&- $X2=F)MA
M*JW7!*B(+QEF+M-*,JVM:L324WBY+GVUVIBAP2IY"7%OEKE$)*\2L+;82N40
MQ[6*URU4H=#SPJ3G PSO1#48%RP# :66:48 THTL!I1I0PF%&E&@T84:4:#8
M@&E&EBT((@[V$0=ZWK?3 HHW*>'?QTE= M\/5E\H8^:IY\FR$*21!0:E\JCF
M^/[D[E3;;SLM7+1UNO(2GQ41>VTB/J$RH*?70L0 AFJ8KY:;-R\G5-TZS0Z8
M6^^<?N1A-JHF:WG&RZRJRJ5=N5]J[J1?*Z=[(D$4I]+-[$G9;JH9&]D;D&S"
M'+M[)$$PD0:Y0S3Y6K[&.<%854X1:1TFVU[1:#E5;;WR-DEEU?)H$?$IHWUW
M&S;BDMMRMQC3-4\1C*AN-)"M:D[8B-2@+V,KLB"%O;FDG#6\Z+063:5O5HMH
MV/39#((W>$>O05=ML,LF/KW2*)'.%7;7\RC#O$ILA5N"]H, W.I"HPM2I1G
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MT-;?C#J+1@7$/RQW!SL1LOPF,<=ZNN0NRK,,Y=2&W:\#-FF/7HLG\ BJMM5
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M%[B;)X9Q=XO-_+>%&R=@K.<Q6(MB4RF'.3W#4MZ"9K0E+A7,7VE-0QI^7LD
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MFP]M;/64-CRV2"6\L(CRW&S6S("_6*VTRF>80XIM9SE($FVQ J4CT Q08$P
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M;DS.DI<'RQH6Q3%U1;4,#!&FPED:E[P80WD 2:$0E   AF;UVMA9O 8# 8#
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M +W/J?2CB)R=#X;V0,2B<O6'=U4/NN_T1ON>[[SM===KLX&1F-U(7Y5;)S;
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MCOZM#XP@OV86=3CNP=KOP]-;[8^@>=EM]O;'B/+AUYR?TC;;*N.8N!!'$CE
M':IJL <C,84W=>]6 I0L0F.Y0CPCZ +$ 6P"%O6M[ 7;[<2R#;B:\Y0$J1W@
M99 S"N(_)\L XX;8_M:<W#&"K C$O.:-[*&5O6R1&[V'8^QOK@?Q_MYN=XS;
M;*"O.4&U$YE*9Y8!*>(_)\2=O;B6:"(1)5?_ /"P>TP]K(TK,T D(P?KP1=>
MT(?0,A,;L;WY?:"EMK_E,E*F-3!A+"$SB5RA($W2/1D\%MT/T15PPI"-ZDJ3
M]>)[1_ZR+YGY@'4/F[W.V.*B<"!7G*+PTEIE#7[>2=Q(Y/\ 8(D1&IT%4XJ2
MO>M$46C/!)$NMF@[1P]%"T(/0(.H>IHNMD;Y&0\&UKR@$G*J"-0#L%<0^3??
M^N69S=UJE4'6ZL"#U>,M>#NQ]KO-BUOJ#7HW@>6(W2A8S:N&Y0#E*J##JH4P
MI_T7Q+Y1';<I":&!:+<R-'U<'2L@.XTL_7CNR?KOP_,_-CZ!Y(K;[<PM=&-Y
M]><G]ZK6/+6B2@3<2.4'<.9YT(!'4PD !567I600YA[W6SPE["#YK6NUZ,#^
ME7 W$LB9M*KSE 4H+O!59!QA7$?E 46;&U5FKYD:VB$"K-#&O-:%>B1E;UW
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M0/P78#X]W&;W53W[P?('X+L!\>[C-[JI[]X/D#\%V ^/=QF]U4]^\'R!^"[
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MGE&N9J-<$1R5P)('L/0SM:[.]"UK?HP)J_Q".+_[I7O^1GS._-_P'^(1Q?\
MW2O?\C/F=^;_ (#_ !".+_[I7O\ D9\SOS?\!_B$<7_W2O?\C/F=^;_@/\0C
MB_\ NE>_Y&?,[\W_  (>N7FOQYL,FEH+&WBTRI'*>6W#QL8BY9QIY-5XR*W
MGDM6+KM&=+;"I^+Q%M4&H6TX1052XC9XP=V7VS!  (.SV P& P& P& P*C\R
M-[U"Z;WK>];^-OQ,].O1OTWU!];_ .?6\"6/%JOIE1]&,^>P'BU7TRH^C&?/
M8#Q:KZ94?1C/GL!XM5],J/HQGSV \6J^F5'T8SY[ >+5?3*CZ,9\]@/%JOIE
M1]&,^>P'BU7TRH^C&?/8#Q:KZ94?1C/GL!XM5],J/HQGSV \6J^F5'T8SY[
M>+5?3*CZ,9\]@/%JOIE1]&,^>P'BU7TRH^C&?/8#Q:KZ94?1C/GL!XM5],J/
MHQGSV \6J^F5'T8SY[ >+5?3*CZ,9\]@/%JOIE1]&,^>P'BU7TRH^C&?/8#Q
M:KZ94?1C/GL!XM5],J/HQGSV \6J^F5'T8SY[ >+5?3*CZ,9\]@/%JOIE1]&
M,^>P'BU7TRH^C&?/8#Q:KZ94?1C/GL!XM5],J/HQGSV \6J^F5'T8SY[ >+5
M?3*CZ,9\]@/%JOIE1]&,^>P'BU7TRH^C&?/8#Q:KZ94?1C/GL!XM5],J/HQG
MSV \6J^F5'T8SY[ >+5?3*CZ,9\]@/%JOIE1]&,^>P'BU7TRH^C&?/8#Q:KZ
M94?1C/GL!XM5],J/HQGSV \6J^F5'T8SY[ >+5?3*CZ,9\]@/%JOIE1]&,^>
MP'BU7TRH^C&?/8#Q:KZ94?1C/GL"LW&8\\&^3/8.-!__ -DWP'YDP8?F0@AO
M9UZ-Z] >N^GZ77 LSXM5],J/HQGSV \6J^F5'T8SY[ >+5?3*CZ,9\]@/%JO
MIE1]&,^>P'BU7TRH^C&?/8#Q:KZ94?1C/GL!XM5],J/HQGSV \6J^F5'T8SY
M[ >+5?3*CZ,9\]@/%JOIE1]&,^>P'BU7TRH^C&?/8#Q:KZ94?1C/GL!XM5],
MJ/HQGSV \6J^F5'T8SY[ >+5?3*CZ,9\]@/%JOIE1]&,^>P'BU7TRH^C&?/8
M#Q:KZ94?1C/GL!XM5],J/HQGSV \6J^F5'T8SY[ >+5?3*CZ,9\]@/%JOIE1
M]&,^>P'BU7TRH^C&?/8#Q:KZ94?1C/GL!XM5],J/HQGSV \6J^F5'T8SY[ >
M+5?3*CZ,9\]@/%JOIE1]&,^>P'BU7TRH^C&?/8#Q:KZ94?1C/GL!XM5],J/H
MQGSV \6J^F5'T8SY[ >+5?3*CZ,9\]@/%JOIE1]&,^>P'BU7TRH^C&?/8#Q:
MKZ94?1C/GL!XM5],J/HQGSV \6J^F5'T8SY[ >+5?3*CZ,9\]@/%JOIE1]&,
M^>P'BU7TRH^C&?/8%'^>9YYD%XUZ,.-,U_B%\!/0,P8M?VE85OY M[U\D.M_
M^3 Z@8# 8# 8# 8# J-S(^TNF_QM^)?]?4'P)1P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P*T\:/D\F?QRKZ_Z
MD,P++;] 1#%O00 UVAC%O00 #UZ=H8Q;T$ >N_D[WK _6P[UVNNNSH(.\%L7
MS(0E]-"[8A;Z:"#L[Z]=^CI@?S0=[[/3770PZ$#>MZV$81>D(@"UUT((OT-Z
M]&\!K6]_H?\ XU__ %P/[V1?I?\ GU@?WNQ]0Z[ NH_^AKL[WVO3T^9Z?]+T
M_I8'X#T$'0P;", A""$8!!&#8@[Z"#H8=[#L0=_)UUZZ_1P&!_>F_D_\G_GZ
M]/\ GZ8'\P&!&%EW#!:@%"#;!<5# SSR8I(&VR<]-K<99Y*YHU:MD32MW$<
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M=G?9_3Z>CY/3]7 _. P& P& P&!2+GA]HW&O_P 0O@)_>4A>!U%P& P& P&
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M0K4BVPH=6I\Y:$MHA2.$,6.B<;JF@NE1HSFT\T9:88Q %H0=] KQX^@V"O\
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M.AB]5O4FAZVQ$1DX82>UW86:=M1J1T)$$(>OB=A](0ZP.GV P& P& P& P&
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M]C,04.0GR/E$)TRD)RUW2+]E@"=H) M;%H8M:W@4K:O+\GD1@G)^IX?9S,1
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M\;L5K?&)O:F3CY?M0'M[B%QVXG/EMI&5.R.I.TJ4U+ZH:Q-@]J^T/1_00>[
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M<I40TFL),@=E+,ET[NH&4X(#&SQ3F W>R=AUH.^O36M=-8$P8# 8# 8# 8#
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MVJ=-D >6=OE\F1!/',VV"SU6R)H2^R4($YVU^FE2)2HT SJ(S6AX%RHE#8K
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MDS^!4D G9'27D0\,=0F)S59:\P3L)L/T'9)1@ ]WOM[#UUU"D-R\0K3G4?\
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M&G\PWD:KK*D4)3A"@W 98H1W>KU#T(FP=5/CQ4:>#K&IE$;W#*KDJ2XT8"U
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MID-L:"L,J5,X#!G%-BYQ2!VX(TYQFM&')"5Q9FB1B^:$3V=[].]X$M8# 8#
M8# 8# 8# 8# 8# K3QH^3R9_'*OK_J0S LM@,!@,!@,!@,!@,!@,!@,!@,#S
M+3E"=$M4)$8W%6G1*U"1N+/*3&.*HA.8:F0 4G_K"8:T\ 2M&&?,%['VA>C6
M\"EU#6IR,M&/\JF^2-]:QFW*YL]?!Z_CIBA<Z0*''G5U$Y(U-<GD36D3NTM(
M:E[Z,:Y:427M0,(P%:"3H&]!KE,63R-M2N[S+9;"A4F'"; ;HW7/(!!5"H31
M.6%H:4*VW#X=7+6[;0S)QBKX!6TL"H!X$#HJT'O>UV!;V$U<1K1E]RT;')G/
M#&@Z;!?II&G\MK;=L:Q(KC$I=&-,FD\7V>JW#9MMK3D"=FG1I@42DP0 BV'>
MM8$-0GERXV'S!]ZV.&1HVC$M=V<:VO1*A"LDU@6'6<ACS5)%3%HI4)6ECC<I
M<53<A*T5LQU.1*5!>MD@+WL(?J/EY=".'WE,KR7>"EL)HB4W;%*)D=&O-2.Z
M=E;71R):75/-5SRLW-X^G$G3H' 04B%00>;LS8.G06PL#PWNN<VTGGS79$K3
MOTKC9=>R$IC6U(Y5#)F!GGD7"^HU)C.J=GI!((<Y+"C=L3F4:!8-.2+2PL!W
M36@_-OR?D4T\B*EKZM;8A06FS7=0_+X"Z5$C<ET.J6!HFP=C2ERG8I2!4J4N
MKJL(;VDK2 O>UK@$/;["<8A!%T,Y.W"]\S5%2N+K%O>T4V]:=:DM8(J6FCZ=
MB@\%:Y,Q*8S<7K$899<1[FM&!ZC'<:VW)@&"V$'==O8>'CERVL^>\@FJK+&7
M,(E4V27N-UK!- G2,2&AG6I944BC+*[25:<87-B)U##?'&&& "()@BS">A!@
M0[#<.7'(2X:XF+_':H=(JPDU9QHF7)V6"DT7]IMSA/&)>WQI!7B<8G%OW&T*
MY+I6:>O(T8J ;LG0-:#H74-QMJ]+@8[$XE)8C&8\SU+<\_KIFELI=G ETDKH
M.<122R,<*88]I-K;*2SHVDHY6[G&Z,,,-*)3E^@X6@\E@6=?<3Y1UA VN55Y
M(HQ8LO(()IIDB2U;+F"D6V.*39I=4ZG1RHDV-+6J7%E)6],$D;<N"8$@ AG]
MO80F/D_.K2K:E)S,JAC3 _RYBCTA=Q*Y2[!;6&)M#+&WE\7RU8BT0H528YN]
M6@*3-9.@;5J3R]&& )":+00S;-L6RS\8JPN9FL^OZQ).K*/S6QY/)(49,7Q_
MD;] FURB<,KJ$D')&M6[36=+@I#">\VH+(,T%( 0];WH-1O"X^5%>4Q35U&A
MAT$./8:RU;5?.$!<Y"C0S:5NS,"8;G4V-="$]3UC%F!2HV-P %2L(<Q%DF=H
M&]8&>Y#<M7&!WA3M15PIBAR-7:M8L5YR5[6MQI4;CME'+M1J*LI!ZM.(4B>F
MQ":YJENM"*;$ 4^Q=!K"]8&'3W]<8>8*NOY8]*:ZI959IM;UTWR&AGD;=:SF
MW5^E>UB-ENPUW2(FQV<WT2LU"5M >2H3HA%@.[0]:T'0W 8# 8# 8# I%SP^
MT;C7_P"(7P$_O*0O ZBX# 8# 8# 8# J-S(^TNF_QM^)?]?4'P)1P& P*S3&
M1\9 W+$I_+[EKICLZHFJ:0EO9G&U8>S;:RY\!I+D"&11Q:XEK=NO1J([C1FR
MAD[WOYD7:] 8R2TWQY=X9RG8GR7@2Q>Y9*4\<@5WM^T(@Q1]TPQIO+3#<C [
M(@G;9VI 9HE7U%O1O>?(,#@:%9]<\:FZT9#-'_E')Z,L&41.$,DC;HOR+C57
MF.D=B34:DARI:R+P;5&! WJC#"SQ;[!O>B&'T;P+"V;756V'4FXQ9[CX^ MS
M?'G\$U<98)D=&A3&2TJY@L-)8"92WF-+^C-* K ZEFEZ$88(6^H#-AV$/U[0
M7%R25;:J-EDA=VQ"YNP7;-ER2T]V0_2C<92 +:P.EA$N.]M&X4G*"<A"0-+I
MN'KOM:T+?:V&'JBF>,[@78$MCUV/5[N(J\?:F?Y[++O;;0<ZYKEU1*=/4;:'
M-*;MOAZ10G+$<>K.*V>?LC0S#1A +6PTW7%KA(0W)9D"<MA#1/V.F*Q997JV
MHV%JDP*%>(ZNA+9'7C>O .DC4.,+0ENNDPS#5VDO8[!>^N!9"#KJ&K6Q;38H
M[:42361;MFGSB:0IRLB-'R+VZ4LK0R#0-<4,6$.S=KU>TI^RB$4:9V^HO3VN
MF!&"7B3Q83H6^J$B9L+L&/RI%=A<D)?8[KD&%Y+G9LQ*ESE)PM_M4<R+)*>)
M./MDZ1&)M^'U\C6\#X3[C=Q1L"#VDQS-_;E$;4<@%5RSE]U8#(C5U]<B\;,F
M5HP/F];)A@5912=*-K5:[9A2GL;ZB&#80FR9L%23B7Q6<2"6-@'WC'(7J5F;
M22YI0HH6Y2.'+6=>.Q$@S#-MZ(<85FJ"@K!)=!#K1VA;!K _=FL54V"RUD[S
M:5MJ%A9+/KVQJ]>D\L:V5L?)NT'GJX.F1N:@8TC\F>1JQ;*2$#V-:'IW8L"'
M#.'_ !H>'2\(^@"K*,L^QZZM*Z(*QRU"6A]HHNK42:.HGB.%)3E#%&98M&8N
M7(3= +<_FA V$OKK \DFX_<19-&[-L!([Q&&5Q9U?-]7V \5Q+H?#JO6,T<F
M@7M X#4M*?V802ULD8A(]KN\T9W9HDXP[%O70/TS<<N*L=M%HEK3(T:2P[&N
M!FY*1EL#83-W\QEK-&I RMZZ+,?32Q[A@VV1KU(TZ/O2S#S1&Z-UK73 UFM*
MWXS06;M['77+.8$N(K#>I"GIQMY+1A9'727OLA7/C^PG5ZD+\8N*<GM0?WZ
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MW0QZ-!O0^T+M==AL. P& P& P& P& P& P& P*T\:/D\F?QRKZ_ZD,P++8#
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M2NNY$[<=#X[2EM-:Q\A<U;+$02231=G&W#=XRZVM#=M3:GCB.7M^@>'VWK'
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M?3@2KQXO'7*:*2Q3+(9  -+.[1H!2>,6?';@8%_C$"*4I&U^TC1-RUBE447
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M[C8*F=4\^TTPH62!IH)!(ZF?D2U.HG+Y$T#^Z E$_4&*==XJVH2E@(",HD
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M14!Z[D(W7LJ>=K4,=J)UK"+Q834;O3.MD$N2R.32L#MM4(H1KPWM2- (G2<
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M4;L!0C#A""$9SQVJ-W\P.$QF&VB8QVQ&YY&I5;<AEMJ&I2--)L4/9(UQ>JB
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M_KPCQ%[-$=\WL7;].!F\!@,!@,!@,!@,!@,!@,!@,!@,"M/&CY/)G\<J^O\
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MG_PQ$_Y-M7?7^ ]X/D_^&(G_ ";:N^O\![P?)_\ #$3_ )-M7?7^ ]X/D_\
MAB)_R;:N^O\  >\'R?\ PQ$_Y-M7?7^ ]X/D_P#AB)_R;:N^O\![P?)_\,1/
M^3;5WU_@/>#Y/_AB)_R;:N^O\![P?)_\,1/^3;5WU_@/>#Y/_AB)_P FVKOK
M_ C+A^TR%CCW(!IEDH]M9&CY>WJ%UE/J1!&_7*@X,.4@4>HVL9C>W;*3G *V
M$H6]#V7V]_-"W@6UP&!H=@67#:O;V5SF;@M0D2.1H(@PD-K&]R)Q=Y*Z)ERQ
M T(&J/M[DXGJE*9L/&'H5V?UO>NO7>M;#%I;JJI<T54_(YPS*&>[W%*T50O
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MO9@E$/M1%+T9&^\"(/<JUC$64;Z.UHH8NSO0NF]!T9P& P& P& P& P& P&
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MJIK94+-"$%?*(&RZ):JWDT?;JTMJGR13"%HDQ35)78ZM[K?FE0L4Z$H4I#2
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MR(>:BC<-(,8AJEQD;F;=2=E*9H-+(M:1EA-:VKO4^_$;V#>NYP*L^_EYO?\
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MH@1@='&EE;X5%Z-,+*WL00]H/:WKIUUUZX%F.2,\YD0TZ&AXL\<Z:O4EQ3O
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MB8>9F]3]MD9?EQ\.9:97#_,PU=,'WGQ+FU]2,\@3K8T>\::P<-7,EC<)1$S
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M>0TI(I$9#Q78RES%"$SJJ]2QE,ZL[.B\4<%-I-HT>Q!V1P& P& P& P& P&
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M$6MZ]&\#[_'S;/= D^\#RE^"K ?'S;/= D^\#RE^"K ?'S;/= D^\#RE^"K
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M,^8NAJ_C#,X_*7N?7&F?Y#,[T8U;;7T03Q2++:<D")^@D"CL>+;8=))F-\V
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M$632XW:JH;A0(G9 X-K8YM+;&W1=!4[7(Y0]!=BDZ-I1G'.*A: U, G9Q!P
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M[5323OCK(&/E$%L?K;ETJD#\N6ODOE]C.9/K96[.!IBP;@K//WO0S18'QD/
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MA#JM'5KNXL+,X2!EU&WU:V(53Q'PN2=Y"R.1Z<LQ:U:=TA9*5ST@4"$5WY8
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M 5B:#4:)Q5DEK#$X!;-"'4? 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MS=S*J98)4?(RO[0LR62EQE==,#+%6.%0F++E:XYP4I]%C*"1KJ>866(/] ^
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M2@[0>\$&_P" P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P*P\B]..U<"TS,3?*7C8I=IIB[L:20U25SVRDZ;X\Z'J0&)R6U[
M5[ E/$8'9>BC1=K79ZX%'N&D.?8]=C*L1TXC0E#BTB23UV=:)F53:I5>-$W'
M(XK7K]+[@L9N?VUY=2Q(34C2D( )*G"HVHT4#1)@=?\  8# 8&MS+[4)5_!M
M\^QBK TZD/YJX=^T%/V378$JX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M$W]V4VAT)XVS^1V-5I;M,#DBR51R?7!6#^ZH$6F]"^N5/VW-JL-D:5&#]83
MD0(>%:(LK]9*,/$ '0(=:P.7M->9C:$B!:Y2F %6.\R"_P!T64 VR!+(Z'9]
M<7Y'6M[SFO)&8_O4!?SI\G,!Q?D/9>VE(O;W QY2 +4:T29@7SNCD [LO$R.
M\JH:>9'(TV-5-7G.D;LWH',]/0JQYB4GN5,MV/9A*->Q5"X.JP*H@7:*4H@[
M#OL;WU"F+CYGC]53##MSNOT%B.DQK2=W(H-C\F4Q]RBY#_6'(GDS3-:N;:1
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MM*_1I![-V-*EAL=3IQ[/8%<4.V(@IM 4+9T6<#VT777S3>>8GW^LC$#89,J
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M52E^;7*G7LC9DT:8?!I_)Z":G7Q0H^Z7_$(;9#,O<H\4LWW)2H80'F&)E0"
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MG9XB=%;T#0N\"')*8>1' 7^OX%"&.Z"8UJ%590=6*O"U6I21N5IJIH:W./\
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M0)PE; 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M XF#M[\2^C:U<M-(,"8%N :)7LH6AZ+[.];P)G=Y PQ\+:)^>FEE"\.Z"/M
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MB$")JW)J14YQGGU.6$C]\R:KD2EV=XE"@1;1*%R>5:1^&US!L<#"'(T'C4)
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MB,!*W"<Z?DA)[R^@UL"C91V]$%)1E!=C 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8$.W;QYH7DM$2(#R(I>K+SA"5V2OR2)6W HQ84>1OB$L\E&\HVF5-C
MHB2.J8A4:6!06 )P2S1AT+LC%K88:AN*W&;BTV/[+QJX^TQ035*UR1SE""GJ
MUA]=)I(XMY!B5 M?BXFT-6G=2@3'#+(&H[S9(!BT#LZ$+J$]X# P,IBL8G,;
M?8;-8XQ2^(2EI7,,FBLG:$#]')"QNB<Q&Y,SXR.J=4VNK6X)#1%'ISRC"C2Q
M;"(.];WK J]3/E]<$^.DV3V50?#CC'3-B(V]>THIU65'UQ"I<A;'4GP[F@0R
M*/1U [(TCBF_6CP%&@"<7O8!ZV'>]8%O\!@,"DDQ\M3R[[#L%WM>><&.)$RL
MR0/H90_SV3\>JJ?)6^R71Y:G<@>GQQBRA>ZO)BDH)@U)XS#C!Z[0A;WZ<"[!
M98"@ **  LLL 2RRRPZ  L -:"   !UH(0!#KIK6O1K6!^\"!;8^WRD_X6+/
MU&W GK 8# 8# UN9?:A*OX-OGV,58&G4A_-7#OV@I^R:[ E7 8# 8# 8# 8#
M 8'X[HOO-'=V#OM V5HWL![S18A!&(O0^G:T 0@ZWO77IO>M8'[P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M>V(&.1V6JD[K-YQ+!<OZ]H]>PE.0EA:R3O[+5<X.>C^UHY=K2+2U1L24M2+
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MIM/AYQ/LZ<N>WJ;6/QJHJ>3%Y$0G2B=I3+ZNBT@D#GM*D+)2IMKW9Q.-[LH
M"P=OH'6M:UK LK@0+;'V^4G_  L6?J-N!/6 P& P&!K<R^U"5?P;?/L8JP-.
MI#^:N'?M!3]DUV!*N P& P(S>J<K*1-MDL[U$&UP;;@<4+M920X:S1<N<6R.
MQN)H%;CLM4 8#$T=B#:D#W.RM=VD!O>MB[6Q!)F P& P& P& P& P& P& P&
M P& P'3_ /'_ )OU,!@,!@,!@,!@,!@,!@,#QN+>B=F]<U.*<"MO<T:IO7I3
M.UHM2B6D#3*DX]@$$>@'$&"#OIO6^F_DX'@C,;8X=&X_$(RW$-$;BK(TQR/-
M*;9@D[6R,: AL:6Y/LX9IVR4*!*64#8Q"%V0ZZ[WOTX&;P& P/$W-K>T(B&Y
MJ0I&UO2A$!,A0IRDB0@(AB,'HE.0 !1>AF#$+?36NHM[WOT[P/;@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@4HY9\/W3D5*:4M>M[
MZGG&F^N/RFPB:XM>$1:NI\ N,6TS,S'9,/D<$M2,RF(OK3(D\:;#RSNY(6HE
MC>282=H&SBS0P/&?A;+J?N:;\CKSY/V+RNO665G&Z5:IC,H'4M6LL)J>-RA\
MG (O'X93T0BC,J7O,OD)RQ>YN&UBLP)*<DK9)16PF!?7 8%>^57'&)<M*$GM
M!35[DL89IJ&-+D<KARAN32J(2V"S"/V' 9BP">&YX93W2)3N)MKB40M2*D2D
M27NE!)I(Q@$%/(YY?EXR2T:7GG*KG_;G***4'9"2YZ_JQPI/CC3L<';+-&9-
M%(M+),^5/7;%+WQ)%V^8+ST[8%:G1FKA%&J G!)"5L.H^ P&!QJ+\J^ZHI )
M;Q]IGS([ZJ'BC)C;);T%&ME(\6I:YPV$6X_R213B$Q>W9C5+M/0H_%S!R+:E
MR\Q<X-I!I0>^.V0 6PZNUC7<7J&MJ]J:#I#V^%U?!XG7<00*51RY0BB\*84$
M:CZ10M4;$>L/3-+82 9H][&8(.Q;].]X&\8$"VQ]OE)_PL6?J-N!/6 P& P&
M!K<R^U"5?P;?/L8JP-.I#^:N'?M!3]DUV!*N P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&! ML?;Y2?\+%
MGZC;@3U@,!@,!@:W,OM0E7\&WS[&*L#3J0_FKAW[04_9-=@2K@42Y7\WV+C5
M;O$VDD$5]O)SR9NJ*P%S2%/B=H)J^M'MPU'5MK2#M)UIZHDV:N;4R-3?H!8W
M1:N-$ P)2)4( 7MP*F\Q^3X.)-:1&T%<0/F+&Z714M=RTE*O&B51>$3J5I6B
M:6(266A7#="ZXB^U;V>BUHL2E,A, $P(MAP(5B'F84:KK"/SV>)93'5*JHFF
MRY'N-1633.'H7U;7#-;:^KXY+F]I)3RRPT5;OZ5\+;4Q7?J&TX(P:V;H9( L
M2V\IJMD$%629G>D;7*=ZN5M9*SG:Q'#9Z\RRB3GI%8\;1QQ>>:XN1D77LH_&
MJ&\"U,4E&!3H8B1@&((*KCG_ !*S(90;^W0N6QQ_M>?5A7DSCLMCL@9C*V?[
M+J]KM1B)<@J&X#J:BE# \I]L2X:0M"K'L92DQ&>684 ,NI\Q&AQM\P$R-MH/
MDCCKHJ8X[$45:R8V0V2XI)%;T35GU^WDI33Y S-CW0\L\6J#HL)*-G,5:T(@
M](-0'BA7/2*N4,6S:=PZ3Q9$V4CP^M-2TL[$_2=Y=W7EVY.$>BC3#4Z1M*U)
MF=/, $LP3]:3K +R5>U*5.062:<&XQWG?1,IEU;0IG!8ASS9+DFCQ1@Z]D!;
M7")>M<+-:4<+LAUV1M'$),J<Z;DI "3A#*V-M#OO-!6(!*@DJZ.3=74'(:TC
MMC*'YO-M.3L\28'9&QJ%; @=I!*8S"60#X[B&2F2^LI5,6Y( HCQ"H #QJ3"
M@(TZE02%:&+S*J97R>Q_7S1,XK6,5B$7ED*L5[B,E0)[*2/$'N>RU2V.MZQJ
M3[/9':#TXJ61U0 P9C\/9I)10#BP@,"0YCS>KNLE/(%;9;7(8G'*(6TNU+1J
MF=46]/*VZE!S=%UI6U0D\71QUQ>AE(RUZER3D)#2E.W#:,LH(S ]3WSTX]1L
MYQ]>.$Y;VUGK5793N_FUQ,1LC:4@I]9R 6056J):C30VBGI1O/D@F )8ENV\
MK>M:VHV$D0;&@YAU.>JAS6]-MCPJ13\$9,B$4G5?OT6DSX7*[.*JIO&B:'(H
M!X](WE6E7KOT4+(L)7'=@D0NR&^6]R$K6CE#.EL%<ZH3Y$QR=YCQ;>RKG43Z
MIB[A$FL^,-?@RQ^*F#RKFB/38VZ_TA>$!XBM;T0;L(5JL?S%:HAC3,%<5@UK
M6<\1&?P:$EL,:BHFX<R02R^$?'9YFM?.K^H;VN71>&V6:>VJS4YG:,5@3Z!K
MPJU,L&$Q1KF)1,KY!O?&!JDYHK?C[<I5.C$<E!HA.YML=B<N?(QM62I/WJ0,
M,8G34L4@V#2?L*M@*.-.3JBB ^EK<NZ9IF<[@,W7R0AS31@N4O3LU15X=XQ&
M4[BV3AVBS3)) B(,0-4AG"6MGP+.C'O9BLY!HK?8,4HPJ W*C+[@_(*./$DA
M"65MA<?>F]B>F::QEQB4A;E;S"XE8K":H:'(.C@I7R#3MI<DX];WO12S11NB
MU!9Q)80HIY[4B3$-3@EEN)Q87.0FLL(,;JAFBD^T6Q+'I;+W&;5D5ZO &7PI
MKB4#=W)2K(%HPI(E+%LKM+FT"P-!)\T;BFX2]_@L?7V3*9(SN[.PMJ:.5C*'
M%'-'60SB*UXPI80[^&*:'X+I)9@D" W1Y9)24!RDX99!0C,#WO'F?</6-=ZN
M73YT\6753E;:Q(1&74]R;FEJ@LOLE5%U[$ OVA)G88; 7A5MLTD$,LU%X8P8
M%1R8@X-S;.>M#.4YKFLMZG[98%E2N;PM!$GB#.K:\L#]7[RR,4C32),HWKLA
M3+)*WF[V@VO$2@5@6GZ)1!-4%AHI/F.U2_O,!8Z\@%L3YPEG(9HX]2- WQQ&
MTNE>.S_5<@MUCE4E;'=R3* LCE%6/O>X^87H]=^!82F4IAIA!)*_F)#XZ[74
MW2B.2XE75UO0JF6"*,4:=GR?6!*YQ$665,)<:8DQ/@'-*^(G,U6D/)5[)+;$
MQIZP2391H !]ZIYOT+=,[:H% '&7.2B0)C!1Z2K81(6F'/CJGK: 6ZNC*!]<
M4B?6I*V5]936N4I3BRMD#V>F$+2I,>2 -[G')BKZ^M:,4Z_G204KDY<8Z+6V
M,NKA%(ZLGSE(V.MFN72HHG3-''*R7^(.:!E+4&:TI5H]ECV5WA&S0U;A_P @
MI3R<JUUMB05PX5<V+;'L2,0V-/FSO:4R,0:6.</(=I&#>MH279R7LIYAA209
MJ<@74D)ANR]FC#7H]SRX]R9S&U('.7)SCW)8GCY[G"GUM13-B21>XI6"=0Y2
MK3E@?8,O1T)*"4S@#LA-4("]=C1:Q&:>&^5-RCKB[)@\1" -5BN 6!@C+X[R
M]=7LD:8 D42^!U_9S!&O;!>D):%,I60.SF=RVD)&9V"CQEB'HXDTH(8N4\OJ
M@AUON%*O89QJ4M12 +@Y-T$D+O%R'9XKR=VHR1HIY;$BK:^2O,'K-[5IT:8H
MXP0T82!=D]4C*4! 9'FJ\1C'.!,JE\G:%TG\F>H@G3F0%Z7IHP_1^1LD<=$L
MS=V/3LQL)"84@3+-J-J34_@MC%L>C"QE!#"RCS6>-@J8LJSZF.DUM/L,9)FY
ML$'C4<=ESG)B8U63W:2"3F;9TSL<T5VXQQF[XYS-+\0C"8$LQ+I4,I.8%R+B
MY!UU0=5IK9M)S]2L*M;$6-$F2B3'K7:4S=P0M$<CC2)6I0(35CDZ. "PF'GI
MTQ1>A&G&%E &,(0/KS'.*?AG)P',WDEH::%1\G5SXHB3Z0RE44Y-2-8TV %R
M-2@3'(79\4FL*9,#8EYK^A5H]$=M,;L(9>%\]:$L34=%"?? E0'9O?W*2'QJ
M!/<E05>GC\EED+/%9[M'0.K1&"'"709W0)%(5"A&=M"8I[[2+6E6PQ9G/2N7
M.?47!H%!K+L(-TS&-10Z1,;"2C:8"1,Z!4\B8L]R73PL1*#DB^#!*,.+3A&-
M*'2@0^HT_<FAM)?,:NF4RSE-C%.< 9J^O-\I$Q:]-3B2-,Y,%&M]X[>)$/N1
MH&YJD4:VH.:%)!RE.L+/0$B$6N4[2%AZZYYK4%:-SK:!B\C<-6@WQH$C6QYT
M:QMQZ4TJ-0>7O4:6%&'"5H93&(_9#*<X)3RB@E#5C) 88>E6%IPVB6<HJMAU
MO-E(N(Y.LFSHD;=EF-4:7K8RC?Y"SS"00Z$NLIWHED:YE-V> NYS6B/.!WVD
M@0F#*&J1!4A3N"<_K3G]><2I:@XY/S2\<OKRDL(B[8YC7#05O64:CDIF9LGG
MZM,5M6=)G*-1%2(@E$2)!U"<=L_L)NPH"=6[FY!BH^ZN\BBE@>O 7A9%,L5<
MP^#26864M5UBV'OTF<E<3:4)YYA+3&D)SD>8A,6)S4QB8I,,]8I)2C#P.GF,
M\6FN36[#]2Q_>)%2ZU&UREHC41>Y*ZN#R=8\0J!>RQMF9$ZY[<W1ALZ>M#*L
M*&F(V!6LZE[,)*/-*"0X)R^J>P+C!0C8BGK/:)5?LEB/49E,+=(^MBS:_MR=
MV0M4F3+>BQJ=? J-=HW90FSQ(1) JQ+ "3Z"TN P& P& P& P& P& P& P&
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M:[ E7 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M& P& P& P& P& P& P& P& P& P& P& P& P&! ML?;Y2?\ "Q9^HVX$]8#
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M!IO"26\4&EY;BG>4<=YQ4*J6.J=<N;5TQGL&>F*0S5Z3%'IW%:4]RM^4N:T
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M& P& P& P& P& P& P& P& P& P& P& P& P&! ML?;Y2?\ "Q9^HVX$]8#
M8# 8&MS+[4)5_!M\^QBK TZD/YJX=^T%/V378$JX# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8$"VQ]OE)
M_P +%GZC;@3U@,!@,!@:W,OM0E7\&WS[&*L#3J0_FKAW[04_9-=@2K@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@0+;'V^4G_  L6?J-N!/6 P& P&!K<R^U"5?P;?/L8JP-.I#^:N'?M
M!3]DUV!*N P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P&! ML?;Y2?\ "Q9^HVX$]8# 8# 8&MS+[4)5_!M\
M^QBK TZD/YJX=^T%/V378$JX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8$"VQ]OE)_P +%GZC;@3U@,!@
M,!@:W,OM0E7\&WS[&*L#3J0_FKAW[04_9-=@2K@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@0+;'V^4G_
M  L6?J-N!/6 P& P-#LJRH?4<06SJ=KG!OCB!QCS2<>U1Z12MS-<I5(6N*L*
M)#'HFU/DA=%"]]>DQ.@)DIP@Z,V,6@EA$((8!%95?6K6,FE-:S6,3J/&,+^F
MV[19Z0/*1.M*:E&U#<N$A/.$WNB38]!/2GZ+4$#^9, $6MZP/M2'\U<._:"G
M[)KL"5<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,"@/(^OHC:G*2BH;8#<OD,434%R-E!<?+E$NC[8*1-]A<96E
MO>5)$5?V+:Y>@;'M800,_9G<EJC= T'MBWL/E\3/C%]RS?WQ;>^$+ ?$SXQ?
M<LW]\6WOA"P'Q,^,7W+-_?%M[X0L!\3/C%]RS?WQ;>^$+ ?$SXQ?<LW]\6WO
MA"P'Q,^,7W+-_?%M[X0L!\3/C%]RS?WQ;>^$+ ?$SXQ?<LW]\6WOA"P'Q,^,
M7W+-_?%M[X0L!\3/C%]RS?WQ;>^$+ ?$SXQ?<LW]\6WOA"P'Q,^,7W+-_?%M
M[X0L!\3/C%]RS?WQ;>^$+ ?$SXQ?<LW]\6WOA"P'Q,^,7W+-_?%M[X0L!\3/
MC%]RS?WQ;>^$+ ?$SXQ?<LW]\6WOA"P'Q,^,7W+-_?%M[X0L!\3/C%]RS?WQ
M;>^$+ ?$SXQ?<LW]\6WOA"P'Q,^,7W+-_?%M[X0L!\3/C%]RS?WQ;>^$+ ?$
MSXQ?<LW]\6WOA"P'Q,^,7W+-_?%M[X0L!\3/C%]RS?WQ;>^$+ ?$SXQ?<LW]
M\6WOA"P'Q,^,7W+-_?%M[X0L!\3/C%]RS?WQ;>^$+ ?$SXQ?<LW]\6WOA"P'
MQ,^,7W+-_?%M[X0L!\3/C%]RS?WQ;>^$+ ?$SXQ?<LW]\6WOA"P'Q,^,7W+-
M_?%M[X0L!\3/C%]RS?WQ;>^$+ ?$SXQ?<LW]\6WOA"P'Q,^,7W+-_?%M[X0L
M!\3/C%]RS?WQ;>^$+ ?$SXQ?<LW]\6WOA"P'Q,^,7W+-_?%M[X0L!\3/C%]R
MS?WQ;>^$+ ?$SXQ?<LW]\6WOA"P/2CX7\8#EB4D=6"T$U204+>K%MS>^R8:$
M.^FAV ,&]]-_HZWK]/6!(O ]2K5\/./)JY<X.2@-;M"?:UV<5[NXG%(QJ$B;
MQ;FZ*%;BN-+3$ !WIYIAHM!ZB%O?IP-[MC[?*3_A8L_4;<">L!@,!@0'R3:I
MD]5HB05\T,CO+_?2HU6SCDC ]RABCXVZYX&X+)FZ1^.R>&.KFDA+>E.=A%@<
MTI>O!Z$;L901EC#18BT2PI9;KY9= 5_ ['7P$2)UNBM'AB?8]:C8B0N/@V]6
MK7-L9LYN<V0T0C=-[JWJT2,M1V4KDJWWG0)AI#^:N'?M!3]DUV!*N P& P&
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M"P2:^"QPIKDT5K($@AL79H>.4.I5=U:MM>1L,MC>W03^>P('HM.:01WRI0C
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MRC=/CVE5 *//$E2)DI8=+,!@,!@,!@,!@,!@,!@,!@,!@>UM_P"T4'[=2_\
MOR\"'^!/]CGCY_1\A_UM;@2#;'V^4G_"Q9^HVX$]8# 8# BB[V2MI!64A06U
M(T\-A!1S ZK)B?+M0(R)/+)(VAXB,E;IEM<VZCSTR2Y"A4(3]G!UXPLL.]#T
M+8!!5^KF6IE$BLZ6P3D$V<CWX%/+H\XREWN.-6--XHU&+%J\AA01V#(&N(QR
M*.ZI/XA0K\.!P7K4Y0#1F%IR=%A:*D/YJX=^T%/V378$JX# 8# 8# 8# 8#
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M8CR*XWM4\2/$,D [+71>%/T0B45GBM-*FJ4P:./WM,DALJ+5D)B@.#$MZIU
M'(:50/N G2[^75E4Y%>.[80Q\<Y+:5UQVX9*ZRIRN1_B7&5G1T;!/;V5H8]9
M!T2=I$]O,G0GEDM11R$@)($KDM/[1+>(DT,8/F=<$[EG$6/4-0T2??C*\3C.
M7[^VV_9CO7,CA$(12N@61R@[46TPF4-CM.2FB[S519BTQ AV<S]T+>M*@B+#
MHX(.N\$ H6S ]O82Q=C81&:[70 NQUWL.QZ_0Z[Z8''>@^>TYE_-KFM 9D3,
MG2AHM$K3?N,*(BJ5[&VR%3PU>&>N.23;6EDGLZ)NNQ[E\VD?B!)DBY?ZB,0:
M3"T1WH@["&JQ\SJV%I'+GD!.VJI7Z$5UP=X1\@:UIRIKK!-(9&W+D?.;N1DJ
MK1L%=!65= 7Q&UE,89>ITD<&]"T,XG!(#81"+V$FUCS@Y --4\O)_*4506Q8
M40\R^IN(E?1>+6FYKZ0C+7:[;Q-K\HICLA!!=2=1'HS*K5<WQ6F/:3G$I<-2
M@V/?8 9H)3Y=<\;VXGPCCDWK^,\:F_(*ZDEOK9% F"TE JUCOO(QM+))"V1V
MQ5D;:U+HX3A$YI!LXUZ-$6VIA*E"_0@(3=##<K[YU2"D[FXX05?6L8:JXN-B
MJQTG<[FLW<MO=<O]O6*U5S%H"KBU<QJ=K&9U,=730$;\\EI(D\N8-MA+BG."
M8>6&:/YHO[;SQ*XC/\&AK!"'<W<=A5C*)D^O$EG,\3T\9<#M'4#1%HJ_0^(/
M3&UI%)9S#)W5C>53<GV[H_$I322# NU-'%6SPJ:O#>9W+@SPV5N[>=LL!NB5
M[7'W%>B.V48$99NBE2< MA%K81=.F];UO>!5KBG=\GO_ (84G8,0FU567R E
M_&2H9E(254N;$$=!:TVK1C>%@IT77B&1.<$;5TF4J=F 3M0QINP,!*87=[+T
M%9ZUY>767PN\N.7PV(L5I71R^E,/J,Y5>%J+D;>T/2^N+BGKU.);.8/5J17+
M3D@:F,*T4BC;5M=I4'H!-L.]Z"/+.\V*:QNE>'=BUKQ@,G\YY1UE;EIN4&5V
M"!E8HPAHM=&&*=0Z/S94S)$CO(G]_DNM,ZQP);T:9N3F*UQ8 Z$  =G$A^U:
M-&KVG4(]K$:16)&KT5I6C$J3EJ-HU>B##B-*DNS.[,[ Q@[8=]D6]=-[#F#
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M"8L;(U,@@,,9T4A<WQ#&U$IGLJ98FB3B7,["\.IA9:IU$,@ B$X#Q " X](
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M5! 6&G,OFJ2J3-LM4):>@L&VGL#V:BS];EOH(?$F5H3H>1CFI2V\J;&:1OD
MF:TCCDI2HDAJ+:90Y/I"8)HAHE/>A/E%<]7.U++4L\RKU@JZKUD0LB4M,JD$
MT/(DL>)JF"<;Y]+3;(:'2/M+!%T!#?R%[@9@'([P8F(TP[YA3K28+)<N)_(*
MWXKWO:\'D13 \5U4\LLMNDA2-"\ITC?"68^7.2L*-6F7HUZ<YD:C]=.[,V(
M^H-=KL[P.35;^9=?$VN5ZL)'!CDM%EJT<6D]*SE6C8; KAT+M3BW3#BICREH
MA2]3,),"16XYN04JU>C0FI-E$@,T,P R WAE\V.R9/6JJ>LG'J*I%"=--IF)
MK?[8*+TF@$,X\ROD(L9W$$=CTC=6JS4Z"*^I5*):E1I2E*TM4 9@"C4^!TDY
M/7T\T903E<$3BK7+G<*Z!(&J//\ )FR*)3?;B5,$=VH$M7GE@<E[4E>A*26M
M,/QSL>2%&D[2@XH.PJ>NYR2MN#(K6+C[7(JZ-X(0/E#!F%C?W5&WJG62ONT+
MQJ4GR2MF:3LC$U'*B3!.XP@VG9"CSU#04H*[(@UNN?,6LB9RMF9SZRJ-PC;?
M8T,K2=2^"VX\RAL6.=@<L;CXI1YZK8S<"1HW]H2.U7DO*[2Q0D&66J.1 V,T
MC1Y@?M;SGN2O82R+WNOX;,'Y-*N:SK9RA7/W!K;F6(\7>2T8J-6V5Z-%6Y)S
ML<Z-LY)$V%NA*820I$$M6J5F"&I$%@>+7+YWY#VS==>KXM#(^AK=I9) SA8I
MRID<V;T;O:][58*.6W$SX\T@KZ;I3J2$X"1%J5P-%N7<]OJE$:<%?KH\RYVK
M6[K@J",5_ IL= 8I+5+"<;9A<2<!S*$J^/93TS2OVP9X^P(BST=_DFI"T:]0
M%0>W%) J=JG$)2,+_<<+A3W]1]<V^G3H$?MLQ"7*T;6)_&@1.B%>M9WA$F%*
M(]%7[9:1U;CB_P#2$! M;#O0>\!V31A-N P& P*9V?\ VR*1_%EY,?UI<4<"
M9,!@,!@,"G7+:IH!-5O'NT[(Y 6;1+5Q]O6&3.'#@IM?%,,IM>=J14K!&F9
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MZ&WI!!A-BTU>7%G*3+(V0^BTXEHPG@+[ 6I>&Q,]L[PQK>\TB?&AT9%NR1:
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M-QZI*&VOO*"AXG4CHUSVF98T12'\D[!BK+6$#A[%ZTCKYQK1K^4#E*WA*US
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M:_"&-/UW/M(5FZ.,V66W&(+-/>BKV)*I1;T]EL^L:"QY8F4M+\G"<2KL:*2
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M"X\O)9[./&EW*)%'7U ZHW!RL=0UM*4]FJI?.FR(('XX57M,Q''PPY1)4C&
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MZFR.KU[@K=5U?.XU19FUD16.BXY0:B%^LC.,V/>M[Z;T'A=Z1IN0/@)._59
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M"#O>MZZLDNUOIO7IUUU@2EWY_P"S&_1!_+P'?G_LQOT0?R\!WY_[,;]$'\O
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M8WZ(/Y> [\_]F-^B#^7@._/_ &8WZ(/Y> [\_P#9C?H@_EX#OS_V8WZ(/Y>
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M,2\I-/3MG2DB7N:1L$T)^_=?&+$Q?A^JDCO D%1Y4_ $52/-WL-U\^)E733
M9-9!#Y$_,<Y4NA+Y'(HRNCVY>IC-V600<OV4T'D:)-&2(M4#91W=B"/00I\[
M\7N T8=(:DEC/YL; TOM><:;$FDB,\R.S5Z.JD'+2P7VLJ;:Y*TH>3ILGECJ
MND[$+3B&)H9 6WISRS-B'T," ,_)^(7E_,U-\6KB8E?F?RM+R[5A25A%?\3*
MTX([-P@UG+[64F3.16AR2A->L04T9A2P&@A>3QG+!%%%!'V^UH/Q/.*WEJ5H
M_75%YA,/-"0/U$47!KQF)2?S".0ZQC6DS13&TJVOX_,@7D&'JYC7NY_%E,E4
M*%R5@:6V4-RX;B)(,XTD,.Q<3>$T@L:N:G31#S6D$ZG42U.5Z%\\TJ1,C1'8
MH.R5=9I']JD;CRV(9[79WE>B&X-QT,,?]K6X0-A#I4+PN@EJ_?+_ ."M#6'6
M-6&+_-"LJ;6>T2B4M;# ?,9O0AT+B$,>8PQ21S9FN=WY"W*PI(C62Y*:7&XT
M4[R%0C+// D[( :-#0'7AKPF:97<L$'%_-F53&K[[@?&J)LJ3S(;7-W=5JV-
M B+8CZ2!K?C)Z2L$<1U2J!(G)RE F$I"@":6((E9)B;0>*$\7O+;F-L*Z+6/
M'FPP2VFR6T'#GF#S[G?R49'=J7<@X9(I?'7 ?A;N<TKBS14<8/;WI0C,4A(5
M*41B?Q"1<E4F!+,RX!>77!5]SLKY9GF. D=+R6M8PLC!?F+\DP2">*[2;*W<
M6!;7;8KN)*>_-B VT&],XFFZ3;1G@,[6M@V2,T(*7<3^)"2L'.U2*9\X9P96
M7D@_\7'9L3>9R_EO*.QV2X&:@DZOL+.7R9N4QE\MIWVUIE)2@9I9:8Q6>22E
M$4:8&[_$Y\O(4R4U23(_,P/NU'94NJ1131?F86_[;%36&<8R.4CF68$7(@+.
M7'5,5/TRIW<2K3<8_P"N[V:%)L*L01*QU!Y8ZYJK!7(W+S8(.[W!QBC7+."1
MJ0>8)>RMQ=*RE=J-57M#9MPCG()[CX)T,#VG?S&H*P0P,.CS>WL](I3E!-'(
MOA7Y>W&BX893LRD'F=O[A*HRSRY:_P 5\R"[/!1]CD%IMM.M RHW*>0<8GL[
M=#IB[$]XW19I?'$M'OO>X$+8"QA'*GCUY:[2)T>9,Y>:[%JR3)7N6LEPN_F
MW\*!22F(3;[71=I7VGVW7XODK#5]53N0M:EZ-=F] X%QER*>R4IJ$M2,@)[@
M'ET<*)[,*>BO7S4(@3>E.3BZX&]S+S">0[65N.061Q!H5L\BCZ:[UTOCDE=V
M*P&1[2$*&_1.D#AHH\TE<2>D+"S/^"=P[^Z?Y@?_ !%.6/PBX#_!.X=_=/\
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M'6"E_/XSW$WU\A75VL\:$ULW,8[[V;;M-*BR"U!P1J F(NT8 903387%VE+
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MC6LV6,G:A&1W1FRC.G;!O>M].@NSK VS 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
78# 8# 8# 8# 8# 8# 8# 8# 8# __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g41684g02v02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g41684g02v02.jpg
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M 0,1 ?_$ ,,  0 " P$! 0$!           '" 4&"00* P(! 0$  @,! 0$
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M5ZBDZ\$I<79>M=7-88&.(2_?KW-Q/5.#@J&$&O6<>:8:8+^4,0A;WO86IP&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P&!YEG_ )-7_P#+'_\ PA8%$N.O_2-RU^SK2O\
MAQ',"QV P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!Z
M4?\ YQ)_\R1_\4.!%?!W_HPY?_\ LE7W]GT>!;/ 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8'F6?^35_P#RQ_\ \(6!1+CK_P!(W+7[.M*_X<1S L=@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>E'_YQ)_\R1_\4.!%?!W_
M *,.7_\ [)5]_9]'@6SP& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!YEG_DU?_RQ_P#\
M(6!1+CK_ -(W+7[.M*_X<1S L=@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@>E'_YQ)_\ ,D?_ !0X$5\'?^C#E_\ ^R5??V?1X%L\
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,#&NKRT,203@^.K:S( F%E"6NJY*W) FF[])18E*LTDG1A
M@ON!UZO;O?\ PP-8^D^M?RAP;\;6#\(8#Z3ZU_*'!OQM8/PA@/I/K7\H<&_&
MU@_"& ^D^M?RAP;\;6#\(8#Z3ZU_*'!OQM8/PA@/I/K7\H<&_&U@_"&!GT[N
MTOC.H<&1T;GA 82K++7-:U,X(QC* ,!H *4AIQ(AECU[!:T+VZW]S>!2/CK_
M -(W+7[.M*_X<1S L=@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@>E'_YQ)_\ ,D?_ !0X$5\'?^C#E_\ ^R5??V?1X%L\!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,"D/:49C4P<N0X[,(W'Y;'G#K)ITX1^4LC7(F-?I/0?0*I/\:SO*5:
MW*OAU1(#2_>%B]V: (P^P0=;T'N_5LYM_P N7/OYD:O_ +JX#]6SFW_+ES[^
M9&K_ .ZN _5LYM_RY<^_F1J_^ZN _5LYM_RY<^_F1J_^ZN _5LYM_P N7/OY
MD:O_ +JX#]6SFW_+ES[^9&K_ .ZN!B.,XW'(BBZTCD2CS%%8ZV=76&4VL$99
MVY@8VXLZMJI4G 0-#2F1MZ,)RDX9H]%EA]9@Q#W[1"WO8>#CK_TC<M?LZTK_
M (<1S L=@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M>E'_ .<2?_,D?_%#@17P=_Z,.7__ +)5]_9]'@6SP& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P*>=8
M?]U<;_M9MW^WSH; EO 8# 8# 8$-<J?^;["_:QL#_#"I<#5N.O\ TC<M?LZT
MK_AQ',"QV P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M!Z4?_G$G_P R1_\ %#@17P=_Z,.7_P#[)5]_9]'@6SP& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P*>
M=8?]U<;_ +6;=_M\Z&P);P& P& P&!$7)00C=>N0"UH01=<SH(@[^[K815I4
M>MZW_P#MO6\#RL'#%715C9HQ&+,ZHC\:CC6@8X\P-/5M])6IC9&I*4A:F=L2
MZG0M)FYL0D )(+UO>BR@!#K_ (8&6_4WA?Y9.M_]6E]?WXP'ZF\+_+)UO_JT
MOK^_& _4WA?Y9.M_]6E]?WXP'ZF\+_+)UO\ ZM+Z_OQ@/U-X7^63K?\ U:7U
M_?C ?J;PO\LG6_\ JTOK^_& _4WA?Y9.M_\ 5I?7]^,!^IO"_P LG6_^K2^O
M[\8#]3>%_EDZW_U:7U_?C ?J;PO\LG6_^K2^O[\8#]3>%_EDZW_U:7U_?C ?
MJ;PO\LG6_P#JTOK^_& _4WA?Y9.M_P#5I?7]^,!^IO"_RR=;_P"K2^O[\8#]
M3>%_EDZW_P!6E]?WXP'ZF\+_ "R=;_ZM+Z_OQ@/U-X7^63K?_5I?7]^,!^IO
M"_RR=;_ZM+Z_OQ@/U-X7^63K?_5I?7]^,!^IO"_RR=;_ .K2^O[\8#]3>%_E
MDZW_ -6E]?WXP'ZF\+_+)UO_ *M+Z_OQ@/U-X7^63K?_ %:7U_?C ?J;PO\
M+)UO_JTOK^_& _4WA?Y9.M_]6E]?WXP'ZF\+_+)UO_JTOK^_& _4WA?Y9.M_
M]6E]?WXP'ZF\+_+)UO\ ZM+Z_OQ@/U-X7^63K?\ U:7U_?C ?J;PO\LG6_\
MJTOK^_& _4WA?Y9.M_\ 5I?7]^,!^IO"_P LG6_^K2^O[\8#]3>%_EDZW_U:
M7U_?C ?J;PO\LG6_^K2^O[\8#]3>%_EDZW_U:7U_?C ?J;PO\LG6_P#JSOK^
M_&!82MZ^BU3P"&5C"$:EOB$!C3/$HTB6N3B\K4S*Q(26]O+6.[NJ6NKHKTG(
M#[U0I.-/.'[1C&(6][V&ZX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M &LV[_;YT-@2W@,!@,!@,"(^1_\ J_6_[74X_P -*BP+B8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M# 8# 8# B/D?_J_6_P"UU./\-*BP+B8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%/.L/^ZN-_P!K-N_V
M^=#8$MX# 8# 8# B/D?_ *OUO^UU./\ #2HL"XF P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!3SK#_NKC
M?]K-N_V^=#8$MX# 8# 8# B/D?\ ZOUO^UU./\-*BP+B8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%/.
ML/\ NKC?]K-N_P!OG0V!+> P& P& P(CY'_ZOUO^UU./\-*BP+B8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@4\ZP_[JXW_:S;O]OG0V!+> P& P&
MP(CY'_ZOUO\ M=3C_#2HL"XF P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P&!3SK#_NKC?\ :S;O]OG0V!+>
M P& P& P(CY'_P"K];_M=3C_  TJ+ N)@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@4\ZP_[JXW_:S;O]
MOG0V!+> P& P& P(CY'_ .K];_M=3C_#2HL"XF P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M# 8%/.L/^ZN-_P!K-N_V^=#8$MX# 8# 8# B/D?_ *OUO^UU./\ #2HL"XF
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M_:S;O]OG0V!+> P& P& P(CY'_ZOUO\ M=3C_#2HL"XF P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MGDH[I/-\GUIRYM5U;1E5^+KB_HB'\\HIK-JNO^EK&O-?(U"]H#8<29VU6W3
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MF2@9?*[4G$JJB'R*4WA5+?1MN.KRW?* K J-J')3$$ DB1488@71U.*8N?\
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M7_:/V^O_ /H'56O5[=^K[OLBGW=>K7MSD_N!]>/#_>W=OA_F_(?Q"3\JXO\
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MT?R"$5-.WV1;+DVQE%_*#>W>I%K1@O29O9>@J1\^?.M_EP\6O^K#J/\ _$[
MMO8S[W>DYW@3K4];<KO?5:G<5^DV%SVVK3C]#,X3FM:.:?,FP&&I9!.WW;>\
MA3EMOQL?0?%)AF#.]R,(0""I'SY\ZW^7#Q:_ZL.H_P#\3\"W*E\[MURRF>4E
M;\L#[2V C:NOU%LVD7S8 >YGM.IT19Y=2F628$%?_P#- ]48#ZG;_E]^PC_F
M,"HWSY\ZW^7#Q:_ZL.H__P 3\"W$+?.[5'-LN=K"K?EAKZY(#(_F+!XA;%I/
M//SB(H9&HGJ4V([U.S6 U:6%[,VO^%CJOW&PA]U[WV[](5'^?/G6_P N'BU_
MU8=1_P#XGX%N:0?.[7&I+*7=&5ORQ%+S2;??HACE.6S:4UJY]T5&"3HU](4K
MF-2PJ41OXN8[,(6_)[4Y>X;M!.+]X=O9.@J*&<^=CTA]?-_BTT+TZ]6@]8]1
M[#H7L^[[-[Y.UO>O;@6XYA?>[WA#/Q=D5MRO G%+IE^C KG*VK3LM(\;,3N^
MY#\^#K%J2M#6'254! %)\"!?[X!A^S-%[+!HP*D[G'G5]N_9SAXM=Z]0O3O?
M6'46M[#[=^G>]?JG_<WL/_'_ /? LYR](?(@\R:3D]F5;R! 8>2Q)C(<NYPN
M:WK,D2^2[< A6))$VV-3-9MS:R@:_:,L].I4G"/UH.RM!WZM!7N1S7S;%2*0
M%1/GKQEKHH4^.Y<76O\ U)TPW/RR-@<5(6)6^-Z#EMQ0('E0U:*&J)(4'DE'
MB&$!@PZT+83+S;)?)N[6*:EZXJ#B6#U1J..AI+WS]>MV6+/12T"IMTS(3(]8
M%%5TPA8#T0U8E*C3CM048 K0"1Z&/8 CNSYAYC4=BS5+3E#^.A^JA/(W(JO'
MJQNE.B8S/72)@.WIH6R^/QWFN3,+,_GD?=4)T;@L3EC^X T>ONX&S4+*O*ZY
MVG'$735*\%1"EC27K<LD%)]!WS.;*1'ELRTR/A8(Q->>X-&W$I4_A3E*]J'1
M-LE((PPO1A@0EB#\;SE?EE;K3E*+FZDN!)92Q(FGYER"YNAK\A-E. !LC<8^
M;DL7AO/,VC;6)/(AJRDOPSHJ]ZC 48/T&#$6 ,+5,O\ ,*MLB%I+LHGQVQZI
M%#ZE+L%[K/I+H>4V V1K83/C%<1CLEYMB[ \/18M ]V0K<49(];WZC0_<P-W
MZ,DWE :K)-2<G4]P]-JBTQ-)A+Y?E[W?7E@BDH]J_EQ(;'8%0]AQ\+*G"$CX
M4_3CLXWU#]98/8'VA$\3FGFN/E48(F_/GC0;H4=(F,J8N$9ZBZ5=9*@BACFE
M!(UL=:W/EUK;7)^2L^SC$:=0J3$'*0@ 8:6 6QA">.H)%Y&&>71TCC6JN.Y[
M!38X(V5N/1UT7#6<I12WY35@"B86JN:7LQK<&#Y'"09M0>K3J/B!#![KT!",
M05L)G'G0V>1I1SEXN0I]GDZ4B)ZNZA&<!-LT&E R0#Y1  9P2?5L&M[UK8O9
MK>]:^[@6RZE?>\6;YC?J7UMRM/\ XD#_ /23^LE;5IUC\DF%:9_FQJ&?1O4E
MF_+8%@C%_P ;M;\#LC11'N]&^\,]V%1Q3GSL>D7HYP\6?K]._1ZNL.H_3ZO9
M_)]7LY/]OI]O_' MU?;YW:V5M6ROF2M^6)?;BL3?]+C'=MLVE!J^9 BCWO73
MZ/I'"JFG,@D6R95_,D?*#:W>\0?SHO0;_-8%1_GSYUO\N'BU_P!6'4?_ .)V
M!;:P'WO!+SI!G6KZVY6>.L%.XQ])$*G%M6FPT&TA.1+!3'<,L)DJ5]GKWM"X
M!3@;OC(\B^))&8([W(@A"(*D_/GSK?Y</%K_ *L.H_\ \3\"W0WSNO\ 58 \
MEUORUOM/W8/77XK9M'7->C=S32<S0;/U4V[)V#5?>U5K?S8]NW?_ )?_ ,O_
M ,Q@5%^?/G6_RX>+7_5AU'_^)^!;:#/O>"GG":.UD5ORLT]:I_G)]'T)AELV
MF^4 YZ*+2[B7SNL-YJ9CGS/M:<(_3A\)'EGPX0@V5[W8A:"%2?GSYUO\N'BU
M_P!6'4?_ .)^!;JB7SNMRJVR%O2M;\LQ*Z$@G?Z)(_2ULVE.*W? %QLLUCW8
M,GFE30>1QT2F6[$0J^3VQQ]TWZT<#UF_S.!4,,Y\['I#Z^</%GZ_3KU^GK#J
M/T^KV?RO3[>3_;Z?;_PP+<<O/O>#R1/-]F5MRO 5*;3)]&@.<+;M.S"7<1A3
MON1ZFH['J2LQL04IP$.D>T6EWO@F'[,T7LL&C J6.<>=3UC]'./BWV7ZQ^[V
M+J_J+0]E^K?N]CUKD_>@CV#V>W6M[UK?_C@68Y>D/D4>)5)">RZKX]@,**CY
M1L1<.<;GN"S),NE.W$@!Z.0-=C4Q6;8W,06G9@PJ$ZI0?M0$(-E>C>QA" 91
M-/-D3)I(3#>>_&<X0\J0/1427R/J+I9LD2Z+EN2H$?6/[:W<N.;<W/BIHT2-
M60G4J""5 A@+-,!K0]A+_.$F\G;M8^TG6M/\10BI?F\ZFZ>Z O:[;$G_ ,Z@
M'(-,J/YNS^B*[8/D)0G$IVI4?*/ORA@+T H>A"V$-!M*7^8E%8TU24O1'CKD
M%3)Y N*KU[LGI/HB+S]TBX1!^3EDOCT;YLE# SOAH?;LXA(XK" ;]F@FB_XX
M&P43*O+"Y6G&472M*<#Q*EC@N_SPD%+="WU.+*0B S+S&+4=C$SYZA$;<M*9
M %,4J^(=$WND@S# >\,"$L0?Y>LK\L3;:<G1<UTGP-+:6)^2/F=(+HZ%ON$6
M4O\ 6RMYC[\XXQ#.>IO&FSX:0B5%)?AG13[U& HP?NS!"+"& JV7^8E;8T*2
M711'CKC]3*) A*L)[K;I/HB3SYKBPA"^4ED0CTDYLC# \/I0/9LE.K<$9!F_
MN"-#_P <#?>CY-Y/&FQ]I.2Z?XAF]2_-]J-T]W_>UVUW/_G2,U?I[1[CT!HF
MQ&#Y#3D!3;3'_*/OS1#,T,H&@AV((BBTT\V)TGC1,SY[\9[?#3I RE2Y?&^H
M^EG.1H8L8Y)02%9'VURY<;&YQ?$K1LX:0A0I3D'* @ 8:6#>QZ"?>H9#Y%&>
M51LGC2J^/9]"38\:;+G#HZY[?K.3(93IR/ 0CC[97-,68VN+$)IT6,1ZA4G/
MTH$(&BM@UH>PK."<>=/9A>C.<?%OHO9@-&[!U?U%L>BO7KWFP:WR?K0AZ![?
M3K>]:WO M3U _=_,ZB#:XUK+DR>I%*!Y%9 ^CK@MBM#VES+&U:8"8877-/V6
M6]HE18UNU9BT2$9.RR=%@,]8]@"J0YSYV/2+T<X>+/U^G?H]76'4?I]7LWZ?
M5[.3_;Z?;_QP+;=#OO>37#:V4<JUMRK,[ 5A%NW6N^+:M2 1)C'\CHA@U7SQ
M!*EG[M(@[?A*"][<$;=OX4!8_9ZQ" $*E;G/G7]F_9SAXM/;[-^SV]8]1^SV
M_P#A[?9R=[?9[<"V-MOW?"&D*Q<:,K/E"1]&K/F[],<4M"WK6BE.,/O8VK-E
M?T<S6,5#*YC)?@I<$@A!\HLK9\0WB&<;[HT(21!4_P"?/G6_RX>+7_5AU'_^
M)^!;*8/O>I'-<1=H'6O*;EUV>8QZG<'E5M6JT<^-Q1AZS4D%%K%:JE=[!=3$
MJ8*?:/2J.I='#&9HS9>@AV(*F_/GSK?Y</%K_JPZC_\ Q/P+7_+W?/ZK?RS]
M&?*'ZZ'Q/L^8'TO6O^K;\)\\?A_7])WT0?21\1\P?^:]/S8]/RM_R_J]Q_S&
M!5#Y\^=;_+AXM?\ 5AU'_P#B?@6RB3[WJ?S3+':<UKRFW=>D&/>H/!HO;5JN
MO/3@26K2:CHI/8SI4K58+68I0B/$LTECBK11H !+V,(A""%3?GSYUO\ +AXM
M?]6'4?\ ^)^!:^I7[OE=1]GN-XUGR?'>C4>I%]#<4K"WK7E5./VRHVD-BOTC
M363U!%9C&=+9<(\A?\G,CG\.WA <5[TT0B0A4_4Y\Z_LU[></%I[?9KV^SK'
MJ/V>W_Q]GMY.]OL]N!;7GI][R=(392CJ>MN5898B0/\ _2)JHJVK4GT/?!_(
MRPS6K">IU4D!>(Z'YP!(*]K>B<=_""&9[/>!"6(*DAG/G8](?7SAXL_7Z=>O
MT]8=1^GU>S^5Z?;R?[?3[?\ A@6NY??N_7@^<Z[*K+DV IDR)F%6P^<;?MBS
M#W9Q,$Z_. J9EV-3]: 9$24 $7PAB(2X9VS#O> +] /6%51SCSIZ,,T7SCXM
M]E:,'HH0^K^H@C$5Z]^[V,.N3]Z"/8/9ZM:WO6M_\-X%F>7I#Y$GB4R4GLNK
M./H#"R6 @V(+^<+FM^S)(ND^W$H*E'(6RQJ9K-M;F,+5L8P'IU*@_:C00;*T
M'>QZ"ODAFOFX*D#\5%>>O&4MBQ3V[%QE:^]2=,-[XLCH'!0%C5/;>AY:<4*%
MX4->BAJB2%!Y)1^Q! 8,.M"V$T<V27R:NUB'I>NJAXF@]4ZC;F<F>N?;TNNQ
M9X.7 5M@6="='[ HNNF$$?/0C6"4*=.&U!1I900$C",8@!%U@3'S-I9W,TU7
M4%XWGFM$\H?":_=YSTUT>PS1SAI;B>".+Y:QL?,C\RL\D5M6BAK$R1<L3$'[
M$ LXT.M#V&]\^2CRH.EH-*/J6F>$X;30VYZ$^/U%W[>D^L=.ZEH#!1\EKC4Y
MH* QQ4@5.>@@5F&N91A)&]B+"8+6@[#7;?EOE[0V9,D=#T9X]9+3Q#J$$ ?;
M5Z.Z#B5B.;+\$D$)1+(W%><9='FAS^4-GAT4D<E97N0@%Z_5L0=!^],2WRY.
M%H1!'T'1WC[B]-'KE89V_P!2=%] 3"QVUN"UKQH38K&9;SG#XX[K#'H*8LT"
MIS2 "F&8,(A#"$ @R%\RKRO-MIR1%S/2G!,NI8HIFW$I!=?0E\P:REQQC,A,
M?]2",0KGN<QIN+32 2DI)M.Z*=G) %F&>[,$(L(:U6$P\QBRQ84EN2A_'2P5
M0HD;:58;U7/2G1,FGK7$QG>QV6Q"/R+FN,L+R_D$?=3IUC@C3F#^X,T&ONX'
M3K 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M# 8# 8&!E4B01",2.6NH5(VN+L+Q(G(",L!RL:!D;U#FL"E),,) :I$G3"T
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MI(^Q9W":I<$ U#4!P0*]%&#(&2/87RP& P& P& P& P& P& P& P& P& P&
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MZQ0A4)S"=C]8?S$^"O*E327Q"3:.<Z\I679?BZ5=LU8\Q.+6ZR<\5I<U:W'
MHA7M5VFR%1VK9 C@LK>FP"Y=(&[3.:(UV2C4"%K:\7N0ZS>,_D._J1F/:G4G
M5YE;M/1/=EW1JSI56M0OKU+*^J2#UO 6VN:P@B69/[)&ETRDZ)C2''.[F!O1
MI3U!P0DE^DOUC#G<W<(^5CF*F>NN N5(_P DV'S)T]8=_P BJCI.U+3G4-L7
MFZ%=/+G5=8<<F]/M-;R=+;#_  X^1N V!:@>$9*DP10UA>@;VF*#]*8^SX46
M#J=R-ZLI:KNEN::LX,XSY?H)^GQZA1+#YQ13/(V*R).X15O5)]1S<F+.2*/;
MI0>5OU^Z+]@0;]H="/,9R1='6O":RC>98_$'BR&6WN<K C$;F,J^9,:6M%.6
MW$)PX-*B2;;7G;9[UGCPRBA?#G;]6]>P.]_<V'.;HOQ[>17OEXZ[Z(Z"K?G^
M@[$>O&I>G"O+//E?W<\6Z4NE-VNP'^4V5:MMN-;UVSMB(SY,2-S<A1MINBP&
M&GGB"(L.C@CV?_9Y&[KB=WFHZPBL)3@=?';Q/S[SE;;%(5#Q+Z?Z%HZ"2%DL
M"1I&<@"$A;%1/H6HM00I]ZG?&L)I&PE^K8@A'5R^++MVZ2_&],K\\>7$73BW
ME3EFX^<K:YV/O5#1U(*Y2KET3)K:VZY'%:H>T32E=(K&!.!S,0S(26]:N/3E
MZ*+ 5O86Y(\?W7<(;_'_ -2<O\H\N<SWCP8KZ9KQ-P>7?LBDM%6#0W1AQ"N2
MZC-^-]6IW.%V."2DC>4?Q,?4H??JC0*1B"$!8PO7':F\B=U<5=TP_K]WHY)<
MG2<"O:)T)2M3*E#A!J'B4UJ1VA$)@4EN!QCD8=+'>UDA6[6NKL:U%$IA'B"G
M]9.@%E!4R<^-#JQ/Q?X?EU,O%2-W;OBLB]/*T4*L=X?#*5M$YOHEJIV[*R6S
M.--2QY8MO[<G'\COI;>H 0<3KWA 0';-*"MG4WC)\BW?3?W+TE?D5Y^J"][1
MX&4\)\K<U5W;#U8D<CL=?K>C=O3J>VQ=+Q!8,A529]>F *5O3H6H:-.W[_G-
MA/UZQA-=!^'1_P#'_P![Q^]N#ZVI2$43T+S:Y4[T>VN")G<9YS5;S"Q%'PVZ
M^?E,G;G!P>XC+'\ "Y/$ .:%M6G%?&"+-'[@"8*Y<^^);N1#V9R3>,[HKB+F
M">\]6H\37I?MKD>>22'R_NZ&'MSXC505_P"88C5]=UQ$@V@K7)E4H.<3E.RU
M ##D6P_=(.#ZQ<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#Y6//#^]7^
MSA?MHSO^U/-^!]4^ P& P&!33R-?N]N[_P!C3I__  1G&!RH^SA_N5>&_P"K
M-L_X_P!JX';K 8# 8# 8# 8# 8# 8# 8# 8# 8$+4K_ZN.J/_M5RE_[]]X%T
M<#YK;B\P'5*7O?KGCVI77Q456V<T3BE(1'E7='64[H>Q[@7W#5\9GB8=>1AC
MA\G32CY)=7L3::$C98PGFI0:"8,W?L"Q4L\B'=]U=$]/4KX\^4*$MF-<1N\>
M@M\V)T#>DJJU)9%TN,43S!_IB@FJ*5W,C-NT9;EB=.>]20QO;?C5.@;"$L.C
M30IK+_/_ &#9BGB<WF=AXNI1EZJY\N6V92^^1J_I)1$4K6PZ,MPNF9U31<RB
M<=?DSU*"):0LT@UM$2)S1I1*=!(#_-X'4KQA][V'Y"^3;!N956U?PVR*^N.[
MJ%1*H=.W6=\^VO)JD6%-;=9]3V-N.M;Q(J8F#DK 60O B,.#\.IT#WH@:]H4
MIH/OSRU6!VCT)RA8]">/5C(XYC]&3_I"40RY>BG,Y? [SB\GE[(73)#U4J$$
M@E[:TQ-4!4G>@,Z("D180*#2Q"-"&M5MY_Z\LSE?QM65&I'R[(>G.S>H^::&
MMSF:,7<QO4ZIN-W5/WF'RV6$P= ^*[!3K(>D1I% 0.:,M.$:L&CA:"(&Q!H5
M<>9KK>Z+YNBNH?*/#G4S%5W:EM\HL]>].=G6!5W3\S15C:&H&AD[%5"2$O:5
MU53Q.8 +* A5Z5KCH9(0!UH.Q!V=\CO8>^$N/;6Z,;8LGG\Z8 Q>(5)6YZE0
MEW9%PV5+&6 5G"@&(PC6^Z=I7(4^U.R=;-+1%'&:]GHWO0<I)OYN+FAGB6MK
MMP[G.(+.N.<^H1\AWOR\FD,A5,;%=#1T"PU(]1IC>42=3(EAKI&9.W.C8+9)
MOO#5Q8?2:#7\H-DL;SGHU*%VG//L B<\JU1X:N@O)Y%G>3NKTVOY5ATC8C-7
MJ^C9:@0 T0V 9'Q6N;WT0/\ G$;HWFDA^X'>\#+\P^;C?4B#Q9&Q.K69@?\
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M3ZX/[6I8YPU_(9H7M.1LO>A%F!"?]P(5BX+\S/6G:4KIA:HE'AWK:)65<[U
MG2D))V9/6OMY+&(E:#_!GT#!0Q\+6I'&P7UEC2AT8&\QP"2XICTQHQDEF[]
M==/&]V7*>W:GNBPY9#6"$K:PZYZ4YR;F^.K7%<E<V&C[ 51!FD2TQSWLXIW>
MD9.C518/YD!OM]&M!^YH.--1><+N<?,5>>1B^>5^8DWCZE-]GTI.'RJKBLP?
M1E4-0K\<N=B;1?H%+H!J!/T;03I&5LY$@?Q+3DRDL>O<_P L( ^I_ 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# ^5CSP_O5_LX7[:,[_M3S?@?5/@,!@,!@4T\C
M7[O;N_\ 8TZ?_P $9Q@<J/LX?[E7AO\ JS;/^/\ :N!VZP& P& P& P& P&
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MNDN*.VQ;O/CQ-N_^9XKN:LLX5TESK=2>7-438HHU*6HQN9W4Y 2XH6U685L
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M/(U^[V[O_8TZ?_P1G&!RH^SA_N5>&_ZLVS_C_:N!VZP& P& P& P& P& P&
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MH*/@S?*Z\4&6P&]GE]:X,E>I:6^[B52R=I01Q4[R%H>56U;6S^@XCXXX0DX
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M3^MYU%IH9$K*E;T:I=&0:X30=LM/K2<.DB3W(9)UXDY<?)@*>NM2,RZ5CD]
M3,3L>YR$0]RCETI](HEZVG^6/A1+8"GDBPLD6P;TK+,"%5H_19>@AL=Y<M4]
MT,XPM_L%OF;;,:[#("(18576I:%)V3&FV6E-Q$M8&ZPJ?F$(F&HQ*BV='MQ;
M#%@T"LQ&G-,)V:G(,+#3HIPIRM!GV*R.(54DC[G"65ACT7VW2*7%HVMJC5<6
M)4[43I 8_&(UBG4'M>0)U"E0 U2M4N(UB@PU8$!X0QKIP+S$XQY@CJ6)3"+
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MRL+G&?V"RP>J(#-H5SOS]$>H>AW6:VDN@4M4U?,9U/82B8:-CB:%21NFL]1
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MV$HC3=(=K2VE&\K%Z54K&'<3 8# 8# ^5CSP_O5_LX7[:,[_ +4\WX'U3X#
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MY:H0ULH=6J7TVA-JV'G)ZW6KGLN3+U44+,:1Z:SU\H) ZGB!]TYU+ L'ZE(
MFZ"2E?/M'+RE1"ZI:_5DK4=OMZPM1%F@T"E#T [E/]X)#PC2[T8GME[( KD
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M-7T#)7B)C;QJ-@%#&(:(0=IM[#@6(=_,9URUF=,/A-55*H:H*HM1F8X6XO\
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MGGGJCV9J.4JE38N4J#6Y(8>H6LI@#F98>:,G9AJII-+"),8+>QD"#K8-AWK
M\":&0]$H>%B.*1I(KD+JA?']4F8FLA0^/;6:2<V/#P>4E :YNK<<F+&0H.V,
MXD18=@%K8=>P/V;(M&&5<Y.C-'&%I<WE2H6.[BV-#>@7.JQ886:K5N2M*G*4
M+E*HTH(C##1"$,0=;WO>]:P,]@8A2P,*PQQ-5LC0J-=TZ)([&*6U&>8YI&TP
M\YN2N(S21"6IT!RHT1(#-B"4(P6PZUL6_:'Y#C$;- VE&QYC,+970U\9RQM*
M 8&EZ4;6[/=VT D^PH70[;DH]:@KT&B^(,]HM^L7M#!@K&MBFY(SEU[!RVA
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M+N6Y&U$E->DM)PIND]:O58GFDIGN*1>OI"[ISD[F(E$ K1*H,[;/=_>)=_\
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M70 )V_Y*(0.%>."B'.S04A+;VM(2!H<F8U/KX4@"3?N_:1_->C W? 8# 8#
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MJ;$FCA8DU-1B4"%(9JZM;*R.$A6_$'G:"M5-4>1$BT7H!?H3A]@=;]N]ANF
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P/E8\\/[U
M?[.%^VC._P"U/-^!]4^ P& P&!33R-?N]N[_ -C3I_\ P1G&!SV^S2?N0>$/
MZJVY_N'MW [J8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MY TL[Q/7Q5&84V."TE,NE,@0QU\ERQG8TQ@M&N"])%XRX+S"R]"V!*C-,W[
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ML/<6(UP3!V80%465LT&O4'VZ^[@:78-\5'6379;C*IU'"E]0UG(;?GT5;71
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M[WK Q@+8JPV1,D0+LN &2V2I@+8Y%P3*.CD3^C,:POA:MD9 N.W)U3&,HPK
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M$M=X"@F,673J/MJ%Y?X4CD#2IEK&T.>]:;75WCA*L;PVMKAO?L(/.) 4;_\
MZ"W@>139%=HY61!%D]A:2<*B5JA+#5,I8R)6I3MK:0\N)Y$>-7!=SB6]H5%*
MCQ!)V$I,8$T6] %H6PPJ:[:96@CYB.W*Q5@ELE40N*C33Z*G@DTQ2! -5$X^
M(IV'IYDJ8!@=F($WO%0-"UO8->W6!_C]<==,3<VN(),TOVGAV;FAK0QAT:GM
MR7C66 PUBO7)$25?[Q2UQF8R-,D=CR_4%O,WL!OL,UH&P]@K>J<"&<N8[/KP
M#;6"PYOLMP%-8T%#7B].7HY0AG*O;GHB)+""A:$,I>).,(=^W>M:P-C)EL54
M,S-(T\FCY\>D8V8N//Q+RVFLS\.1G)T\> S.@%(D+H-]/5E 1Z(&/:H9H-%^
MK8M:V&FS2YJZ@C>TNCY)6P:-W?\ <?(,0.+8J^'-22!-&9"YK/:N*T0R0UW5
M@+>E/MV%LW[=':"+V!V$.4=W/RQT8Y-S54=OQ>2*WZ(5S.8H U:4TBF<>M&+
M.<RC!L/(=1HU<B7D,#.I,<D:8L:II&4(M6628$0=!;7 8# 8# ^5CSP_O5_L
MX7[:,[_M3S?@?5/@,!@,!@4T\C7[O;N_]C3I_P#P1G&!SV^S2?N0>$/ZJVY_
MN'MW [J8# 8# CJWXBYS^I;1@;*H1)'B;5U-HBTJG(1H6Y,YR2-.;,@4+Q$$
M*CPHB52T C=@*,'H&M^P(M_<V'-5I\8++7/(M:U92CB@B-]UHZ\GVNED,UG-
MP6C5<DN?E=<P/K2VO+5+Y6XO3+7$K6H7! ?MD*;5*1.M*5@3F'(R$^!J=J\#
MW[UK,)#:73!=+0YV?'7D2!I*IJ*RK5>F)KHZA.DTG0EFN+G<8H/5,T>;,G[B
M'X9F)0,S(D8TZ(!>UAQBQ0H*"TG%7'8^.WSI2'L08\\T[9=GH;1K22/#W*I=
M>.BI!'4[9*JZN*9S/3L^3YCKMP:2R(:YK7=P7$QQ66U'@+"V%'K YSUIX@IS
M&H(L:Y!&^9$\]AD0X]@5-RYC)=ERIA2<S]T7#TK)IFE<E-9L[E G^Q8%.&H
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M"ZL2FLD-1M8(^HK$1?,\ I)\D@(^WMK$QMDG!(XD-Q3B1FF>_++(&:: WU!
M% *N\5%H)#8,LG<#X\KY)7SQP QA@M,I) Y0JP&?C>R)=+Y5=TI(?ZOBVF^V
M9ZPRP;6U-7PSCMJ0@,3J7]< [0B L=Y . YWU=/WJ1P]+4!S7..0+(YAE:NP
ME+LA?&O4CN.H[19QH -4*D^I#$WQMACPUNB4U6@$F^-+,+ J"8<6$*A=)^'&
MQ+ L*P))5_T1(ZTE5C7TJ8J,2S1?2L,C\2OFE>5X,[3,M2QT#;Z!)+T<OHQ\
M$XM+<TH1NS:^A.)?F]7[\!@=">T>-9YT)SM4]+P*31U,ZUVV6.U+7F>NLC.
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MQR1DJM$'G@*V$K3CM+E"M)(DA\^O^LHE)ED[55H6S/DE2(EA,V0(H8O7LK@
MS?I:]($]BL'OU*G9*,DUZ1%#-"8I) ,-,>/()R3"'1ICMKWE6%4RJ13:?0N-
M1N6SR,_'O1E?W&^T8Y.Y1S8X+D*!M^D%CVWJ=JC21-:\\M&NTG5;]U@;L=VA
MR>GD5N1-3T'52604.QO4DM]N5RUL2B@3'&E*5!*'%[4J#2T828JYKTZ-UT48
M:-L6J24RK11YQ98@UU%WWQ>X!J_:3I6IQBN9U6L5<$&2=,G5/[RW28B$K6LY
M&H"4J8%R>:JBF79;D!&+;P:!%K6U0PE;#?+>ZKYPH*20Z(7/=$ K:33XPL,5
M9I4_)FY:XD&NJ)B+<SP#V(+0Q#?').BTX+=IT.UAX"/>^]$$&P]T%Z:Y_LVT
M)Y2U?V[!I=:M8_'?/N"LCVG6/\>^270EB?/B$H-^E3J.OZDMO<_AQ'?)C@8!
M,J]R>()>PA24>2C@>%/\OBTMZUH^.R* O#@P3)F=INV(U\>>&64*X9(D+B0:
M/0BS8K)$1B=XWKVA9P^DY;L@D8#!!NDC[BY#B$[FE92;H>KF6=5VP/4GFT=7
M25*6JCC/&F1))I*8X'ZT)$%=&XPN)='%& T2Q V&:5GE%I_YS E1]O.GXPS6
M[(I%8T49F"@R1*+H>G%U(2M=9D@AS58)IDO7&;TF9PD0=]1.IGO!:]VA5%&B
M]@!AWL(8;>^^,'B-Q67-'2=4ND>G%GJ*6B*]NDA"T4AMA*D2.9U?M:), UP4
MR?Y%<$[D%+HKUF-1Y:X/M1C"=L/(D\AG#R^-6!,D/4]*K(K5DCCL3G\@33=J
M/:HV^S%Y61R')U2PLT12A++Y$WJ&]I5I]FI'-<G-(3&FFEC $,P7W7QT<GJ!
M63TC4AJ:^P^NHSRI<W&%S,'S@U$-C2" ,6FX 9EOY$%M;\-H+W__ "[?L6ZV
M1@:6X>17E!+;;94:&T8Z]K?EJR(E-96UNK:9#ZPGM:RNO8*XP">.IZHC;9+'
M.8V0B;"$Q8#O<K"S"U.R!;+T,+$NE]TLR0VS+#>K0A+/!*9=G]AM28.K^@;H
MW WJ+)T2F1-<C>%AI*%O7,P'$@)Y8A^H!QFBM_SOM!@0NH\@G$B1FJJ0K.H:
M:1,UVK7!NK!<MF;8D+DZQHD">(O)00*3"CF?3)+UA+0N&X!2@1.QQ:(_9:HP
M!6PP;]Y*N!HL_2:+R/K:CF.0PQ_/B\I9W.<-B-<Q/J&6.,&>$#@2<,.R11J6
M-)Z)W,^Z4SF!UM:). 8!"":V;IOGV17,^\\,=P0-TNV-(SUKW6J-^2'29"6C
M2H%[@F$D"+W9[HTM[LD4K410QK$2942<>466:6(01;!^[N;9IT%:/+9MA,$4
MO2LI\X03Z/)0]LJ"0S+Y+J:!W&LD430%KSS530")SG8PE'Z(7& :7!0$C:5,
M,_ B"S_*OR'#(S 7ROI^SWVXV5T/7_,\8C]62.+&GZG]A%N+BV.#R[R9ZC[&
MTPTN-LBYQ*=1J!)G(A-L*#:H>_9H)63>13AE;"YO8B'JBF%T)KB3QZ'322()
MDWK6UED<P4KT,+;Q&)1&C7!FZYJ5$,AZ4)Z=Y/3FEHC#QEB#H)5@'4?.]J6/
M*JAKJXH',+-A*(;C*(4R/B=4^M*1.<A2N1AB37I^($Q+G1*F<P$[,,:U:DHA
M6$@XP -A39Q\O_$L>LV25S,[&+K]-#+*Z!J*7SN=FM4;AK#/N<P4^;,F@Y8J
M<Q+E2=P37 2H2*2B!DEI&=P4*MIB"0F&!<HGJ+G91<B+GM-<U?*;I<F=.^H*
MZ3R)"?(5C>K8]RA)I.428-.:XK(H';L2BT9\8:TZVM 5M+KWN!HMG=W<<TQ/
MG2K+6Z0JB!6,S(BE[G"Y)*4;?(4A*J/CE3:28W&;V<)P?& HQ0VI Z$J<]%&
M!2EG#+&$(9%J[8Y(?))4T19NB*H=9%>L;9)?4;:WRYM5CG4=D^ENHLY,QY!H
MTGIE)K8J*:RSC"CG$](H*3 --(-  (KLWR9\65C!K0GI]V1>9-M-S*O8-8K;
M %J>3O<?>+)LYIJ)B5#1)SB@+V-)-7,:98M2C.3D&(E1.A"5$B(P-B:O(1R*
M=*(?7TFO6KX;9<_DR^,PZOW6=QM<_/RC5JSRG(TJ2&,R]>W%E3.<5VX-R !I
MQ9ORJ#Y-,"!QUM-@2' NPN7;2N"54!75[5M-+HA),F42FMX])$;E*&=-"WIL
MC4P4GH2!"]\EBTF>$[8XF%", C<A[2&[ H 86$- ZYZPF?+1<$<FGF&T+VCD
MWF$%KK3_ %]-J3C9+%/K0G\=K6OHVYMUHV/"'51J0R63I@B6)23T:,G8AGF
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MOFZYRT*AP.KQ2^D ?R IHNIG!R%07K6TR=]U"49KR%M&8%P&TEB6!)VFULW
MC&V?(3RM4!]'I7VR$#VKZ%D-0LM;)XIZ'LQP;;X:I\[53-%@2S2AI85,2JT=
MBDBX.C/>GD>G0-Z]0@AKU->3;BJYZ(6= M-\5['8E&875\QLQMD<J8RGVJQ6
M\WIU$+C<P3-ZY>G%('=X,.9TI: Q:6N>DBA$E&<H)&7H,[,O(ER!&(E'),U7
MO5\O53VO)':%9L;-.XTF43Z'Q,UT1R%Z:G5U7HF-K:6)U952%P6.*A(F;EY.
MTRD91_L+V&13>0SBA3*++A8ND*W;Y53T;D<PLID>W)7'UL4B\3E:""/[\M"^
MHFX"AL0S5U2M.C4XC@G.*DI.5ZS3 !V&D7?Y/>+J.I)%>+K=L(E#+)8I-937
M$:C,D91RVS U^K"TR=EBS6[+6S13TV20PMG/*7C1Z3O)Q:$W8%1@"MA+=O\
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MI30MAZ=@9%;5?=8+TY[CCMSN0X2-ODZ[KR,=;/#?>%@%V8GD=@M2)T95C"W
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ME_!A7FMVE>AI]#"G*"-&OPW(&U]OL)MEP.01*Q6/I1)6A,ZKBTK%D,/<^G;
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M*0B&E]IV@M1$>J*7G,W9JXC,A<7":/4KOF& 8M1Q^)4MKUS7(F:+6UM\,-0
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MJ6FU5,+-Y3>K+25VUUCT?&X5:<&J"63F. 0W"URALC<0>[':7@39(_FF\OC
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M#S7**R@R.CKLOB:VG&;<F3'&:700!0M;XO2*&'.L]=7I98E@5ZSI/<MTT3?
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MQN4]602FY=6CH]R"DDQ[>NOZ-*'ZMFM^K,NX=W6Z-P%19:!Y>F2..; UK#@
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M](+&E=AN<^L*43V:R22VRB"CGSTMF<F7N#_M6^F;&?K6CO=)33-A3@*)"64
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M'U3X# 8# 8%-/(U^[V[O_8TZ?_P1G&!SV^S2?N0>$/ZJVY_N'MW [J8# 8#
M@CJ2=2*K^9.B[+B"PINEM=T1;LZB[@>C3.)"&11*OY"_LBPYO6!&C7%)G)O*
M&(DT.RS=!](M;#O>!RP4>6:S*W@L/B]M<QZUTE,$_-@H7$XE8$QLR$RZ/] 5
M9;ECHYO*'ZE^?I]/HBY1U/S_ "PEY9&2%R;2966BVB5+&]08O3!I46\E?4<L
MOL^0IZ:,9*YFM4\D0&C>9IU(1UA+5?272DRN\$CD5Z2*642JF]?PZ"L% /\
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M>LZHJ!JN6Y;O4V&HC47D=G)JBA3?&ZEA@IG.G5VGZJ(S8XES&6H1-[2B TC
ML6K@C4GH49"E44%*)WY;'6&,TVM$OFO3K0$6E%AU WSHF[XLHG#Q?E><Y/\
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MK!RJ6NX443&6RMJHBTGDC7+;"/KZ-L4;:5;>^6<_1UI.>U2Q8O$;II3 3:3
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M%(#1+F4H'I UK!;.3:*,WL6!O& P& P& P& P& P& P& P& P& P& P& P&
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MUOVZW]W6]?=UO6_^&];P/$4Y-QR]6UDKT1KF@(2J5S<4J(,7HTR[9X42A6D
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MX(-\;?"O5M6]I0'I#K-@E#S,TGC0B--O-FOEMGSM>DGY75-X21@J>8JTTN5
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M]6B1EJ/2E<E6_>>P((^S2?N0>$/ZJVY_N'MW [J8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M[EITZKJ"H;WMZ/H)C8D'159 XO#S[ED3U5MU26BY?MACK_/H_%CT:.3Q)<N
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M;*3FA[XOYB>0IGJ,RJ-BL=TY^F?3Q/(T6ZV)C\=US0]VVJAH9,WJ44Z'+PO
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M=3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MAHL@Y8< (6WWH;[]FD_<@\(?U5MS_</;N!W4P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M2&^_9I/W(/"']5;<_P!P]NX'=3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M& P*:>1K]WMW?^QIT_\ X(SC Y[?9I/W(/"']5;<_P!P]NX'=3 8# 8# 8#
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MM-]L6MTK9[QT/?53 ZXJ*L*GO6(0)!3;LTR9+2KA\J5BXL\AGU82R?0="W.
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M\OW'.K^N^8U><9(Z\A,$TX5>_FFK)FC*&R*%B-LKE7M1HHT91"E8B3"'\2J
M5H/L^P& P& P&!STO+Q->-7I6PG:V;SXFYZL:RY!L Y#.'JOVHB1R,\L.@ 6
MR)S:PMY[\Y!*"$'Q2O9RCW80@]?I#K6@A_ZA[P[_ ,/'FS\3!_T_ ?4/>'?^
M'CS9^)@_Z?@/J'O#O_#QYL_$P?\ 3\!]0]X=_P"'CS9^)@_Z?@/J'O#O_#QY
ML_$P?]/P'U#WAW_AX\V?B8/^GX#ZA[P[_P /'FS\3!_T_ ?4/>'?^'CS9^)@
M_P"GX#ZA[P[_ ,/'FS\3!_T_ ?4/>'?^'CS9^)@_Z?@/J'O#O_#QYL_$P?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g41684g07d97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g41684g07d97.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MMT@"@ H * "@ H * "@ H * $Z4M@(H[B&622..56>,X=0<E3[^E-IK<":@
MH * "@ H * "@ H * *6IZC#I6G3WMPV(H5+'W]A[FJA!SDH+J%[:DMG.US9
MP3LC1F1%?8W5<C.#4M<K:!;'+^)KVYU>_7POI4QCEE3??3C_ )80GL#_ 'F[
M?Y-;TDHKGE_3!G3:=I]MI=A#96D0B@A4*BC_ #UK&4G.5V!89U1<L< =SVI>
M0',V?BJ:\UZWLTL'6RN0_D7+.,OM')V_W>F#[UTSH*,.9O5=";ZV.HKF*"@
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M6-YJ,ABL;1.9#&I_3D<D\?+GO6]=RJVA?1;L2TU.DGCBTZ/^WO%=S&\Z$>3
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MWT("OC.['$FFV"$]06ED4?3&T_G57H1W38_>$;PIJ5Y@ZAXIU%^/NVI6!3^
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g41684g89m19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g41684g89m19.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M"CH*^D1\B+0 4 !Z4 >!Z[_R,.I?]?4G_H1KYVK_ !)>I]70_A1]$>O>#/\
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M#DR-TCN&"^PVJ?ZUZ.!;=-GE9DDJM_([4=!7<>:% !0!E^)/^17U?_KSE_\
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M'E6QZ]X*TF72/#D44Z[)I6,KKZ$]/T KVL-3=.G9[GSF,JJK5;6QT==)RA0
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M*K^6*2.6-HX2KQG*L/,3D>U2MQO8X&1-5UMO"VA:Q:VFF6;K'+;W0Y:90H
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M=(*0SRGQA86<WBJ\DEM()'.S+-&"3\B]ZM;$/<ZSP#;PV^@RI#"D2>>QVHH
MSM7TI/<:.7UO2M./Q)MT-A;%9&5G!A7#$]2>.30!ZDH & ,5)1SNA0Q1^(]?
M=(T5WDC+,% +<'KZT^@@\20Q2:IH321JY2Z!4LH.T\<CTH0F;-_;P75A/#<0
MI+$R'<DBAE/U!I%' _#73[*.\U&9+.!94;:KB,!E'/ /:J9*+WQ+L;2?1X9Y
LK6&297"AVC!8#TS1$)&[X0MH+;PO8K;PQQ*5W$(H4$GOQ2>XT;M(84 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
